WO2023014839A1 - Methods for the treatment of sickle cell disease - Google Patents
Methods for the treatment of sickle cell disease Download PDFInfo
- Publication number
- WO2023014839A1 WO2023014839A1 PCT/US2022/039341 US2022039341W WO2023014839A1 WO 2023014839 A1 WO2023014839 A1 WO 2023014839A1 US 2022039341 W US2022039341 W US 2022039341W WO 2023014839 A1 WO2023014839 A1 WO 2023014839A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- cells
- genetically modified
- cell
- administration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 171
- 208000007056 sickle cell anemia Diseases 0.000 title claims abstract description 113
- 238000011282 treatment Methods 0.000 title claims description 62
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 210000004027 cell Anatomy 0.000 claims description 380
- 108020004999 messenger RNA Proteins 0.000 claims description 68
- 238000001802 infusion Methods 0.000 claims description 62
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 49
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 49
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 claims description 47
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 claims description 45
- 238000001990 intravenous administration Methods 0.000 claims description 44
- 210000003743 erythrocyte Anatomy 0.000 claims description 39
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 37
- 108010054147 Hemoglobins Proteins 0.000 claims description 36
- 102000001554 Hemoglobins Human genes 0.000 claims description 36
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 36
- 229960002092 busulfan Drugs 0.000 claims description 36
- 238000003776 cleavage reaction Methods 0.000 claims description 34
- 230000007017 scission Effects 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 31
- 238000002617 apheresis Methods 0.000 claims description 29
- 238000002560 therapeutic procedure Methods 0.000 claims description 26
- 238000012239 gene modification Methods 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 23
- 229960002169 plerixafor Drugs 0.000 claims description 21
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 20
- 210000001185 bone marrow Anatomy 0.000 claims description 19
- 229910052742 iron Inorganic materials 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 18
- 238000012986 modification Methods 0.000 claims description 18
- 230000002829 reductive effect Effects 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 15
- 108010044495 Fetal Hemoglobin Proteins 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 14
- 230000005017 genetic modification Effects 0.000 claims description 14
- 235000013617 genetically modified food Nutrition 0.000 claims description 14
- 239000000090 biomarker Substances 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 206010065973 Iron Overload Diseases 0.000 claims description 11
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims description 11
- 230000001400 myeloablative effect Effects 0.000 claims description 11
- 210000000440 neutrophil Anatomy 0.000 claims description 11
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 10
- 230000003394 haemopoietic effect Effects 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 9
- 102000003951 Erythropoietin Human genes 0.000 claims description 8
- 108090000394 Erythropoietin Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229940105423 erythropoietin Drugs 0.000 claims description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 8
- 238000011374 additional therapy Methods 0.000 claims description 7
- 210000003714 granulocyte Anatomy 0.000 claims description 7
- 102000014702 Haptoglobin Human genes 0.000 claims description 6
- 108050005077 Haptoglobin Proteins 0.000 claims description 6
- 230000001668 ameliorated effect Effects 0.000 claims description 6
- 238000010362 genome editing Methods 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 230000035790 physiological processes and functions Effects 0.000 claims description 6
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims description 5
- 238000002655 chelation therapy Methods 0.000 claims description 5
- 102000018511 hepcidin Human genes 0.000 claims description 5
- 108060003558 hepcidin Proteins 0.000 claims description 5
- 229940066919 hepcidin Drugs 0.000 claims description 5
- 239000012503 blood component Substances 0.000 claims description 4
- 230000010438 iron metabolism Effects 0.000 claims description 4
- 239000000537 myeloablative agonist Substances 0.000 claims description 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 92
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 39
- 150000007523 nucleic acids Chemical class 0.000 description 38
- 102000039446 nucleic acids Human genes 0.000 description 34
- 108020004707 nucleic acids Proteins 0.000 description 34
- 210000000130 stem cell Anatomy 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 28
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 239000013598 vector Substances 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 230000027455 binding Effects 0.000 description 23
- 101100493741 Homo sapiens BCL11A gene Proteins 0.000 description 22
- 101710163270 Nuclease Proteins 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 210000003995 blood forming stem cell Anatomy 0.000 description 21
- 239000002157 polynucleotide Substances 0.000 description 21
- 102000040430 polynucleotide Human genes 0.000 description 21
- 108091033319 polynucleotide Proteins 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 20
- 239000003623 enhancer Substances 0.000 description 20
- 230000000925 erythroid effect Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 16
- 101710185494 Zinc finger protein Proteins 0.000 description 16
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 241000702421 Dependoparvovirus Species 0.000 description 15
- 230000003750 conditioning effect Effects 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 108010077544 Chromatin Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000003483 chromatin Anatomy 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- -1 polymerases Proteins 0.000 description 12
- 230000004568 DNA-binding Effects 0.000 description 11
- 239000000306 component Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 108060003196 globin Proteins 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 206010051895 acute chest syndrome Diseases 0.000 description 9
- 102000018146 globin Human genes 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 210000005259 peripheral blood Anatomy 0.000 description 9
- 239000011886 peripheral blood Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 238000005138 cryopreservation Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 6
- 101100506246 Gadus morhua hba2 gene Proteins 0.000 description 6
- 101150071666 HBA gene Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 101100338386 Xenopus tropicalis hba-A gene Proteins 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000010836 blood and blood product Substances 0.000 description 6
- 229940125691 blood product Drugs 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 208000020451 hereditary persistence of fetal hemoglobin Diseases 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000009850 completed effect Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000003319 supportive effect Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- 230000007018 DNA scission Effects 0.000 description 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 4
- 210000000267 erythroid cell Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002489 hematologic effect Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012317 liver biopsy Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002106 pulse oximetry Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 206010060935 Alloimmunisation Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 208000002903 Thalassemia Diseases 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000009583 bone marrow aspiration Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000003013 erythroid precursor cell Anatomy 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- 229940075525 iron chelating agent Drugs 0.000 description 3
- 239000000797 iron chelating agent Substances 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 229940021317 other blood product in atc Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 201000011264 priapism Diseases 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000023516 stroke disease Diseases 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000000591 tricuspid valve Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 238000008789 Direct Bilirubin Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000021127 protein binding proteins Human genes 0.000 description 2
- 108091011138 protein binding proteins Proteins 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 108010085686 Hemoglobin C Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010051792 Infusion related reaction Diseases 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101150066745 Saraf gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007106 neurocognition Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007979 neuropsychological functioning Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940075461 other therapeutic product in atc Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000000468 rubriblast Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000018019 sickle cell-hemoglobin c disease syndrome Diseases 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000009225 splenic sequestration Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Definitions
- Sickle cell disease is a genetic hematologic disorder affecting an estimated 70,000 to 100,000 individuals in the United States. SCD is caused by a mutation in the p- globin gene (Glu6Val) that results in the abnormal hemoglobin, sickle hemoglobin (HbS). When inherited on both alleles, the sickle mutation produces the homozygous genotype HbSS. This genotype, occurring in >70% of cases worldwide, gives rise to the most severe form of the disease. Saraf et a/. (2014) Paediatr Respir Rev. 15(1):4-12.
- the sickle mutation can also be inherited in trans with an allele specifying a dysfunctional p-globin (genotype HbS-p[+]- thalassemia), an absent p-globin (genotype HbS-p°-thalassemia), or a different p-globin point mutation, such as hemoglobin C (leading to HbSC disease).
- HbS-p°-thalassemia is clinically indistinguishable from genotype HbSS, while the other 2 genotypes are generally less severe in phenotype.
- Hydoxyurea (HU) treatment reduces the likelihood of patient pain crisis that requires hospitalization and prevents acute chest syndrome (ACS).
- ACS acute chest syndrome
- VOC vaso-occlusive crisis
- Transfusion therapy is used in SCD in the context of some acute complications, such as stroke, ACS, splenic sequestration, or aplastic crisis, or chronically for severe anemia, stroke, and pain crisis prevention.
- RBC chronic red blood cell
- an ex vivo method of treating sickle cell disease (SCD) in a subject comprising: administering to the subject in need thereof a composition comprising a genetically modified cell comprising a red blood cell (RBC) precursor cell, wherein the precursor cell comprises SB-mRENH1 mRNAs and SB-mRENH2 mRNAs, which encode a ZFN pair; and a genomic modification made following cleavage by the ZFN pair, wherein the modification is within an endogenous BCL11A enhancer sequence.
- the composition further comprises a cell descended from the genetically modified cell comprising the SB-mRENH1 mRNAs and the SB-mRENH2 mRNAs.
- the sickle cell disease is severe sickle cell disease.
- the subject has adequate physiological function by BMT CNT guidelines prior to administering of the composition.
- the fetal hemoglobin (HbF) production in the subject is increased after administration of the disclosed composition comprising the genetically modified cells.
- one or more clinical symptoms of sickle cell disease in the subject are decreased, ameliorated, or eliminated.
- one of the clinical symptoms in the subject that is decreased, ameliorated, or eliminated is vaso-occlusive crisis (VOC).
- VOC vaso-occlusive crisis
- a change from baseline of clinical laboratory hemoglobin fractions in grams/dL plasma and/or percent HbF of total hemoglobin (Hb) is achieved in the subject.
- the effect of the composition on the subject is realized within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
- the levels of SCD-related disease biomarkers in the subject are altered following treatment.
- the SCD-related disease biomarkers are changes in iron metabolism and/or changes in levels of erythropoietin, haptoglobin, and/or hepcidin.
- the clinical symptoms associated with iron overload or associated with baseline transfusion therapy in the subject are ameliorated or eliminated in the subject.
- the need for RBC transfusions and infusion platelet transfusion, intravenous immunoglobin (IVIG) transfusion, plasma transfusion and/or granulocyte transfusion in the subject is reduced or eliminated.
- the number and/or percent of F cells in the subject is modified following administration of the composition comprising the genetically modified cells.
- the genetically modified cell(s) are autologous or allogeneic.
- the BCL11 A-genetically modified cells further comprise one or more additional genetic modifications.
- the genetically modified cells are hematopoietic stem cells isolated from the subject.
- the hematopoietic stem cells are CD34+ hematopoietic stem or precursor cells (HSC/PC).
- the CD34+ HSC/PC are mobilized in the subject by treatment with one or more doses of plerixafor.
- at least 25 x 10 6 CD34+ HSPCs/kg are mobilized in the subject.
- the mobilized cells are harvested by one or more apheresis cycles.
- the methods further comprise administering one or more myeloablative condition agents to the subject prior to administration of the composition comprising the genetically modified cells.
- the myeloablative agent comprises busulfan.
- the dose of genetically modified cells administered to the subject is between 3 x 10 6 cells/kg and 20 x 10 6 cells/kg. In some embodiments of the methods disclosed herein, the dose of cells administered to the subject is between 3 x 10 6 cells/kg and 20 x 10 6 cells/kg. In some embodiments of the methods disclosed herein, the dose of genetically modified cells administered to the subject is about 3.2 x 10 6 cells/kg and about 9.7 x 10 6 cells/kg. In some embodiments of the methods disclosed herein, the dose of genetically modified cells administered to the subject is about 5.17 x 10 6 cells/kg.
- the genetically modified cells administered to the subject are formulated with approximately 1.0-2.0 x 10 8 cells per bag at a concentration of approximately 1 x 10 7 cells/mL.
- the genetically modified cells are cryopreserved prior to administration to the subject.
- the methods disclosed herein further comprise monitoring the subject’s vital signs prior to, during and/or after administration of the genetically modified cells. In some embodiments, the methods further comprise assessing hemoglobin, neutrophil and/or platelet levels in the subject prior to administration of the genetically modified cells to determine baseline levels of hemoglobin in the subject.
- the hemoglobin, neutrophil and/or platelet levels in the subject after administration of the genetically modified cells increase as compared to baseline levels for weeks or months after administration. In some embodiments, the hemoglobin, neutrophil and/or platelet levels in the subject remain stable as compared to baseline levels for weeks or months after administration.
- the methods disclosed herein further comprise assessing the subject using a health-related quality of life (HRQoL) survey. In some embodiments, the methods disclosed herein further comprise assessing the subject using the Patient-Reported Outcomes Measurement Information System 57 (PROMIS-57). In some embodiments, the methods disclosed herein further comprise assessing the subject using the Karnofsky Performance Scale.
- HRQoL health-related quality of life
- PROMIS-57 Patient-Reported Outcomes Measurement Information System 57
- the methods disclosed herein further comprise assessing the subject using the Karnofsky Performance Scale.
- the subject receives one or more packed red blood cell (PRBC) transfusions prior to and/or after administration of the genetically modified cells.
- PRBC packed red blood cell
- the need for additional therapies such as a bone marrow transplant, blood component and/or iron chelation therapy PRBC transfusions in the subject is reduced or eliminated.
- the need for additional therapies is reduced or eliminated within 1-20 days of administration of the genetically modified cells.
- the need for additional therapies in the subject is reduced or eliminated within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
- a pharmaceutical composition comprising a genetically modified cell comprising a red blood cell (RBC) precursor cell, wherein the precursor cell comprises SB-mRENH1 mRNAs and SB-mRENH2 mRNAs, which encode a ZFN pair; and a genomic modification made following cleavage by the ZFN pair, wherein the modification is within an endogenous BCL11A enhancer sequence, and wherein the composition is formulated in cryopreservation buffer.
- the cryopreservation buffer is CryoStor® CS-10 cryomedia.
- FIG. 1 is an illustration (adapted from Hardison & Blobel (2013) Science 342(6155):206-7) of effects of low, elevated and high fetal hemoglobin levels on subjects comprising adult hemoglobin mutations (for example sickle cell disease). Shown on the far left (“low fetal hemoglobin:”) is a subject with a mutation in adult hemoglobin and wild-type ESE BCL11A, in this case the subject has normal (low) levels of fetal hemoglobin, resulting in disease symptoms in the subject.
- low fetal hemoglobin Shown on the far left (“low fetal hemoglobin:”) is a subject with a mutation in adult hemoglobin and wild-type ESE BCL11A, in this case the subject has normal (low) levels of fetal hemoglobin, resulting in disease symptoms in the subject.
- the subject In the middle (“elevated fetal hemoglobin”), the subject has the adult hemoglobin mutation, but also has mutations in their BCL11A gene such that BCL11A expression is decreased but not eliminated, which results in elevated fetal globin levels. The subject experiences some disease amelioration due to the fetal globin “replacing” some adult globin functioning. In the far right (“high fetal hemoglobin), the subject has the adult globin mutation but has a deletion in the BCL11 A enhancer, such that the subject exhibits full expression of fetal globin. This subject will experience even greater in symptom improvement by virtue of full BCL11A inactivation.
- FIG. 2 is a schematic depicting a treatment protocol using genetically modified HSPC (also referred to as SAR445136).
- HSPC refers to hematopoietic stem progenitor cells
- IV refers to intravenous
- RBC refers to red blood cells
- ZFN refers to zinc finger nuclease.
- FIG. 3 is a schematic depicting the design of the clinical study.
- SOE schedule of events
- FIG. 4 is a graph showing total Hb and Hb fractionation in four subjects after SAR445136 infusion.
- HbA refers to adult hemoglobin
- HbA2 refers to variant adult hemoglobin
- HbF refers to fetal hemoglobin
- HbS refers to sickle hemoglobin.
- FIG. 5 is a graph showing percentage of F cells over time for treated subjects. Further data remaining to be collected is noted by an asterisk (*).
- FIG. 6 is a graph depicting HbF/F cell levels above the threshold range for preventing HbS polymerization for all four treated subjects.
- HbF fetal hemoglobin. Further data remaining to be collected is noted by an asterisk (*).
- FIG. 7 is a graphical depiction of the number of severe vaso-occlusive crises (VOCs) reported pre- and post-SAR445136 infusion in all four subjects.
- VOCs vaso-occlusive crises
- Disclosed herein are methods for treating and/or preventing sickle cell disease events in a subject in need thereof.
- the present disclosure provides methods and compositions for genome editing and/or gene transfer.
- the present disclosure also provides methods and compositions for cell therapy for the treatment of subjects lacking sufficient expression of beta globin.
- the methods and compositions disclosed herein are used to treat a subject with SCD comprising administering cells that have been modified using engineered nucleases to the subject.
- SAR445136 is a novel therapeutic product consisting of autologous CD34+ HSPCs that have been modified ex vivo by zinc finger nucleases (ZFN), targeting the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous production of HbF.
- ZFN zinc finger nucleases
- ESE erythroid-specific enhancer
- the term “approximately” or “about” as applied to one or more values of interest refers to a value that is similar to a stated reference value. In some embodiments, the term refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context.
- nucleic acid refers to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
- polynucleotide refers to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
- these terms are not to be construed as limiting with respect to the length of a polymer.
- the terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones).
- an analogue of a particular nucleotide has the same base-pairing specificity; /.e., an analogue of A will base-pair with T.
- polypeptide “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues.
- the term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.
- Binding refers to a sequence-specific, non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a binding interaction need be sequence-specific (e.g., contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation constant (Kd) of 10 -6 M -1 or lower. “Affinity” refers to the strength of binding: increased binding affinity being correlated with a lower Kd.
- a “binding protein” is a protein that is able to bind non-covalently to another molecule.
- a binding protein can bind to, for example, a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein- binding protein).
- a DNA-binding protein a DNA-binding protein
- an RNA-binding protein an RNA-binding protein
- a protein-binding protein it can bind to itself (to form homodimers, homotrimers, etc.) and/or it can bind to one or more molecules of a different protein or proteins.
- a binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein-binding activity.
- a “zinc finger DNA binding protein” (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion.
- the term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.
- the term “zinc finger nuclease” includes one ZFN as well as a pair of ZFNs (the members of the pair are referred to as “left and right” or “first and second” or “pair”) that dimerize to cleave the target gene.
- a “TALE DNA binding domain” or “TALE” is a polypeptide comprising one or more TALE repeat domains/units. The repeat domains are involved in binding of the TALE to its cognate target DNA sequence.
- a single “repeat unit” (also referred to as a “repeat”) is typically 33-35 amino acids in length and exhibits at least some sequence homology with other TALE repeat sequences within a naturally occurring TALE protein. See, e.g., U.S. Patent Nos. 8,586,526 and 9,458,205.
- TALEN includes one TALEN as well as a pair of TALENs (the members of the pair are referred to as “left and right” or “first and second” or “pair”) that dimerize to cleave the target gene.
- Zinc finger and TALE binding domains can be “engineered” to bind to a predetermined nucleotide sequence, for example via engineering (altering one or more amino acids) of the recognition helix region of a naturally occurring zinc finger or TALE protein. Therefore, engineered DNA binding proteins (zinc fingers or TALEs) are proteins that are non-naturally occurring. Non-limiting examples of methods for engineering DNA-binding proteins are design and selection.
- a designed DNA binding protein is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP and/or TALE designs and binding data. See, for example, U.S. Patent Nos. 8,568,526; 6,140,081 ; 6,453,242; and 6,534,261 ; see also International Patent Publication Nos. WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536; and WO 03/016496.
- a “selected” zinc finger protein or TALE is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See e.g., U.S. Patent Nos. 8,586,526; 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,200,759; and International Patent Publication Nos. WO 95/19431 ; WO 96/06166; WO 98/53057; WO 98/54311 ; WO 00/27878; WO 01/60970; WO 01/88197 and WO 02/099084.
- “Recombination” refers to a process of exchange of genetic information between two polynucleotides.
- “homologous recombination (HR)” refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a “donor” molecule to template repair of a “target” molecule (/.e., the one that experienced the double-strand break), and is variously known as “non-crossover gene conversion” or “short tract gene conversion,” because it leads to the transfer of genetic information from the donor to the target.
- such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or “synthesis-dependent strand annealing,” in which the donor is used to re-synthesize genetic information that will become part of the target, and/or related processes.
- Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.
- one or more targeted nucleases as described herein create a double-stranded break in the target sequence ⁇ e.g., cellular chromatin) at a predetermined site, and a “donor” polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell.
- a “donor” polynucleotide having homology to the nucleotide sequence in the region of the break, can be introduced into the cell.
- the presence of the double-stranded break has been shown to facilitate integration of the donor sequence.
- the donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin.
- a first sequence in cellular chromatin can be altered and, in some embodiments, can be converted into a sequence present in a donor polynucleotide.
- replacement or replacement can be understood to represent replacement of one nucleotide sequence by another, (/.e., replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.
- additional pairs of zinc-finger or TALEN proteins can be used for additional double-stranded cleavage of additional target sites within the cell.
- a chromosomal sequence is altered by homologous recombination with an exogenous “donor” nucleotide sequence.
- homologous recombination is stimulated by the presence of a doublestranded break in cellular chromatin, if sequences homologous to the region of the break are present.
- the first nucleotide sequence can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest.
- portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced.
- the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs.
- a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest.
- the non-homologous sequence is generally flanked by sequences of 50-1 ,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1 ,000, that are homologous or identical to sequences in the region of interest.
- the donor sequence is non-homologous to the first sequence and is inserted into the genome by non-homologous recombination mechanisms.
- Any of the methods described herein can be used for partial or complete inactivation of one or more target sequences in a cell by targeted integration of donor sequence that disrupts expression of the gene(s) of interest.
- Cell lines with partially or completely inactivated genes are also provided.
- the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences.
- the exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA molecules, or any type of coding or non-coding sequence, as well as one or more control elements (e.g., promoters).
- the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).
- Cleavage refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and doublestranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In some embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.
- a “cleavage half-domain” is a polypeptide sequence which, in conjunction with a second polypeptide (either identical or different) forms a complex having cleavage activity (preferably double-strand cleavage activity).
- first and second cleavage half- domains;” “+ and - cleavage half-domains” and “right and left cleavage half-domains” are used interchangeably to refer to pairs of cleavage half-domains that dimerize.
- An “engineered cleavage half-domain” is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half-domain (e.g., another engineered cleavage half-domain). See, U.S. Patent Nos. 7,888,121 ; 7,914,796; 8,034,598; and 8,823,618, incorporated herein by reference in their entireties.
- sequence refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded.
- donor sequence refers to a nucleotide sequence that is inserted into a genome.
- a donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 1 ,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.
- a “disease associated gene” is one that is defective in some manner in a monogenic disease.
- monogenic diseases include severe combined immunodeficiency, cystic fibrosis, lysosomal storage diseases (e.g., Gaucher’s, Hurler’s Hunter’s, Fabry’s, Neimann-Pick, Tay-Sach’s, etc.), sickle cell anemia, and thalassemia.
- a “chromosome” is a chromatin complex comprising all or a portion of the genome of a cell.
- the genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell.
- the genome of a cell can comprise one or more chromosomes.
- An “episome” is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell.
- Examples of episomes include plasmids and certain viral genomes.
- a “target site” or “target sequence” is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.
- an “exogenous” molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. “Normal presence in the cell” is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell.
- An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally- functioning endogenous molecule.
- An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules.
- Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251.
- Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.
- an exogenous molecule can be the same type of molecule as an endogenous molecule, e.g., an exogenous protein or nucleic acid.
- an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell.
- exogenous molecules are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (/.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE- dextran-mediated transfer and viral vector-mediated transfer.
- An exogenous molecule can also be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from.
- a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster.
- an “endogenous” molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions.
- an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally-occurring episomal nucleic acid.
- Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.
- a “fusion” molecule is a molecule in which two or more subunit molecules are linked, preferably covalently.
- the subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules.
- Examples of fusion molecules include, but are not limited to, fusion proteins (for example, a fusion between a protein DNA- binding domain and a cleavage domain), fusions between a polynucleotide DNA-binding domain (e.g., sgRNA) operatively associated with a cleavage domain, and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein).
- Fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein.
- Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.
- Gene expression refers to the conversion of the information, contained in a gene, into a gene product.
- a gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of an mRNA.
- Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.
- Modulation of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing ⁇ e.g., cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP or TALEN as described herein. Thus, gene inactivation may be partial or complete.
- a “region of interest” is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination.
- a region of interest can be present in a chromosome, an episome, an organellar genome (e.g., mitochondrial, chloroplast), or an infecting viral genome, for example.
- a region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region.
- a region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.
- “Eukaryotic” cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., stem cells, or precursor cells).
- stem cells or “precursor cells” refer to pluripotent and multipotent stem cells, including but not limited to hematopoietic stem cells, which are also referred to as hematopoietic progenitor stem cells (HPSC) or hematopoietic stem cell/precursor cells (HSC/PC).
- HPSC hematopoietic progenitor stem cells
- HSC/PC hematopoietic stem cell/precursor cells
- RBCs Red Blood Cells
- erythrocytes are terminally differentiated cells derived from hematopoietic stem cells. They lack a nuclease and most cellular organelles. RBCs contain hemoglobin to carry oxygen from the lungs to the peripheral tissues. In fact, 33% of an individual RBC is hemoglobin. They also carry CO2 produced by cells during metabolism out of the tissues and back to the lungs for release during exhale. RBCs are produced in the bone marrow in response to blood hypoxia which is mediated by release of erythropoietin (EPO) by the kidney. EPO causes an increase in the number of proerythroblasts and shortens the time required for full RBC maturation.
- EPO erythropoietin
- the cells are removed from circulation by either the phagocytic activities of macrophages in the liver, spleen and lymph nodes (-90%) or by hemolysis in the plasma (-10%). Following macrophage engulfment, chemical components of the RBC are broken down within vacuoles of the macrophages due to the action of lysosomal enzymes.
- operative linkage and “operatively linked” (or “operably linked”) are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components.
- a transcriptional regulatory sequence such as a promoter
- a transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it.
- an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.
- the term “operatively linked” can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked.
- the ZFP or TALE DNA-binding domain and the activation domain are in operative linkage if, in the fusion polypeptide, the ZFP or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the activation domain is able to up-regulate gene expression.
- the ZFP or TALE DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFP or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
- a “functional” protein, polypeptide or nucleic acid includes any protein, polypeptide or nucleic acid that provides the same function as the wild-type protein, polypeptide or nucleic acid.
- a “functional fragment” of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid.
- a functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions.
- nucleic acid e.g., coding function, ability to hybridize to another nucleic acid
- methods for determining protein function are well-known.
- the DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See, Ausubel et al., supra.
- the ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, both genetic and biochemical. See, for example, Fields et al. (1989) Nature 340:245-246; U.S. Patent No. 5,585,245 and International Patent Publication No. WO 98/44350.
- a “vector” is capable of transferring gene sequences to target cells.
- vector construct means any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells.
- vector transfer vector mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells.
- the term includes cloning, and expression vehicles, as well as integrating vectors.
- reporter gene refers to any sequence that produces a protein product that is easily measured, preferably although not necessarily in a routine assay.
- Suitable reporter genes include, but are not limited to, sequences encoding proteins that mediate antibiotic resistance (e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance), sequences encoding colored or fluorescent or luminescent proteins (e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase), and proteins which mediate enhanced cell growth and/or gene amplification (e.g., dihydrofolate reductase).
- antibiotic resistance e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance
- sequences encoding colored or fluorescent or luminescent proteins e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase
- proteins which mediate enhanced cell growth and/or gene amplification e.g., dihydrofolate reduc
- Epitope tags include, for example, one or more copies of FLAG, His, myc, Tap, HA or any detectable amino acid sequence. “Expression tags” include sequences that encode reporters that may be operably linked to a desired gene sequence in order to monitor expression of the gene of interest.
- subject and “patient” are used interchangeably and refer to mammals such as human subjects and non-human primates, as well as experimental animals such as rabbits, dogs, cats, rats, mice, and other animals. Accordingly, the term “subject” or “patient” as used herein means any mammalian subject or patient to which the altered cells of the invention and/or proteins produced by the altered cells of the invention can be administered. In some embodiments, the subject has a confirmed diagnosis of SCD. In some embodiments, the subject has a confirmed diagnosis of severe SCD.
- SCD sickle cell disease
- Hb S hemoglobin S
- Hb SS homozygosity for the sickle mutation
- Hb SC disease compound heterozygosity with another beta globin variant
- severe SCD or “severe sickle cell disease” refers to a sickle cell disease having one or more of the following manifestations consistent with Bone Marrow Transplant Clinical Trial Network (BMT CTN) guidelines: (1) clinically significant neurologic event (stroke) or any neurological deficit lasting >24 hours; (2) history of 2 or more episodes of ACS in the 2-year period preceding informed consent despite adequate supportive care measures (i.e.
- BMT CTN Bone Marrow Transplant Clinical Trial Network
- asthma therapy (3) three or more pain crises per year in the 2-year period preceding informed consent (requiring IV pain management in the outpatient or inpatient hospital setting); (4) history of two or more episodes of priapism with subject seeking medical care in the 2-year period preceding informed consent; (5) administration of regular RBC transfusion therapy in the year preceding informed consent, defined as receiving 8 or more transfusions to prevent vaso-occlusive clinical complications (i.e., pain, stroke, or ACS); and/or (6) an echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >2.5 m/s.
- TRJ tricuspid valve regurgitant jet
- the subjects disclosed herein are eligible for treatment for sickle cell disease.
- a subject can be one who is experiencing, has experienced, or is likely to experience, one or more signs, symptoms or other indicators of sickle cell disease; has been diagnosed with sickle cell disease, whether, for example, newly diagnosed, and/or is at risk for developing sickle cell disease.
- One suffering from or at risk for suffering from sickle cell disease may optionally be identified as one who has been screened for abnormally low levels of hemoglobin in their blood or plasma.
- treatment is an approach for obtaining beneficial or desired results including clinical results.
- beneficial or desired clinical results include, but are not limited to, one or more of the following: decreasing one or more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), delay or slowing the progression of the disease, ameliorating the disease state, decreasing the dose of one or more other medications required to treat the disease, and/or increasing the quality of life.
- “delaying” or “slowing” the progression of sickle cell disease means to prevent, defer, hinder, slow, retard, stabilize, and/or postpone development of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated.
- “at the time of starting treatment” refers to the time period at or prior to the first exposure to a sickle cell disease therapeutic composition such as the compositions disclosed herein. In some embodiments, “at the time of starting treatment” is about any of one year, nine months, six months, three months, second months, or one month prior to a sickle cell disease drug. In some embodiments, “at the time of starting treatment” is immediately prior to coincidental with the first exposure to a sickle cell disease therapeutic composition.
- “based upon” includes (1) assessing, determining, or measuring the subject characteristics as described herein (and preferably selecting a subject suitable for receiving treatment; and (2) administering the treatment(s) as described herein.
- a “symptom” of sickle cell disease is any phenomenon or departure from the normal in structure, function, or sensation, experienced by the subject and indicative of sickle cell disease.
- support surgery refers to surgical procedures that may be performed on a subject to alleviate symptoms that may be associated with a disease.
- immunosuppressive agent refers to substances that act to suppress or mask the immune system of the mammal being treated herein. This would include substances that suppress cytokine production, down-regulate or suppress self-antigen expression, or mask the MHC antigens. Examples of such agents include 2-amino-6-aryl-5-substituted pyrimidines (see, U.S. Patent No.
- nonsteroidal anti-inflammatory drugs NSAIDUA
- ganciclovir tacrolimus, glucocorticoids such as cortisol or aldosterone
- anti-inflammatory agents such as a cyclooxygenase inhibitor, a 5 - lipoxygenase inhibitor, or a leukotriene receptor antagonist
- purine antagonists such as azathioprine or mycophenolate mofetil (MMF)
- alkylating agents such as cyclophosphamide; bromocryptine; danazol; dapsone; glutaraldehyde (which masks the MHC antigens, as described in U.S. Patent No.
- anti-idiotypic antibodies for MHC antigens and MHC fragments include cyclosporin A; steroids such as corticosteroids or glucocorticosteroids or glucocorticoid analogs, e.g., prednisone, methylprednisolone, and dexamethasone; dihydrofolate reductase inhibitors such as methotrexate (oral or subcutaneous); hydroxychloroquine; sulfasalazine; leflunomide; cytokine or cytokine receptor antagonists including anti-interferon-alpha, -beta, or -gamma antibodies, anti-tumor necrosis factor-alpha antibodies (infliximab or adalimumab), anti-TNF-alpha immunoahesin (etanercept), anti-tumor necrosis factor-beta antibodies, anti-interleukin-2 antibodies and anti-IL-2 receptor antibodies; anti-idiotypic antibodies
- WO 90/08187 published 7/26/90); streptokinase; TGF-beta; streptodornase; RNA or DNA from the host; FK506; RS-61443; deoxyspergualin; rapamycin; T-cell receptor (Cohen et al., U.S. Patent No. 5,114,721); T-cell receptor fragments (Offner et al. (1991) Science 251 :430-432; International Patent Publication No. WO 90/11294; Janeway (1989) Nature 341 :482; and International Patent Publication No. WO 91/01133); and T cell receptor antibodies such as T10B9.
- Corticosteroid refers to any one of several synthetic or naturally occurring substances with the general chemical structure of steroids that mimic or augment the effects of the naturally occurring corticosteroids.
- synthetic corticosteroids include prednisone, prednisolone (including methylprednisolone), dexamethasone, glucocorticoid and betamethasone.
- Iron chelation is a type of therapy to remove excess iron from the body.
- Each unit of blood given in a transfusion comprises about 250 milligrams of iron, and the body cannot excrete it except in small ( ⁇ 1 mg) amounts that are lost in skin and perspiration.
- Excess iron is trapped in the tissues of vital organs, such as the anterior pituitary, heart, liver, pancreas and joints. When the iron reaches toxic levels, damage can result in diseases such as diabetes, cirrhosis, osteoarthritis, heart attack, and hormone imbalances. Hypothyroidism, hypogonadism, infertility, impotence and sterility can result from these hormone imbalances. If not addressed, excess iron can result in complete organ failure and death. Iron reduction is accomplished with chelation therapy, which is the removal of iron pharmacologically with an iron-chelating agent such as desferrioxamine or deferasirox.
- a “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications, other therapeutic products to be combined with the packaged product, and/or warnings concerning the use of such therapeutic products, etc.
- a “label” is used herein to refer to information customarily included with commercial packages of pharmaceutical formulations including containers such as vials and package inserts, as well as other types of packaging.
- MOLECULAR CLONING A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001 ; Ausubel et a/., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, “Chromatin” (P.M. Wassarman and A. P.
- the subject has received a diagnosis of severe SCD.
- Severe SCD was defined as having 1 or more of the following manifestations consistent with Bone Marrow Transplant Clinical Trial Network (BMT CTN) guidelines: (1) clinically significant neurologic event (stroke) or any neurological deficit lasting >24 hours; (2) history of 2 or more episodes of ACS in the 2-year period preceding informed consent despite adequate supportive care measures (i.e.
- BMT CTN Bone Marrow Transplant Clinical Trial Network
- the subject is required to have adequate physiological function consistent with BMT CNT guidelines to receive the treatments described herein.
- adequate physiological function may be measured by (a) Karnofsky/Lansky Performance Scale score >60; (b) cardiac function - left ventricular ejection fraction (LVEF) >40% or left ventricular shortening fraction >26% by cardiac echocardiogram (ECHO) or by multiple gated acquisition (MLIGA) scan (c) pulmonary function - pulse oximetry with a baseline oxygen (02) saturation of >85% and diffusing capacity for carbon monoxide (DLCO) >50% (corrected for hemoglobin); and (d) hepatic function - alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ⁇ 5* the upper limit of normal as per local laboratory: serum conjugated (direct) bilirubin ⁇ 3* the upper limit of normal for age as per local laboratory.
- LVEF left ventricular ejection fraction
- ECHO cardiac echocardiogram
- MLIGA multiple gated acquisition
- MRI liver magnetic resonance imaging
- LIC liver iron content
- modified autologous HSC/PC that are delivered to a subject with SCD according to the disclosed methods.
- Two mRNAs encoding the right and left ZFN partners are delivered to the harvested HSC/PC which are targeted to the BCL11a erythroid enhancer sequence.
- the mRNAs include SB- mRENHI and SB-mRENH2.
- the CD34+ HSC/PCs are harvested ⁇ e.g., apheresis) after mobilization in the subject by treating the subject with one or more doses of plerixafor prior to isolation and the mobilized cells.
- At least about 25 x 10 6 CD34+ HSPCs/kg are harvested in total or per apheresis cycle and may be cultured for any length of time.
- the resulting genetically modified cells may be cultured and descendants thereof will include the specific BCL11A genetic modification ⁇ e.g., less than 1% of cells having off-target (non-BCL11 A) modifications), but not necessarily the mRNA(s).
- Cells comprising the BCL11A knockout can then be infused into the subjects.
- additional modifications such for example inactivation of HLA genes may be made in the specific BCL11A genetically modified cells.
- the methods described herein disclose genetically modified cells that are hematopoietic stem cells e.g., CD34+ HSC/PC) isolated from the subject, optionally in which the CD34+ HSC/PCs are mobilized ⁇ e.g., at least 25 x 10 6 CD34+ HSPCs/kg) in each subject by treatment with one or more doses of plerixafor prior to isolation and the mobilized cells are harvested by one or more apheresis cycles.
- CD34+ HSC/PC hematopoietic stem cells
- the methods described herein disclose genetically modified cells that are hematopoietic stem cells e.g., CD34+ HSC/PC) isolated from the subject, optionally in which the CD34+ HSC/PCs are mobilized ⁇ e.g., at least 25 x 10 6 CD34+ HSPCs/kg) in each subject by treatment with one or more doses of plerixafor prior to isolation and the mobilized cells are harvested by one or more ap
- Methods of altering expression of hemoglobin include methods that result in a change from baseline of clinical laboratory hemoglobin fractions (adult hemoglobin, HbA and fetal hemoglobin, HbF) in terms of both changes in grams/dL plasma and percent HbF of total Hb in a subject. See, e.g. FIG. 4.
- the methods of treatment described herein result in a change from baseline in the number and percent of F cells.
- F cells are RBCs that contain measurable amounts of HbF. Evaluation of a change in F cells as a result of the treatment methods can be measured by methods known in the art (see e.g., Wood et al. (1975) Blood 46(5):671).
- the number and/or percentage of F cells is increased in a subject treated as described herein, as compared to an untreated subject.
- HbF normally only plays a minor role in normal adult physiology. In patients with SCD, clinical studies demonstrate that mortality and disease severity correlate with HbF levels. See, e.g., Sankaran (2011). Am Soc Hematol Educ Program Book. 2011 :459-465. HbF achieves this disease amelioration by reducing HbS content and disrupting HbS polymer formation within the red cell. The effects of low, elevated, and high HbF levels are depicted in FIG. 1. Elevation of HbF concentration up to 20% is a primary mechanism for the activity of hydroxyurea (HU).
- HU hydroxyurea
- use of the methods of treatment disclosed herein may result in a change of SCD-related disease biomarkers.
- changes in the SCD- related disease biomarkers may include, but are not limited to, changes in iron metabolism and/or changes in levels of erythropoietin, haptoglobin and hepcidin levels.
- the methods of treatment may result in a change in a patient’s symptoms associated with iron overload associated with baseline transfusion therapy. Changes in iron overload symptoms may include a decrease in endocrine dysfunction caused by iron deposition in endocrine organs.
- Endocrine dysfunction may be evaluated by measurement of factors (levels and/or activity) such as, but not limited to, thyroid hormones, IGF-1 , morning cortisol, adrenocorticotropic hormone (ACTH), HbA1C, and/or vitamin D. Determination of all the above factors, including HbA, HbF, erythropoietin, haptoglobin, hepcidin, thyroid hormones, IGF-1 , cortisol, ACTH, and vitamin D may be measured by standard clinical laboratory protocols.
- factors levels and/or activity
- factors such as, but not limited to, thyroid hormones, IGF-1 , morning cortisol, adrenocorticotropic hormone (ACTH), HbA1C, and/or vitamin D. Determination of all the above factors, including HbA, HbF, erythropoietin, haptoglobin, hepcidin, thyroid hormones, IGF-1 , cortisol, ACTH
- kits for treatment that reduce, delay, and/or eliminate additional treatment procedures as compared with a subject that has not been treated with the methods and compositions as disclosed herein, for example wherein an effective amount of modified HSC/PC are administered to a subject in need thereof, wherein the subject has a reduced, delayed, and/or eliminated need for additional treatment procedures after treatment.
- the additional treatment procedures can include, but are not limited to, a bone marrow transplant, PRBC and/or other blood component transfusions, and treatments related to iron chelation therapy.
- the uses and methods of treatment described herein will result in a decrease in the need for (use of) RBC transfusions and infusion of other blood products including, but not limited to, platelets, intravenous immunoglobin (IVIG) , plasma and granulocytes in a subject with sickle cell disease.
- Change in the use of RBC and other blood product infusions in a subject treated with the methods and compositions of the invention can be evaluated by keeping a log of use for the subject. The log can be used to calculate an annualized frequency and volume of packed red blood cells (PRBC) after infusion with the compositions disclosed herein, and compared to the subject’s past PRBC and other blood products usage prior to treatment.
- PRBC packed red blood cells
- disclosed herein is a method of reducing, delaying or eliminating the SCD-related disease biomarkers following treatment with the methods and compositions in a subject with SCD as compared with the subject prior to treatment with the methods and compositions disclosed herein.
- the subject is administered an effective amount of modified HSC/PC such that the subject has reduced, delayed or eliminated SCD-related disease biomarkers after treatment.
- levels of HbF increase by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400% or more (or any value therebetween) following treatment by the methods disclosed herein.
- the effects of the disclosed methods on the subject are realized within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
- a method of reducing, delaying or eliminating the use of PRBC transfusions and infusion of other blood products including, but not limited to, platelets, intravenous immunoglobin (IVIG), plasma and granulocytes following treatment with the methods and compositions in a subject with SCD as compared with a subject that has not been treated with the methods and compositions of the invention.
- the use of PRBC and/or other blood product is decreased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any value therebetween in a subject treated with the methods disclosed herein as compared to the subject prior to receiving treatment.
- the use of PRBC and/or other blood product infusions is eliminated.
- markers of endocrine dysfunction as a result of iron deposition in endocrine organs (for example, thyroid markers, IGF-1 , morning cortisol, HbA1C and Vitamin D) become normalized in a subject after treatment with the methods and compositions of the invention as compared to the marker levels prior to treatment.
- iron overload in the liver and heart is decreased in a subject following treatment with the methods and compositions disclosed herein as compared with the subject prior to treatment. Iron overload can be evaluated by standard MRI procedures.
- iron over load in the liver and/or heart detected by MRI is decreased by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any value therebetween in a subject treated with the methods disclosed herein as compared to the subject prior to receiving treatment.
- ex vivo therapies for SCD are described using the genetically modified cells as described herein.
- the genetically modified cells are autologous cells obtained from the subject to be treated, which cells are then genetically modified as described herein and administered back to the same subject. Cells obtained from the subject may be mobilized using treatment with plerixafor. See, e.g., llchida et al. (2020) Haematologica. 105(10): e497-e501.
- any amount of cells may be mobilized, for example about 5 x 10 5 , about 10 x 10 5 , about 15 x 10 5 , about 20 x 10 5 , about 5 x 10 6 , about 10 x 10 6 , about 15 x 10 6 , about 20 x 10 6 , about 25 x 10 6 CD34+ HSPCs/kg for genetic modification are mobilized in the subject.
- Plerixafor reversibly inhibits binding of stromal cell-derived factor-1-alpha (SDF- 1a), expressed on bone marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4), resulting in mobilization of CD34+ HSPCs from bone marrow into peripheral blood.
- Plerixafor is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
- G-CSF stromal cell-derived factor-1-alpha
- Plerixafor is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
- the use of G-CSF in patients with SCD is contraindicated due to risk of vaso
- mobilized CD34+ HSPCs are collected from each subject one or more days ⁇ e.g., 3, 4, 5, 6, 7 or more days) after mobilization by apheresis, for example on 2 or more consecutive days until sufficient cells are collected. In some embodiments, at least about 1 x 10 4 to 1 x 10 7 e.g., 25 x 10 6 ) CD34+ HSPCs/kg are collected. If needed, a second mobilization and apheresis cycle may be performed 1 , 2, 3, or more weeks after the first cycle. In some embodiments, a portion of collected cells are subject to genetic modification as described herein and the remainder maintained ⁇ e.g., cryopreserved) in the event a rescue treatment for the subject is indicated.
- the modified HSPC are evaluated prior to returning to the subject.
- the modified cells are evaluated for the presence and type of nuclease-induced mutations in the BCL11A enhancer region.
- the mutations can be insertions of nucleotides, deletions of nucleotides or both (“indels”).
- the cells are evaluated for off-target cleavage by the nucleases.
- the cells are evaluated for insertions and/or deletions within BCL11 A (on-target modifications) and/or other non-BCL11A region (off-target modifications).
- the cells are evaluated for molecular translocations and/or karyotyping of the cellular chromosomes following nuclease cleavage. In some embodiments, the cells are evaluated for off-target transcriptional activity. In some embodiments, the cells are evaluated for endotoxin load. In some embodiments, the cells can be evaluated for one or more of the above characteristics.
- the autologous cells are genetically modified as described herein and cryopreserved e.g., using a controlled rate freezer) according to standard techniques with each aliquot ⁇ e.g., infusion bag) having a total cell count of approximately 1.0 x 10 8 to 2.0 x 10 8 cells and can be stored in vapor phase liquid nitrogen (at ⁇ -150°C) at the manufacturing facility until they are ready to be shipped to the site where they will be administered to a subject.
- the ex vivo therapies comprise thawing the frozen genetically modified HSPC and infusing the cells into the subject, preferably within about 15 to about 45 minutes of thawing.
- the volume of frozen modified HSPC administered is determined by the subject’s weight.
- Vital signs blood pressure, temperature, heart rate, respiratory rate and pulse oximetry
- the subjects are monitored using blood tests as well as analysis of HbF levels (baseline levels of HbF fractions (A and F in g/dL) and percent HbF is determined based on the last assessment on or prior to the date of first administration of IV busulfan), endocrine function, and/or performing MRIs to assess iron load.
- the ex vivo therapies result in neutrophil and platelet recovery to within normal levels in the subject in about two to four weeks of infusion.
- Subjects may also receive PRBC transfusions 0, 1 , or more times following HSPC infusion.
- total hemoglobin levels in the subject remain stable or continue to rise by week 2, 3, 4, 5, 6, 7, or more after infusion with the modified HSPC.
- the subject can receive conditioning therapy prior to ex vivo therapy with genetically modified cells, for example, via intravenous (IV) administration of one or more myeloablative condition agents prior to infusion with the modified CD34+ HSC/PC.
- the myeloablative condition agent is busulfan.
- the busulfan is used with other agents such as cyclophosphamide.
- Busulfan can be administered using known effective doses and regimens. According to standard procedures, for example, busulfan is dosed at between about 0.5 to 5 mg/kg (or any value therebetween).
- subjects will receive a myeloablative regimen of busulfan (about 3.2 mg/kg/day; IV via central venous catheter) for up to 4 days (total dose of about 12.8 mg/kg prior to infusion), for example on Days -6 through -3 before infusion of the modified HSPC on Day 0.
- IV busulfan may be dosed once daily (total of 4 doses) or every 6 hours (total of 16 doses) according to study center practices or guidelines.
- the IV busulfan dose can be adjusted based on pharmacokinetic sampling and study center practices to target an area under the curve (AUG) of 4,000-5,000 mmol*min for daily dosing or an AUG of 1 ,000-1 ,250 mmol*min for every 6 hour dosing for a total regimen target AUG of 16,000-20,000 mmol*min.
- IV busulfan pharmacokinetic targeting may be modified for subsequent subjects.
- therapeutic drug monitoring is conducted to determine clearance of busulfan after 4 days of dosing is complete.
- any dose of genetically modified cells can be used, for example, between 3 x 10 6 cells/kg and 20 x 10 6 cells/kg e.g., where the cells are formulated with approximately 1 .0- 2.0 x 10 8 cells per bag at a concentration of approximately 1 x 10 7 cells/mL). In some embodiments, a dose of about 3 x 10 6 cells/kg to about 20 x 10 6 cells/kg (or any value therebetween) of the genetically modified cells is administered ⁇ e.g., via intravenous infusion) to the subject. In some embodiments, the cells are formulated in infusible cryomedia containing 10% DMSO.
- the cells are formulated with approximately 1.0- 2.0 x 10 8 cells per bag at a concentration of approximately 1 x 10 7 cells/mL.
- the dose of genetically modified cells administered to the subject is between about 3.2 x 10 6 cells/kg and 9.7 x 10 6 cells/kg. In some embodiments, the dose of genetically modified cells administered to the subject is about 5.17 x 10 6 cells/kg. In some embodiments, the dose of cells administered to the subject is between about 3.2 x 10 6 cells/kg and 9.7 x 10 6 cells/kg. In some embodiments, the dose of cells administered to the subject is about 5.17 x 10 6 cells/kg.
- the subject has delayed, reduced or eliminated need, for example, for additional therapeutic procedures after receiving a total dose of between about 3.0 x 10 6 to about 20 x 10 6 cells/kg.
- the subject has delayed, reduced or eliminated need, for example, for additional therapeutic procedures after receiving a total dose of between 3.2 x 10 6 cells/kg and 9.7 x 10 6 cells/kg. In some embodiments, the subject has delayed, reduced or eliminated need, for example, for additional therapeutic procedures after receiving a total dose of about 5.17 x 10 6 cells/kg.
- the methods and compositions disclosed herein comprise dosing of a composition of the invention (for example, the modified HSC/PC), for example, via a peripheral vein catheter.
- the composition is administered to the subject which is then followed by administration of normal saline (NS) or phosphate buffered saline (PBS).
- NS normal saline
- PBS phosphate buffered saline
- the modified HSPC may be monitored in the patient to determine engraftment efficiency and/or modification heterogenicity. This can be done, for example, by determining the genetic modification (“indel”) profile.
- Cell samples may be purified from the peripheral blood, bone marrow aspirate or other tissue samples (preferably about 5 x 10 4 to 1 x 10 7 cells) and subject to genomic DNA isolation for assessment. Bone marrow aspirate or other tissue samples may be taken at various timepoints, including at between about 6-9 months.
- the indel profile is monitored over time to determine the likelihood of any one particular cell type (indel profile) aberrantly overgrowing the population.
- the cells and subject are monitored before and/or after administration, for example to determine the indel profile of cells isolated from peripheral blood samples, bone marrow aspirates, or other tissue sources in comparison with the indel profile of the infused cells to in order to monitor stability of the graft in the subject.
- genomic DNA from cells isolated from a treated subject is isolated and the region comprising the BCL11A target sequence is amplified.
- the percent modified cells within the cell population is determined and re-tested over time post dosing to evaluate stability of the modified cell population with the treated subject.
- the methods may further comprise monitoring the subject’s vital signs prior to, during and/or after administration of the genetically modified cells; and/or assessing hemoglobin, neutrophil and/or platelet levels in the subject prior to administration of the genetically modified cells to determine baseline levels of hemoglobin in the subject.
- hemoglobin, neutrophil and/or platelet levels in the subject after administration of the genetically modified cells increase or remain stable as compared to baseline levels for weeks or months after administration.
- the subject may receive one or more PRBC transfusions prior to and/or after administration of the genetically modified cells.
- the need for additional therapies such as a bone marrow transplant, blood component, iron chelation, and/or therapy PRBC transfusions in the subject are reduced or eliminated.
- the need for additional therapies in the subject is reduced or eliminated within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
- the subject has a confirmed diagnosis of sickle cell disease (SCD). In some embodiments, the subject has a confirmed diagnosis of severe SCD.
- SCD sickle cell disease
- the subjects with SCD that are treated may exhibit one or more of the following: (1) a change from baseline of clinical laboratory hemoglobin fractions (adult hemoglobin, HbA and fetal hemoglobin, HbF) in grams/dL plasma and/or percent HbF of total Hb; (2) alteration (e.g., to or near normal levels) of SCD-related disease biomarkers such biomarkers of iron metabolism; and/or levels of erythropoietin, haptoglobin and/or hepcidin; (3) reduction or elimination of symptoms in the subject associated with iron overload associated with baseline transfusion therapy; (4) reduction or elimination of the need for blood product infusions, including PRBC transfusions, platelet infusions, I VIG, plasma transfusion and/or granulocyte transfusion; and/or (5) a change from baseline (pre-treatment levels) in the number and percent of F cells.
- a change from baseline of clinical laboratory hemoglobin fractions adult hemoglobin, HbA and fetal hemoglobin, Hb
- provided herein is a method of improving or maintaining (slowing the decline) of SCD-related disease biomarkers in a human subject having sickle cell disease as compared with a subject that has not been treated with the methods and compositions of the invention.
- a subject with SCD is assessed for improvement in SCD.
- the improvement in SCD is assessed by the decrease, amelioration, or elimination of one or more clinical symptoms of SCD.
- the subject with SCD is assessed using a health-related quality of life (HRQoL) survey.
- the subject with SCD is assessed using the Patient-Reported Outcomes Measurement Information System 57 (PROMIS-57).
- PROMIS-57 is a collection of 8-item short forms assessing physical and mental well-being in patients with SCD. Exemplary PROMIS measures include pain impact, pain behavior, physical functioning, anxiety, depression, fatigue, satisfaction with discretionary social activities, satisfaction with social roles, sleep disturbance, and sleep-related impairment.
- a subject with SCD can be assessed using the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me).
- ASCQ-Me Adult Sickle Cell Quality of Life Measurement System
- a subject with SCD can be assessed using the Karnofsky Performance Scale. This is a simple, widely-accepted tool for evaluating functional impairment in patients. Each subject will be evaluated and scored at the specified visit using the Karnofsky Performance Status Scale Definitions Rating Criteria. See, e.g., Canver & Orkin (2016). Blood. 127(21):2536-2545.
- compositions comprising one or more mRNAs encoding one or more zinc finger proteins (ZFNs) that cleave an endogenous BCL11A sequence e.g., an endogenous BCL11A enhancer sequence).
- the one or more mRNAs comprise SB-mRENH1 mRNAs and/or SB-mRENH2 mRNAs (SEQ ID NO:15 and SEQ ID NO:16, respectively). See U.S. Patent No. 10,563,184; U.S. Patent Publication No. 2018/0087072.
- pharmaceutical compositions comprising one or more of the same or different mRNAs, including compositions comprising SB-mRENH1 and SB-mRENH2 mRNAs.
- the target sites for the ZFNs disclosed herein are within a BCL11A gene. See, e.g., U.S. Patent Nos. 10,563,184; 9,963,715; 9,650,648; U.S. Patent Publication Nos. 2015/0132269; 2018/0111975; and 2019/0177709.
- BCL11A is a transcription factor that is active in both neurological development and hematopoiesis. Genome-wide association and functional follow-up studies in cell and animal models have shown that BCL11A is an important silencer of HbF expression. In a seminal study involving a humanized mouse model of SCD, genetically engineered BCL11 A disruption in erythroid cells led to an absence of hemoglobin switching, maintenance of high levels of HbF, and improvements in hematologic and pathologic characteristics of SCD. (Xu et al. (2011) Science 334(6058): 993-6).
- genetically modified cells ⁇ e.g., red blood cell (RBC) precursor cell such as a CD34+ hematopoietic stem cell or erythroid precursor cell) comprising a genetic modification within an endogenous BCL11A enhancer sequence, such that the BCL11 A gene is inactivated in the cell.
- cell populations comprising these genetically modified cells; genetically modified cells descended from therefrom; cell populations comprising the genetically modified cells and cells descended therefrom; and compositions comprising the genetically modified cells and/or cells descended therefrom.
- the cells, cell populations, and compositions described herein may be autologous (from the subject) and/or allogeneic cells.
- the genetically modified cells may include one or more additional genetic modifications, including but not limited to cells in which one or more selfmarkers or antigens are inactivated (knocked-out).
- the methods disclosed herein comprise a knock out of the BCL11A enhancer sequence in a cell to block the expression of the BCL11A protein.
- the methods and compositions of the invention also can be used in any circumstance wherein it is desired to knock out the BCL11A erythroid enhancer in a hematopoietic stem cell such that mature cells (e.g., RBCs) derived from these cells contain the therapeutic knockout.
- stem cells can be differentiated in vitro or in vivo and may be derived from a universal donor type of cell which can be used for all subjects. Additionally, the cells may contain a transmembrane protein to traffic the cells in the body.
- Treatment can also comprise use of subject cells containing the therapeutic transgene where the cells are developed ex vivo and then introduced back into the subject.
- subject cells containing the therapeutic transgene where the cells are developed ex vivo and then introduced back into the subject.
- HSC/PC containing a BCL11A erythroid enhancer knockout may be inserted into a subject via an autologous bone marrow transplant.
- a ZFN pair comprising first and second (left and right) ZFNs, namely a 6-finger ZFN comprising a ZFP designated 63014 comprising the recognition helix regions as shown in Table 1 (e.g., encoded by mRNA SB-mRENH1) and a 5-finger ZFN comprising a ZFP designated 65722 comprising the recognition helix regions as shown in Table 1 (e.g., encoded by mRNA SB-mRENH2) is used for altering hemoglobin levels in an isolated cell or cell of a subject.
- the ZFN pair binds to a 33-base pair (combined) target site in the erythroid- specific enhancer of the human BCL11A gene at location chr2:60, 495, 250-60, 495, 290 in the GRCh38/hg38 assembly of the human genome.
- one mRNA encodes both ZFNs of the pair.
- separate mRNAs, each encoding one ZFN of the pair are employed.
- the mRNA sequences are SEQ ID NO:15 and SEQ ID NO:16.
- the ZFN useful in the compositions and methods disclosed herein ⁇ e.g., a ZFN in which the members of the ZFN pair (left and right) ZFNs are delivered by two separate mRNAs) include mRNAs designated SB-mRENH1 and SB-mRENH2.
- the ZFNs in the BCL11A-specific pair are delivered (e.g., to the HSC/PC) via electroporation, for example, wherein one AAV comprises the left ZFN (e.g., SB-mRENH1) and another comprises the right ZFN (e.g., SB-mRENH2).
- the cells are removed from the subject (autologous) and treated with nucleases that target a gene involved in the regulation of fetal hemoglobin (HbF) production.
- the gene is a repressor of HbF production.
- the gene is the BCL11A gene.
- the nucleases target and cleave the erythroid-specific enhancer region of the BCL11A gene.
- the nucleases are delivered to the cells as mRNAs.
- the cleavage of the erythroid-specific enhancer region results in error-prone repair of the cleavage site by the cellular repair machinery such that a binding site for the erythroid transcription factor GATA1 (see Vierstra et al. (2015) Nat Methods 12(10):927-30; Canver et al. (2015) Nature 527(7577): 192-7) is disrupted.
- the nucleases target the erythroid-specific enhancer region of the BCL11A gene such that it is not expressed in hematopoietic stem cells.
- Enhancer regions targeted may be within or outside the coding region including but not limited to +58, +55 and/or +62 regions within intron 2 of endogenous BCL11A, numbered in accordance with the distance in kilobases from the transcription start site of BCL11A, which enhancer regions are roughly 350 (+55); 550 (+58); and 350 (+62) nucleotides in length. See, e.g., Bauer et al. (2013) Science 343:253-257; U.S. Patent Nos. 9,963,715; 10,072,066; and U.S. Patent Publication Nos. 2015/0132269 and 2018/0362926.
- the cells (populations of cells and compositions comprising these cells and populations of cells) described herein are specifically genetically modified by the mRNA(s) at the BCL11A locus, including genetically modified cell populations (and compositions comprising these cells) in which less than 10% (0 to 10% of any value therebetween), preferably less than 5% (0 to 5% or any value therebetween), even more preferably less than 1 % of the cells (0 to 1% or any value therebetween) and even more preferably less than 0.5% (0 to 1 % or any value therebetween) of the genetically modified cells include genetic modifications made by the mRNA(s) outside the BCL11A locus (but may include additional modifications such as inactivation of HLA markers).
- the nuclease is encoded by an mRNA and the mRNA optionally comprises elements for increasing transcriptional and translational efficiency.
- composition comprising genetically modified cells specifically modified at the BCL11 A locus by the mRNA(s) as described herein, including in which less than 10% (0 to 10% or any value therebetween), preferably less than 5% (0 to 5% or any value therebetween), even more preferably less than 1% of the cells (0 to 1% or any value therebetween) and even more preferably less than 0.5% (0 to 1% or any value therebetween) of the genetically modified cells include genetic modifications made by the mRNA(s) outside the BCL11A locus (but may include additional modifications such as inactivation of HLA markers).
- the polynucleotides encoding the zinc finger nuclease may comprise a left ZFN known as SB63014 (see, U.S. Patent No. 10,563,184 and U.S. Patent Publication No. 2018/0087072), encoded by a mRNA SB-mRENH1 .
- the right ZFN is SB65722 (see, U.S. Patent No. 10,563,184 and U.S. Patent Publication No. 2018/0087072), encoded by a mRNA SB-mRENH2.
- the left and right (first and second) ZFNs of the ZFN are carried on the same vector and in other embodiments, the paired components of the ZFN are carried on different vectors.
- two mRNAs vectors one designated SB-mRENH1 mRNA (an mRNA encoding the ZFN comprising the ZFP designated 63014) and the other designated SB-mRENH2 mRNA (an mRNA encoding the ZFN comprising the ZFP designated 65722).
- the nuclease comprises a zinc finger nuclease (ZFN). It will be appreciated that this is for purposes of exemplification only and that other nucleases or nuclease systems can be used, for instance homing endonucleases (meganucleases) with engineered DNA-binding domains and/or fusions of naturally occurring of engineered homing endonucleases (meganucleases) DNA-binding domains and heterologous cleavage domains and/or a CRISPR/Cas system comprising an engineered single guide RNA.
- ZFN zinc finger nuclease
- host cells including isolated hematopoietic stem cells (HSPC such as CD34+), comprising the ZFNs and/or polynucleotides ⁇ e.g., mRNAs) as described herein.
- HSPC hematopoietic stem cells
- Cells may be isolated from healthy subjects or, alternatively, are autologous cells obtained from a subject with the condition to be treated ⁇ e.g., SCD) and purified using standard techniques.
- the ZFNs genetically modify the cells via insertions and/or deletions following cleavage.
- expanded (cultured) cells may no longer include the ZFNs (or polynucleotides encoding these ZFNs) but maintain the genetic modifications in culture e.g., insertions and/or deletions within BCL11a).
- Genetically modified cells as described herein exhibit different ratios of globin (a-, p- and y-globin levels) as compared to untreated (non-genetically modified) cells. In some embodiments, the ratio of y-globin to - globin and of y-globin to a-globin is increased about 2 to 5 or more-fold, including 3 to 4-fold as compared to untreated (untransfected) HSPCs.
- the genetically modified cells described herein differentiate into all hematopoietic lineages, including erythroid progenitors (CFLI-E and BFLI-E), granulocyte/macrophage progenitors (CFU-G/M/GM), and multipotential progenitors (CFU-GEMM) and exhibit normal karyotypes and morphology, which is indicative of a reconstitution of hematopoiesis.
- erythroid progenitors CFLI-E and BFLI-E
- CFU-G/M/GM granulocyte/macrophage progenitors
- CFU-GEMM multipotential progenitors
- HSC/PC comprising a targeted knockout of the BCL11 A erythroid enhancer.
- the knockout is created by treating harvested HSC/PC with mRNAs encoding the right and left ZFN partners which when translated, will result in an active ZFN.
- the ZFN cleaves the BCL11A erythroid enhancer such that a double strand break in the DNA occurs.
- the cellular machinery repairs the double strand break using error-prone non-homologous end joining (NHEJ) which results in the insertion and deletion of nucleotides (indels) around the cleavage site.
- NHEJ error-prone non-homologous end joining
- Both autologous ⁇ e.g., subject-derived) and allogenic (healthy donor derived) HSC/PC can be used in the performance of the method.
- the cells as described herein are useful in cell therapy for treating and/or preventing sickle cell disease in a subject with the disorder.
- modified stem cells after infusion into the subject, in vivo differentiation of these precursors into cells expressing the functional protein (from the inserted donor) also occurs.
- compositions comprising the cells as described herein are also provided.
- the cells may be cryopreserved prior to administration to a subject.
- the cell populations (and compositions) described herein comprise genetically modified cells specifically at the BCL11A locus, including genetically modified cell populations in which less than 10% (0 to 10% of any value therebetween), preferably less than 5% (0 to 5% or any value therebetween), even more preferably less than 1% of the cells (0 to 1% or any value therebetween) and even more preferably less than 0.5% (0 to 1% or any value therebetween) of the cells include genetic modifications outside the BCL11A locus (but may include additional modifications such as inactivation of HLA markers).
- the genetically modified cells may be stem cells (e.g., CD34+ HSC/PC, ST-400) and may be autologous or allogeneic (e.g., isolated from healthy donors) and the allogeneic cells may be further modified (e.g., in addition to BCL11A inactivation), for example to remove one or more self-antigens e.g., HLA complexes) to from the allogeneic cells.
- stem cells e.g., CD34+ HSC/PC, ST-400
- allogeneic cells may be further modified (e.g., in addition to BCL11A inactivation), for example to remove one or more self-antigens e.g., HLA complexes) to from the allogeneic cells.
- allogeneic cells may be further modified (e.g., in addition to BCL11A inactivation), for example to remove one or more self-antigens e.g., HLA complexes) to from the allogeneic cells.
- Autologous cells may be mobilized in the subject prior to modification ex vivo by treating the subject with one or more doses of plerixafor and the mobilized cells are harvested by one or more apheresis cycles.
- at least about 25 x 10 6 CD34+ HSPCs/kg are mobilized in the subject.
- the cells may be genetically modified to inactivate BCL11A using one or more nucleases, for example wherein the nucleases are introduced into the cell as mRNAs as disclosed herein (SEQ ID NO:15 and SEQ ID NO:16). Following ex vivo genetic modification, the cells may be evaluated for insertions and/or deletions within BCL11A.
- Isolated cells and isolated populations of cells comprising one or more mRNAs and/or one or more pharmaceutical compositions comprising these mRNAs are also provided. Also described are compositions comprising genetically modified cells and cells descended therefrom, including, but not limited to, progeny of the genetically modified cells.
- the genetically modified progeny cells may be obtained by in vitro methods (culture of the genetically modified cells) and/or in vivo following administration of the genetically modified cells to a subject.
- the genetically modified progeny cells may include fully or partially differentiated progeny descended from the genetically modified cells.
- the genetically modified cell compositions comprise genetically modified hematopoietic stem cells (also referred to as hematopoietic progenitor stem cells (HPSC) or hematopoietic stem cell/precursor cells (HSC/PC)) and/or genetically modified cells descended or produced (cultured) therefrom, including genetically modified cells in which the BCL11A sequence is cleaved and hemoglobin ⁇ e.g., HbF and/or HbA) levels in the cells are increased e.g., 3 to 4- fold or more) as compared to cells which are not genetically modified.
- HPSC hematopoietic progenitor stem cells
- HSC/PC hematopoietic stem cell/precursor cells
- the genetically modified cells of the cell populations and compositions of cells described herein may comprise one or more mRNAs and/or pharmaceutical compositions comprising these mRNAs.
- described herein are cells, cell populations and compositions comprising these cells, which cells, cell populations and compositions comprise genetically modified cells comprising the mRNAs described herein and cells descended therefrom.
- the cells, cell populations and compositions comprising these cells and cell populations may comprise autologous and/or allogeneic cells.
- compositions comprising genetically modified cells ⁇ e.g., erythroid progenitor cells such as HPSCs that exhibit increased globin expression as compared to unmodified cells) as described herein are also provided.
- genetically modified cells e.g., erythroid progenitor cells such as HPSCs that exhibit increased globin expression as compared to unmodified cells
- Methods of manufacturing (making) genetically modified isolated cells are also provided, including methods of making genetically modified populations of cells in which a BCL11 A sequence (e.g., enhancer sequence) is genetically modified such that hemoglobin ⁇ e.g., HbF and/or HbA) levels in the genetically modified cells are increased as compared to unmodified cells e.g., 2 or more fold).
- a BCL11 A sequence e.g., enhancer sequence
- the methods comprising administering one or more mRNAs (or pharmaceutical compositions comprising the one or more mRNAs) as described herein to the cell e.g., via transfection).
- the cells may be autologous and/or allogeneic and may be HSPCs.
- the methods further comprise culturing the genetically modified cells to produce a composition comprising a population of genetically modified cells ⁇ e.g., HPSC cells) and/or genetically modified cells descended therefrom ⁇ e.g., other erythroid progenitor cells and/or mature erythroid cells such as RBCs) exhibiting increased globin production.
- the compositions may comprise genetically modified cells comprising the mRNAs and/or genetically modified cells descended from such cells that no longer comprise the mRNAs but maintain the genetic modification (BCL11A- specific modifications).
- compositions comprising genetically modified cell populations and/or cells descended therefrom are also provided.
- the methods and compositions disclosed herein relate to treating a subject with cells that have been modified ex vivo.
- the cells are isolated from the subject, modified ex vivo, and then returned to the subject.
- the cells are isolated from healthy donors, modified ex vivo, and then used to treat the subject.
- the cells isolated from healthy donors are further modified ex vivo to remove self-markers ⁇ e.g., HLA complexes) to avoid rejection of the cells by the subject.
- the cells isolated are stem cells.
- the stem cells are hematopoietic stem cell/progenitor cells ⁇ e.g., CD34+ HSC/PC).
- the CD34+ HSC/PC are mobilized in each subject by treatment with one or more doses of plerixafor.
- the dose of plerixafor used is about 240 pg/kg/day.
- the mobilized cells are harvested by one or more apheresis cycles.
- Mobilized human CD34+ HSPCs may be collected by apheresis from healthy or SCD subjects and purified prior to administration of (transfection with) one or more mRNAs (or pharmaceutical compositions comprising the one or more mRNAs) as described herein.
- the purified HSPCs are transfected with ZFN mRNAs SBmRENHI (SEQ ID NO:15) and SBmRENH2 (SEQ ID NO:16) to manufacture SAR445136.
- Transfected genetically modified CD34+ HSPCs may be cultured, harvested and/or frozen for use.
- compositions comprising genetically modified cells (at least 50%, preferably at least 70% or more, even more preferably at least 75-80% or more of the cells are genetically modified following mRNA administration, preferably specifically modified at the BCL11A enhancer sequence as compared to other genetic loci) as described herein may include HSPCs as well as cells descended therefrom, for instance HSPC differentiated into all hematopoietic lineages, including erythroid progenitors (CFLI-E and BFLI-E), granulocyte/macrophage progenitors (CFU-G/M/GM), and multi-potential progenitors (CFU-GEMM).
- some, none or all of the genetically modified cells of the composition (population) of cells comprise one or more of mRNAs.
- an article of manufacture comprising a package (for example, a bag) comprising compositions comprising genetically modified autologous HSC/PC as described herein.
- the article of manufacture ⁇ e.g., bag) may be formulated for frozen storage, for example in CryoStor® CS-10 cryomedia (SigmaAldrich) containing 10% DMSO.
- Each bag can contain any concentration of cells. In some embodiments, each bag contains approximately 1 .0 - 2.0 x 10 8 cells per bag at a concentration of approximately 1 x 10 7 cells/mL.
- compositions comprising (1) BCL11A gene ESE-modified CD34+ HSPC at 10 x 10 6 cells/mL; and (2) 1 mL of cryopreservation buffer containing 10% dimethyl sulfoxide (DMSO).
- the cryopreservation buffer is CryoStor® CS10.
- the composition is SAR445136.
- nucleases The ex vivo delivery of nucleases, polynucleotides encoding these nucleases, donor polynucleotides and compositions comprising the proteins and/or polynucleotides described herein may be delivered to the harvested HSC/PC by any suitable means.
- Nucleases and/or donor constructs as described herein may also be delivered using vectors containing sequences encoding one or more of the zinc finger, TAL-effector domain and/or Cas protein(s).
- Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno-associated virus vectors, etc. See, also, U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, incorporated by reference herein in their entireties.
- Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
- Methods of non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipidmucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.
- nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus Therapeutics Inc, (see for example U.S. Patent No. 6,008,336).
- Lipofection is described in e.g., U.S. Patent Nos. 5,049,386; 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM).
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, International Patent Publication Nos. WO 91/17424, WO 91/16024.
- lipidmucleic acid complexes including targeted liposomes such as immunolipid complexes
- crystal (1995) Science 270:404-410 Blaese et al. (1995) Cancer Gene Ther. 2:291-297; Behr et al. (1994) Bioconjugate Chem. 5:382-389; Remy et al. (1994) Bioconjugate Chem. 5:647-654; Gao et al. (1995) Gene Therapy 2:710-722; Ahmad et al. (1992) Cancer Res. 52:4817-4820; U.S. Patent Nos. 4,186,183; 4,217,344; 4,235,871; 4,261 ,975; 4,485,054; 4,501,728; 4,774,085; 4,837,028; and 4,946,787).
- Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGenelC delivery vehicles (EDVs). These EDVs are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see, MacDiarmid et al. (2009) Nature Biotechnology 27(7):643).
- EDVs EnGenelC delivery vehicles
- RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered ZFPs take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus.
- Viral vectors can be used to treat cells in vitro and the modified cells are administered to subjects (ex vivo).
- Conventional viral based systems for the delivery of ZFPs include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated, vaccinia and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been measured in many different cell types and target tissues.
- rAAV Recombinant adeno-associated virus vectors
- All vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system.
- AAV serotypes including by non-limiting example, AAV1 , AAV3, AAV4, AAV5, AAV6, AAV8, AAV 8.2, AAV9 and AAV rh10 and pseudotyped AAV such as AAV2/8, AAV2/5 and AAV2/6 can also be used in accordance with the present invention.
- AAV serotypes that are capable of crossing the blood brain barrier are used.
- Ad Replication-deficient recombinant adenoviral vectors
- Ad can be produced at high titer and readily infect a number of different cell types.
- Most adenovirus vectors are engineered such that a transgene replaces the Ad E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans.
- Ad vectors can transduce multiple types of tissues in vivo, including nondividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity.
- Ad vector An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for anti-tumor immunization with intramuscular injection (Sterman et al. (1998) Hum. Gene Ther. 7:1083-9). Additional examples of the use of adenovirus vectors for gene transfer in clinical trials include Rosenecker et al. (1996) Infection 24(1):5-10; Sterman et al. (1998) Hum. Gene Ther. 9(7): 1083-1089; Welsh et al. (1995) Hum. Gene Ther. 2:205-18; Alvarez et al. (1997) Hum. Gene Ther. 5:597-613; Topf et al. (1998) Gene Ther. 5:507-513; Sterman et al. (1998) Hum. Gene Ther. 7:1083-1089.
- Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and i 2 cells or PA317 cells, which package retrovirus.
- Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The missing viral functions are supplied in trans by the packaging cell line.
- AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome.
- ITR inverted terminal repeat
- Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
- the cell line is also infected with adenovirus as a helper.
- the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
- the helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g. , heat treatment to which adenovirus is more sensitive than AAV.
- compositions comprising genetically modified cells as described herein may be delivered to a subject in any suitable manner, including by infusion.
- the subject Prior to administration of composition comprising the genetically modified cells, the subject may be treated with (administered) one or more myeloablative condition agents one or more times, for example, busulfan administered: intravenously (IV) at between about 0.5 to 5 mg/kg for one or more times; IV at about 3.2 mg/kg/day; IV via central venous catheter for 4 days total dose of about 12.8 mg/kg prior to infusion on Days -6 through -3 before infusion of the composition comprising the genetically modified cells on Day 0; or IV once daily or every 6 hours.
- IV intravenously
- any dose of genetically modified cells can be used, for example, between about 3 x 10 6 cells/kg and about 20 x 10 6 cells/kg (e.g., where the cells are formulated with approximately 1.0- 2. O x 10 8 cells per bag at a concentration of approximately 1 x 10 7 cells/mL).
- Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions available, as described below (see, e.g., Remington’s Pharmaceutical Sciences, 17th ed., 1989).
- Formulations for both ex vivo and in vivo administrations include suspensions in liquid or emulsified liquids.
- the active ingredients often are mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient.
- Suitable excipients include, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof.
- the composition may contain minor amounts of auxiliary substances, such as, wetting or emulsifying agents, pH buffering agents, stabilizing agents or other reagents that enhance the effectiveness of the pharmaceutical composition.
- the ZFN pair is made up of a 6-finger ZFN (encoded by mRNA SB-mRENH1) and a 5-finger ZFN (encoded by mRNA SB-mRENH2) that binds to a 33 base pair (combined) target site in the erythroid-specific enhancer of the human BCL11A gene at location chr2:60, 495, 250-60, 495, 290 in the GRCh38/hg38 assembly of the human genome.
- the preparation of the ZFN and polynucleotides encoding them is as follows: The SB- mRENHIand SB-mRENH2 mRNAs are produced in vitro by methods known in the art.
- the mRNAs comprise sequences encoding the ZFN partners, and also comprise features such as nuclear localization sequences and peptides.
- Table 1 shows the helices associated with each partner ZFN (see U.S. Patent No. 10,563,184; U.S. Patent Publication No. 2018/0087072):
- Example 2 Clinical study of zinc finger nuclease-modified autologous CD34+ hematopoietic stem/progenitor cells for sickle cell disease
- HSPCs modified hematopoietic stem/progenitor cells
- SCD sickle cell disease
- Sickle cell disease is an inherited condition caused by pathologic variants in both alleles of the p-globin gene, affecting approximately 100,000 patients in the US. Strouse J. (2016) Handbook Clin Neurol. 138:311-24. Elevated fetal hemoglobin (HbF) levels have been shown to ameliorate symptoms and improve survival in SCD patients. Hebert N, et al. (2020). Am J Hematol. 95:1235-1245.
- SAR445136 is a novel therapeutic product which is composed of a patient’s own
- HSPC autologous hematopoietic stem/progenitor cells
- the target for gene editing is an erythroid-specific enhancer (ESE) in the BCL11A gene. Mutations at the ESE locus down-regulate BCL11A expression specifically in erythroid precursors, resulting in elevated levels of HbF synthesis. Following myeloablation of the patient’s bone marrow, the genetically modified HSPC are returned to the donor to repopulate the hematopoietic lineages including erythrocytes.
- ESE erythroid-specific enhancer
- Newly synthesized RBCs derived from the edited SAR445136 stem cell population may have an HbF level that is protective against the pathophysiologic changes underlying SCD.
- the primary objective of the study is to evaluate the safety and tolerability of SAR445136 in subjects with severe SCD.
- the primary safety and tolerability endpoints are as follows: (1) Survival at post-transplantation Day 100, Week 52, and Week 104 (Last Study Visit); (2) Successful engraftment as defined in the protocol; and (3) occurrence of adverse events (AEs) and serious adverse events (SAEs).
- AEs adverse events
- SAEs serious adverse events
- the secondary objectives of the study are to evaluate the success and kinetics of SAR445136 stem cell collection, manufacturing, and engraftment and SAR445136 efficacy.
- the endpoints related to the success and kinetics of SAR445136 stem cell collection, manufacturing, and engraftment are as follows: (1) CD34+ HSPC yield from plerixafor stem cell mobilization; (2) proportion of subjects who achieve sufficient stem cell mobilization for rescue aliquot and SAR445136 production; (3) yield of ZFN-edited CD34+ HSPC (investigational product); (4) time to initial neutrophil recovery following SAR445136 infusion (first of 3 consecutive days with an absolute neutrophil count [ANC] >500/pL); (5) time to platelet recovery following SAR445136 infusion (first of 3 consecutive measurements with a platelet count >50,000/pL at least 1 week [7 days] following last platelet transfusion); (6) maintenance of ANC >500/pL and platelet count >50,000/pL to last patient visit;
- the endpoints related to efficacy include change from baseline in blood markers, including peripheral blood HbF, %F cells, and HbS; peripheral blood total Hb concentration; and markers of hemolysis including reticulocyte count, lactate dehydrogenase (LDH), haptoglobin, and serum bilirubin.
- Other efficacy endpoints include change from baseline in clinical assessments, including frequency and severity of SCD-related clinical events (e.g., VOC, pain episodes, etc.); quality of life (QoL) measures including fatigue; and RBC transfusion requirements, such as annualized number and total volume.
- Exploratory objectives of the study relate to changes in clinical parameters, features of the edited cell product, and biomarkers of disease.
- the exploratory endpoints may include the following: (1) changes from pretransplant baseline in clinical laboratory tests, physical examination, and vital sign parameters (2); assessment of on-target BCL11A gene modification in drug product and its correlation with HbF response (3) assessment of on-target BCL11A gene modification in peripheral blood white blood cell (WBC) populations and bone marrow erythroid progenitors from SAR445136 transplantation through the last study visit (4) assessment of off-target editing profile that may include karyotyping in SAR445136 retains and post-infusion peripheral blood and bone marrow samples up to the last study visit; (5) assessment of subject DNA sequence variation that may be associated with study safety or efficacy outcomes; and/or (6) changes from baseline through last study visit in SCD-related hematologic disease biomarkers in blood cells, plasma, or serum; end-organ function/imaging, including but not limited to central nervous system (CNS
- Diagnosis and inclusion criteria for the study included eight adult subjects with a diagnosis of severe SCD, 18 to 40 years of age at screening, who were willing and able to undergo autologous HSPC transplantation.
- the male and female participating subjects were between the ages of 18 and 40 years old, inclusive, at the time of informed consent with clinical diagnosis of SCD and confirmed molecular genetic diagnosis of an HbSS or HbSp 0 genotype.
- Subjects completed age appropriate cancer screening, used double- barrier method of contraception through the entire study period, and consented to receive blood transfusions.
- Severe SCD was defined as having 1 or more of the following manifestations consistent with Bone Marrow T ransplant Clinical T rial Network (BMT CTN) guidelines: (1) clinically significant neurologic event (stroke) or any neurological deficit lasting >24 hours; (2) history of 2 or more episodes of ACS in the 2-year period preceding informed consent despite adequate supportive care measures (i.e.
- BMT CTN Bone Marrow T ransplant Clinical T rial Network
- asthma therapy (3) three or more pain crises per year in the 2-year period preceding informed consent (requiring IV pain management in the outpatient or inpatient hospital setting); (4) history of two or more episodes of priapism with subject seeking medical care in the 2-year period preceding informed consent; (5) administration of regular RBC transfusion therapy in the year preceding informed consent, defined as receiving 8 or more transfusions to prevent vaso-occlusive clinical complications (i.e., pain, stroke, or ACS); and/or (6) an echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >2.5 m/s.
- TRJ tricuspid valve regurgitant jet
- MRI liver magnetic resonance imaging
- LIC liver iron content
- subject must have either a liver magnetic resonance imaging (MRI) with a liver iron content (LIC) ⁇ 10 mg/g dry weight, or a liver biopsy demonstrating absence of bridging fibrosis, liver cirrhosis, and active hepatitis in order to participate (results of liver biopsies obtained within the past 12 months are allowed).
- Subjects with hyperbilirubinemia as a consequence of hyperhemolysis or who experienced a sudden, profound change in the serum hemoglobin after an RBC transfusion were not excluded.
- the key exclusion criteria for subjects in the study were as follows: previous receipt of an autologous or allogeneic HSCT or solid organ transplantation; previous treatment with gene therapy; current enrollment in an interventional study or having received an investigational drug within 30 days of study enrollment; pregnant or breastfeeding female; female or male who plans to become pregnant or impregnate a partner, respectively, during the anticipated study period; known to have a y-globin allelic variant associated with clinically significant altered oxygen affinity; a diagnosis of hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration >20% at screening; medical contraindication to use plerixafor, apheresis, or busulfan; ANC ⁇ 1000 cells/pL; platelet count ⁇ 100,000 cells/pL known history of platelet alloimmunization precluding ability to provide transfusion support, extensive RBC alloimmunization precluding ability to provide transfusion support; treatment with prohibited medications in the previous 30 days (e.g., prohibited
- the key subject withdrawal criteria were as follows: request by the subject to withdrawal; request of the Investigator and/or Sponsor if she/he thinks the study is no longer in the best interest of the subject; pregnancy of subject prior to IV busulfan infusion; subject judged by the Investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results; subject’s drug product does not fulfill release criteria or is otherwise determined to be unsuitable to administer to the subject (e.g., due to manufacturer/shipping problems); and/or withdrawal request at the discretion of the institutional review board (IRB), Office of Human Research, regulatory authority (e.g., FDA), Investigator, and/or the Sponsor.
- IRB institutional review board
- a subject withdrew consent or discontinued from the study post-study treatment a conference between the Investigator and the Medical Monitor took place to ensure and document that the subject understood the importance of the study follow-up and that the study treatment could not be revised even if the subject dropped out of the study follow-up. If the subject agreed, a reduced follow-up testing schedule may have been arranged including telephone calls and clinical laboratory tests to assess AEs and clinical status for up to 104 weeks after infusion. Subjects continued to be followed for overall survival unless consent to do so was withdrawn.
- IV intravenous
- HRQoL Health-related quality of life was assessed via the PROMIS-57 survey at four timepoints (screening, Week 26, Week 52, early termination visit).
- the apheresis procedure required a temporary central IV catheter after one or more rounds of plerixafor administration.
- the minimum yield to secure sufficient stem cells for both the manufacturing of the investigational product and the rescue aliquot is approximately 10.0 x 10 6 CD34+ HSPC/kg.
- a yield of 20 x 10 6 CD34+ HSPC/kg may be required to achieve the target SAR445136 dose of 10 x 10 6 CD34+ HSPC/kg.
- Lower yields from a single apheresis cycle were acceptable but may trigger additional rounds of mobilization/apheresis.
- the timing of subsequent apheresis was at the discretion of the Investigator based on the subject’s clinical status.
- the time from stem cell harvest to edited stem cell infusion (SAR445136) was approximately 20 weeks.
- An aliquot of unmanipulated cells from the apheresis was also collected and stored at the site if needed to secure a rescue treatment.
- the rescue aliquot portion comprised a minimum of 1.5 x 10 6 CD34+ HSPC/kg.
- the remaining CD34+ HSPC were transfected ex vivo with ZFN mRNAs targeting the BCL11A locus to manufacture the investigational product SAR445136.
- the rescue aliquot was cryopreserved unmodified and stored at the study site for back-up infusion if the subject did not demonstrate evidence for engraftment by Day 42 post-SAR445136 infusion or developed subsequent graft failure with aplasia.
- the rescue treatment may have been administered at any time after SAR445136 infusion at the discretion of the investigator.
- the modified HSPC were cryopreserved in 50 mL CryoMACS® freezing bags (fill volume of approximately 10 to 20 mL; total cell count of approximately 1.0 x 10 8 to 2.0 x 10 8 cells) using a controlled rate freezer. Multiple freezing bags were used if cell yield exceeds the capacity of a single bag. Infusion bags were stored in vapor phase liquid nitrogen (at ⁇ -150 oC ; with temperature monitoring) at the manufacturing facility until they were ready to be shipped to the clinical study center.
- SAR445136 components include (1) BCL11A gene ESE-modified CD34+ HSPC at 10 x 10 6 cells/mL, and (2) 1 mL of cryopreservation buffer (CryoStor® CS10) containing 10% dimethyl sulfoxide (DMSO).
- cryoStor® CS10 cryopreservation buffer
- the subjects proceeded with IV busulfan conditioning in a dedicated transplant unit for approximately 4 to 7 days total.
- Subjects received a myeloablative regimen of busulfan (3.2 mg/kg/day; IV via central venous catheter) for 4 days (total dose of 12.8 mg/kg, which is considered standard-of-care for autologous transplantation) on Days -6 through -3 before infusion of SAR445136 on Day 1 (72 hour rest period prior to infusion).
- the IV busulfan dose was adjusted based on pharmacokinetic (PK) sampling and study center practices to target an area under the curve (AUC) of 4,000-5,000 pmol*min for daily dosing.
- PK pharmacokinetic
- PK samples taken and analyzed after the first IV busulfan dose may have been used to adjust the third IV busulfan dose
- PK samples taken after the second IV busulfan dose may have been used to adjust the fourth IV busulfan dose.
- Seizure prophylaxis was required starting prior to and continuing at least 24 hours after the final dose of IV busulfan conditioning and iron-chelating agents were discontinued 2 weeks prior to IV busulfan.
- Modified HSPC infusion After myeloablative conditioning with intravenous busulfan, patients received the thawed CD34+ HSPCs (SAR445136) product by central venous catheter infusion. The frozen modified HSPC were thawed and infused, such that the thawing of the infusion bags would take approximately 2-5 mins/bag and the cells were within 40 minutes (from start of thaw to completion of infusion). The volume of frozen modified HSPC was determined by the subject’s weight. Vital signs (blood pressure, temperature, heart rate, respiratory rate and pulse oximetry) were monitored prior to infusion and afterwards.
- An Adverse Event is any untoward medical occurrence in a subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
- An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Determination of whether an abnormal laboratory value, vital sign result, and/or ECG result meet the definition of an AE was made by the Investigator.
- Abnormal results are not considered AEs unless 1 or more of the following criteria are met: (1) the result meets the criteria for an SAE (2) the result requires the subject to receive specific corrective therapy or (3) the result is considered by the Investigator to be clinically significant.
- Myeloablation is intended through the use of the pretransplant conditioning regimen (busulfan at the full, myeloablative dose) and required for treatment efficacy.
- hematologic abnormalities that are a direct consequence of the conditioning regimen are not considered AEs in this study and need not be reported as such unless the abnormality is of unanticipated severity or duration. Complications that are associated with these hematologic abnormalities (i.e. , fever, infection, and bleeding) must be reported as AEs.
- a Serious Adverse Event is any AE that results in any of the following outcomes: death, life-threatening threatening event (j.e., an event that places the subject at immediate risk of death); however, this does not include an event that, had it occurred in a more severe form, might have caused death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect in the offspring of an exposed subject, or a medically important event.
- life-threatening threatening event j.e., an event that places the subject at immediate risk of death
- this does not include an event that, had it occurred in a more severe form, might have caused death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect in the offspring of an exposed subject, or a medically important event.
- Pre-apheresis peripheral blood WBC ranged from 23.2 to 36.9 x 10 3 /pL (mean: 28.7 x 10 3 /pL) and percent CD34+ was 0.09% to 0.36 % (mean: 0.22%) with absolute CD34+ counts of 20 to 80 pL (mean: 60 pL).
- Four of the mobilized subjects were successfully infused with SAR445136 at a single dose ranging from 3.2 to 9.7 x 10 6 CD34+ HSPC/kg (mean: 5.17 x 10 6 CD34+ HSPC/kg). All 4 subjects engrafted with a median time to platelet and neutrophil recovery of 24.5 and 21 .5 days, respectively. No rescue doses were required.
- the percent HbF levels were 1 % to 11% at screening, and increased to a range of 15% to 29% by Week 13 in all 4 subjects.
- the percent HbF levels increased to a range of 14% to 39% by Week 26 in all four subjects with at least 26 weeks follow up, and persisted at 35% in 1 subject at 65 weeks follow up (FIG. 4).
- the percent HbF level was 38% in one subject at 91 weeks.
- Percent F cells increased to a range of 48% to 94% in all four subjects with at least 26 weeks follow up, and persisted at 99% in 1 subject with 91 weeks follow up. The fourth subject had 94% F cells at 26 weeks follow up. (FIG. 5).
- SAR445136 has the potential to induce hematologic changes in a subject and could provide a level of protection against the clinical sequelae of SCD.
- Table B Schedule of Events: Screening, Stem Cell Mobilization, Apheresis, and Conditioning
- Any scheduled vaccinations (e.g., influenza) were completed at least 30 days prior to the conditioning phase.
- Plerixafor dosing, timing, or route of administration may have been modified or discontinued at the discretion of the Investigator based on the clinical status of the subject or if the WBC exceeds 100,000/pL.
- the stem cell mobilization procedure may have been repeated.
- the timing of repeat apheresis cycles were at the discretion of the Investigator based on the subject’s clinical status.
- Seizure prophylaxis was required starting prior to and continuing at least 24 hours after the final dose of IV busulfan conditioning. Iron- chelating agents were discontinued 2 weeks prior to busulfan administration and may be restarted after successful SAR445136 engraftment or at the discretion of the Investigator. Concomitant acetaminophen or metronidazole was avoided.
- AE adverse event
- DXA dual-energy x-ray absorptiometry
- HbF fetal hemoglobin
- HSPC hematopoietic stem and progenitor cells
- MUGA multiple gated acquisition
- PBL peripheral blood lymphocytes
- PBMC peripheral blood mononuclear cells
- PFT pulmonary function test
- PROMIS-57 patient-reported outcomes measurement information system 57
- SAE serious adverse event
- SCD slowle cell disease
- Wk week
- Unscheduled bone marrow aspiration may also be conducted at any time if clinically indicated, e.g., to evaluate the potential development of hematological malignancy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed herein are ex vivo methods and compositions for treating sickle cell disease.
Description
METHODS FOR THE TREATMENT OF SICKLE CELL DISEASE
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Patent Application No. 63/228,988, filed August 3, 2021 , and No. 63/280,482, filed November 17, 2021 . The disclosures of both priority applications are incorporated by reference herein in their entirety.
BACKGROUND
[0002] Sickle cell disease (SCD) is a genetic hematologic disorder affecting an estimated 70,000 to 100,000 individuals in the United States. SCD is caused by a mutation in the p- globin gene (Glu6Val) that results in the abnormal hemoglobin, sickle hemoglobin (HbS). When inherited on both alleles, the sickle mutation produces the homozygous genotype HbSS. This genotype, occurring in >70% of cases worldwide, gives rise to the most severe form of the disease. Saraf et a/. (2014) Paediatr Respir Rev. 15(1):4-12. The sickle mutation can also be inherited in trans with an allele specifying a dysfunctional p-globin (genotype HbS-p[+]- thalassemia), an absent p-globin (genotype HbS-p°-thalassemia), or a different p-globin point mutation, such as hemoglobin C (leading to HbSC disease). HbS-p°-thalassemia is clinically indistinguishable from genotype HbSS, while the other 2 genotypes are generally less severe in phenotype.
[0003] For the majority of patients with SCD, treatment focuses on supportive care, pain management, and the surgical or medical management of end organ damage. Hydoxyurea (HU) treatment reduces the likelihood of patient pain crisis that requires hospitalization and prevents acute chest syndrome (ACS). Recently, two compounds have been approved in the US for preventing vaso-occlusive crisis (VOC) and to mitigate anemia . Transfusion therapy is used in SCD in the context of some acute complications, such as stroke, ACS, splenic sequestration, or aplastic crisis, or chronically for severe anemia, stroke, and pain crisis prevention. Despite its benefits, use of chronic red blood cell (RBC) transfusion leads to iron overload in the heart and liver (and the need for chelation therapy) and increases the risks of alloimmunization, autoantibody formation, and blood-borne infection.
[0004] The only curative therapy currently available for SCD is a hematopoietic stem cell transplant (HSCT) from an immunologically matched donor. However, only about 20% of SCD patients are estimated to have a matched donor available. Hsieh et al. (2011). Blood. 118(5): 1197-1207. There remains a need for compositions and methods for treating and/or preventing SCD.
SUMMARY OF THE DISCLOSURE
[0005] From the description herein, it will be appreciated that that the present disclosure encompasses multiple aspects and embodiments which include, but are not limited to, the following:
[0006] In one aspect, disclosed herein is an ex vivo method of treating sickle cell disease (SCD) in a subject, the method comprising: administering to the subject in need thereof a composition comprising a genetically modified cell comprising a red blood cell (RBC) precursor cell, wherein the precursor cell comprises SB-mRENH1 mRNAs and SB-mRENH2 mRNAs, which encode a ZFN pair; and a genomic modification made following cleavage by the ZFN pair, wherein the modification is within an endogenous BCL11A enhancer sequence. In some embodiments, the composition further comprises a cell descended from the genetically modified cell comprising the SB-mRENH1 mRNAs and the SB-mRENH2 mRNAs.
[0007] In some embodiments of the methods disclosed herein, the sickle cell disease is severe sickle cell disease. In some embodiments of the methods disclosed herein, the subject has adequate physiological function by BMT CNT guidelines prior to administering of the composition.
[0008] In some embodiments of the methods disclosed herein, the fetal hemoglobin (HbF) production in the subject (i.e. with SCD) is increased after administration of the disclosed composition comprising the genetically modified cells. In some embodiments of the methods disclosed herein, one or more clinical symptoms of sickle cell disease in the subject are decreased, ameliorated, or eliminated. In some embodiments of the methods disclosed herein, one of the clinical symptoms in the subject that is decreased, ameliorated, or eliminated is vaso-occlusive crisis (VOC). In some embodiments of the methods disclosed herein, a change from baseline of clinical laboratory hemoglobin fractions in grams/dL plasma and/or percent HbF of total hemoglobin (Hb) is achieved in the subject. In some embodiments, the effect of the composition on the subject is realized within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
[0009] In some embodiments of the methods disclosed herein, the levels of SCD-related disease biomarkers in the subject are altered following treatment. In some embodiments, the SCD-related disease biomarkers are changes in iron metabolism and/or changes in levels of erythropoietin, haptoglobin, and/or hepcidin.
[0010] In some embodiments of the methods disclosed herein, the clinical symptoms associated with iron overload or associated with baseline transfusion therapy in the subject are ameliorated or eliminated in the subject.
[0011] In some embodiments of the methods disclosed herein, the need for RBC transfusions and infusion platelet transfusion, intravenous immunoglobin (IVIG) transfusion, plasma transfusion and/or granulocyte transfusion in the subject is reduced or eliminated.
[0012] In some embodiments of the methods disclosed herein, the number and/or percent of F cells in the subject is modified following administration of the composition comprising the genetically modified cells.
[0013] In some embodiments of the methods disclosed herein, the genetically modified cell(s) are autologous or allogeneic. In some embodiments, the BCL11 A-genetically modified cells further comprise one or more additional genetic modifications.
In some embodiments of the methods disclosed herein, the genetically modified cells are hematopoietic stem cells isolated from the subject. In some embodiments, the hematopoietic stem cells are CD34+ hematopoietic stem or precursor cells (HSC/PC). In some embodiments, the CD34+ HSC/PC are mobilized in the subject by treatment with one or more doses of plerixafor. In some embodiments, at least 25 x 106 CD34+ HSPCs/kg are mobilized in the subject. In some embodiments, the mobilized cells are harvested by one or more apheresis cycles.
[0014] In some embodiments of the methods disclosed herein, the methods further comprise administering one or more myeloablative condition agents to the subject prior to administration of the composition comprising the genetically modified cells. In some embodiments, the myeloablative agent comprises busulfan.
[0015] In some embodiments of the methods disclosed herein, the dose of genetically modified cells administered to the subject is between 3 x 106 cells/kg and 20 x 106 cells/kg. In some embodiments of the methods disclosed herein, the dose of cells administered to the subject is between 3 x 106 cells/kg and 20 x 106 cells/kg. In some embodiments of the methods disclosed herein, the dose of genetically modified cells administered to the subject is about 3.2 x 106 cells/kg and about 9.7 x 106 cells/kg. In some embodiments of the methods disclosed herein, the dose of genetically modified cells administered to the subject is about 5.17 x 106 cells/kg.
[0016] In some embodiments of the methods disclosed herein, the genetically modified cells administered to the subject are formulated with approximately 1.0-2.0 x 108 cells per bag at a concentration of approximately 1 x 107 cells/mL.
[0017] In some embodiments of the methods disclosed herein, the genetically modified cells are cryopreserved prior to administration to the subject.
[0018] In some embodiments, the methods disclosed herein further comprise monitoring the subject’s vital signs prior to, during and/or after administration of the genetically modified cells. In some embodiments, the methods further comprise assessing hemoglobin, neutrophil
and/or platelet levels in the subject prior to administration of the genetically modified cells to determine baseline levels of hemoglobin in the subject.
[0019] In some embodiments of the methods disclosed herein, the hemoglobin, neutrophil and/or platelet levels in the subject after administration of the genetically modified cells increase as compared to baseline levels for weeks or months after administration. In some embodiments, the hemoglobin, neutrophil and/or platelet levels in the subject remain stable as compared to baseline levels for weeks or months after administration.
[0020] In some embodiments, the methods disclosed herein further comprise assessing the subject using a health-related quality of life (HRQoL) survey. In some embodiments, the methods disclosed herein further comprise assessing the subject using the Patient-Reported Outcomes Measurement Information System 57 (PROMIS-57). In some embodiments, the methods disclosed herein further comprise assessing the subject using the Karnofsky Performance Scale.
[0021] In some embodiments of the methods disclosed herein, the subject receives one or more packed red blood cell (PRBC) transfusions prior to and/or after administration of the genetically modified cells.
[0022] In some embodiments of the methods disclosed herein, the need for additional therapies such as a bone marrow transplant, blood component and/or iron chelation therapy PRBC transfusions in the subject is reduced or eliminated. In some embodiments, the need for additional therapies is reduced or eliminated within 1-20 days of administration of the genetically modified cells. In some embodiments, the need for additional therapies in the subject is reduced or eliminated within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
[0023] In another aspect, disclosed herein is a pharmaceutical composition comprising a genetically modified cell comprising a red blood cell (RBC) precursor cell, wherein the precursor cell comprises SB-mRENH1 mRNAs and SB-mRENH2 mRNAs, which encode a ZFN pair; and a genomic modification made following cleavage by the ZFN pair, wherein the modification is within an endogenous BCL11A enhancer sequence, and wherein the composition is formulated in cryopreservation buffer. In some embodiments, the cryopreservation buffer is CryoStor® CS-10 cryomedia.
[0024] These and other aspects will be readily apparent to the skilled artisan in light of disclosure as a whole.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] FIG. 1 is an illustration (adapted from Hardison & Blobel (2013) Science 342(6155):206-7) of effects of low, elevated and high fetal hemoglobin levels on subjects
comprising adult hemoglobin mutations (for example sickle cell disease). Shown on the far left (“low fetal hemoglobin:”) is a subject with a mutation in adult hemoglobin and wild-type ESE BCL11A, in this case the subject has normal (low) levels of fetal hemoglobin, resulting in disease symptoms in the subject. In the middle (“elevated fetal hemoglobin”), the subject has the adult hemoglobin mutation, but also has mutations in their BCL11A gene such that BCL11A expression is decreased but not eliminated, which results in elevated fetal globin levels. The subject experiences some disease amelioration due to the fetal globin “replacing” some adult globin functioning. In the far right (“high fetal hemoglobin), the subject has the adult globin mutation but has a deletion in the BCL11 A enhancer, such that the subject exhibits full expression of fetal globin. This subject will experience even greater in symptom improvement by virtue of full BCL11A inactivation.
[0026] FIG. 2 is a schematic depicting a treatment protocol using genetically modified HSPC (also referred to as SAR445136). “HSPC” refers to hematopoietic stem progenitor cells; “IV” refers to intravenous; “RBC” refers to red blood cells; and “ZFN” refers to zinc finger nuclease.
[0027] FIG. 3 is a schematic depicting the design of the clinical study. For a detailed schedule of events (SOE), see Tables 3 and 4.
[0028] FIG. 4 is a graph showing total Hb and Hb fractionation in four subjects after SAR445136 infusion. “HbA” refers to adult hemoglobin; “HbA2” refers to variant adult hemoglobin; “HbF” refers to fetal hemoglobin; and “HbS” refers to sickle hemoglobin.
[0029] FIG. 5 is a graph showing percentage of F cells over time for treated subjects. Further data remaining to be collected is noted by an asterisk (*).
[0030] FIG. 6 is a graph depicting HbF/F cell levels above the threshold range for preventing HbS polymerization for all four treated subjects. HbF: fetal hemoglobin. Further data remaining to be collected is noted by an asterisk (*).
[0031] FIG. 7 is a graphical depiction of the number of severe vaso-occlusive crises (VOCs) reported pre- and post-SAR445136 infusion in all four subjects.
DETAILED DESCRIPTION
[0032] Disclosed herein are methods for treating and/or preventing sickle cell disease events in a subject in need thereof. The present disclosure provides methods and compositions for genome editing and/or gene transfer. The present disclosure also provides methods and compositions for cell therapy for the treatment of subjects lacking sufficient expression of beta globin. In some embodiments, the methods and compositions disclosed herein are used to treat a subject with SCD comprising administering cells that have been modified using engineered nucleases to the subject.
[0033] Also disclosed herein is SAR445136, which is a novel therapeutic product consisting of autologous CD34+ HSPCs that have been modified ex vivo by zinc finger nucleases (ZFN), targeting the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous production of HbF.
Definitions
[0034] As used herein, the term “approximately” or “about” as applied to one or more values of interest refers to a value that is similar to a stated reference value. In some embodiments, the term refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context.
[0035] The phrase “and/or” as used in the present disclosure will be understood to mean any one of the recited members individually or a combination of any two or more thereof - for example, “A, B, and/or C” would mean “A, B, C, A and B, A and C, B and C, or the combination of A, B, and C.”
[0036] The terms “nucleic acid,” “polynucleotide,” and “oligonucleotide” are used interchangeably and refer to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form. For the purposes of the present disclosure, these terms are not to be construed as limiting with respect to the length of a polymer. The terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones). In general, an analogue of a particular nucleotide has the same base-pairing specificity; /.e., an analogue of A will base-pair with T.
[0037] The terms “polypeptide,” “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.
[0038] “Binding” refers to a sequence-specific, non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a binding interaction need be sequence-specific (e.g., contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation constant (Kd) of 10-6 M-1 or lower. “Affinity” refers to the strength of binding: increased binding affinity being correlated with a lower Kd.
[0039] A “binding protein” is a protein that is able to bind non-covalently to another molecule. A binding protein can bind to, for example, a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein-
binding protein). In the case of a protein-binding protein, it can bind to itself (to form homodimers, homotrimers, etc.) and/or it can bind to one or more molecules of a different protein or proteins. A binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein-binding activity.
[0040] A “zinc finger DNA binding protein” (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion. The term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP. The term “zinc finger nuclease” includes one ZFN as well as a pair of ZFNs (the members of the pair are referred to as “left and right” or “first and second” or “pair”) that dimerize to cleave the target gene.
[0041] A “TALE DNA binding domain” or “TALE” is a polypeptide comprising one or more TALE repeat domains/units. The repeat domains are involved in binding of the TALE to its cognate target DNA sequence. A single “repeat unit” (also referred to as a “repeat”) is typically 33-35 amino acids in length and exhibits at least some sequence homology with other TALE repeat sequences within a naturally occurring TALE protein. See, e.g., U.S. Patent Nos. 8,586,526 and 9,458,205. The term “TALEN” includes one TALEN as well as a pair of TALENs (the members of the pair are referred to as “left and right” or “first and second” or “pair”) that dimerize to cleave the target gene. Zinc finger and TALE binding domains can be “engineered” to bind to a predetermined nucleotide sequence, for example via engineering (altering one or more amino acids) of the recognition helix region of a naturally occurring zinc finger or TALE protein. Therefore, engineered DNA binding proteins (zinc fingers or TALEs) are proteins that are non-naturally occurring. Non-limiting examples of methods for engineering DNA-binding proteins are design and selection. A designed DNA binding protein is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP and/or TALE designs and binding data. See, for example, U.S. Patent Nos. 8,568,526; 6,140,081 ; 6,453,242; and 6,534,261 ; see also International Patent Publication Nos. WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536; and WO 03/016496.
[0042] A “selected” zinc finger protein or TALE is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See e.g., U.S. Patent Nos. 8,586,526; 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,200,759; and International Patent Publication Nos. WO 95/19431 ; WO 96/06166; WO 98/53057; WO 98/54311 ; WO 00/27878; WO 01/60970; WO 01/88197 and WO 02/099084.
[0043] “Recombination” refers to a process of exchange of genetic information between two polynucleotides. For the purposes of this disclosure, “homologous recombination (HR)” refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a “donor” molecule to template repair of a “target” molecule (/.e., the one that experienced the double-strand break), and is variously known as “non-crossover gene conversion” or “short tract gene conversion,” because it leads to the transfer of genetic information from the donor to the target. Without wishing to be bound by any particular theory, such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or “synthesis-dependent strand annealing,” in which the donor is used to re-synthesize genetic information that will become part of the target, and/or related processes. Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.
[0044] In the methods of the disclosure, one or more targeted nucleases as described herein create a double-stranded break in the target sequence {e.g., cellular chromatin) at a predetermined site, and a “donor” polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell. The presence of the double-stranded break has been shown to facilitate integration of the donor sequence. The donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin. Thus, a first sequence in cellular chromatin can be altered and, in some embodiments, can be converted into a sequence present in a donor polynucleotide. Thus, the use of the terms “replace” or “replacement” can be understood to represent replacement of one nucleotide sequence by another, (/.e., replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.
[0045] In any of the methods described herein, additional pairs of zinc-finger or TALEN proteins can be used for additional double-stranded cleavage of additional target sites within the cell.
[0046] In some embodiments of methods for targeted recombination and/or replacement and/or alteration of a sequence in a region of interest in cellular chromatin, a chromosomal sequence is altered by homologous recombination with an exogenous “donor” nucleotide sequence. Such homologous recombination is stimulated by the presence of a doublestranded break in cellular chromatin, if sequences homologous to the region of the break are present.
[0047] In any of the methods described herein, the first nucleotide sequence (the “donor sequence”) can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest. Thus, in some embodiments, portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced. In other embodiments, the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs. In certain cases, a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest. In these instances, the non-homologous sequence is generally flanked by sequences of 50-1 ,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1 ,000, that are homologous or identical to sequences in the region of interest. In other embodiments, the donor sequence is non-homologous to the first sequence and is inserted into the genome by non-homologous recombination mechanisms.
[0048] Any of the methods described herein can be used for partial or complete inactivation of one or more target sequences in a cell by targeted integration of donor sequence that disrupts expression of the gene(s) of interest. Cell lines with partially or completely inactivated genes are also provided.
[0049] Furthermore, the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences. The exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA molecules, or any type of coding or non-coding sequence, as well as one or more control elements (e.g., promoters). In addition, the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).
[0050] “Cleavage” refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and doublestranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In some embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.
[0051] A “cleavage half-domain” is a polypeptide sequence which, in conjunction with a second polypeptide (either identical or different) forms a complex having cleavage activity (preferably double-strand cleavage activity). The terms “first and second cleavage half-
domains;” “+ and - cleavage half-domains” and “right and left cleavage half-domains” are used interchangeably to refer to pairs of cleavage half-domains that dimerize.
[0052] An “engineered cleavage half-domain” is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half-domain (e.g., another engineered cleavage half-domain). See, U.S. Patent Nos. 7,888,121 ; 7,914,796; 8,034,598; and 8,823,618, incorporated herein by reference in their entireties.
[0053] The term “sequence” refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded. The term “donor sequence” refers to a nucleotide sequence that is inserted into a genome. A donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 1 ,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.
[0054] A “disease associated gene” is one that is defective in some manner in a monogenic disease. Non-limiting examples of monogenic diseases include severe combined immunodeficiency, cystic fibrosis, lysosomal storage diseases (e.g., Gaucher’s, Hurler’s Hunter’s, Fabry’s, Neimann-Pick, Tay-Sach’s, etc.), sickle cell anemia, and thalassemia.
[0055] A “chromosome” is a chromatin complex comprising all or a portion of the genome of a cell. The genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell. The genome of a cell can comprise one or more chromosomes.
[0056] An “episome” is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell. Examples of episomes include plasmids and certain viral genomes.
[0057] A “target site” or “target sequence” is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.
[0058] An “exogenous” molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. “Normal presence in the cell” is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell. An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally- functioning endogenous molecule.
[0059] An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules. Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.
[0060] An exogenous molecule can be the same type of molecule as an endogenous molecule, e.g., an exogenous protein or nucleic acid. For example, an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell. Methods for the introduction of exogenous molecules into cells are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (/.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE- dextran-mediated transfer and viral vector-mediated transfer. An exogenous molecule can also be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from. For example, a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster.
[0061] By contrast, an “endogenous” molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions. For example, an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally-occurring episomal nucleic acid. Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.
[0062] A “fusion” molecule is a molecule in which two or more subunit molecules are linked, preferably covalently. The subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules. Examples of fusion molecules include, but are not limited to, fusion proteins (for example, a fusion between a protein DNA- binding domain and a cleavage domain), fusions between a polynucleotide DNA-binding domain (e.g., sgRNA) operatively associated with a cleavage domain, and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein).
[0063] Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.
[0064] A “gene,” for the purposes of the present disclosure, includes a DNA region encoding a gene product (see infra), as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
[0065] “Gene expression” refers to the conversion of the information, contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of an mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.
[0066] “Modulation” of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing {e.g., cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP or TALEN as described herein. Thus, gene inactivation may be partial or complete.
[0067] A “region of interest” is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination. A region of interest can be present in a chromosome, an episome, an organellar genome (e.g., mitochondrial, chloroplast), or an infecting viral genome, for example. A region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region. A region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.
[0068] “Eukaryotic” cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., stem cells, or precursor cells). The term “stem cells” or “precursor cells” refer to pluripotent and multipotent stem cells, including but not limited to hematopoietic stem cells, which are also referred to as hematopoietic progenitor stem cells (HPSC) or hematopoietic stem cell/precursor cells (HSC/PC).
[0069] “Red Blood Cells” (RBCs) or erythrocytes are terminally differentiated cells derived from hematopoietic stem cells. They lack a nuclease and most cellular organelles. RBCs contain hemoglobin to carry oxygen from the lungs to the peripheral tissues. In fact, 33% of an individual RBC is hemoglobin. They also carry CO2 produced by cells during metabolism out of the tissues and back to the lungs for release during exhale. RBCs are produced in the bone marrow in response to blood hypoxia which is mediated by release of erythropoietin (EPO) by the kidney. EPO causes an increase in the number of proerythroblasts and shortens the time required for full RBC maturation. After approximately 120 days, since the RBC do not contain a nucleus or any other regenerative capabilities, the cells are removed from circulation by either the phagocytic activities of macrophages in the liver, spleen and lymph nodes (-90%) or by hemolysis in the plasma (-10%). Following macrophage engulfment, chemical components of the RBC are broken down within vacuoles of the macrophages due to the action of lysosomal enzymes.
[0070] The terms “operative linkage” and “operatively linked” (or “operably linked”) are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. By way of illustration, a transcriptional regulatory sequence, such as a promoter, is operatively linked to a coding sequence if the transcriptional regulatory sequence controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors. A transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it. For example, an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.
[0071] With respect to fusion polypeptides, the term “operatively linked” can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked. For example, with respect to a fusion polypeptide in which a ZFP or TALE DNA-binding domain is fused to an activation domain, the ZFP or TALE DNA- binding domain and the activation domain are in operative linkage if, in the fusion polypeptide, the ZFP or TALE DNA-binding domain portion is able to bind its target site and/or its binding
site, while the activation domain is able to up-regulate gene expression. When a fusion polypeptide in which a ZFP or TALE DNA-binding domain is fused to a cleavage domain, the ZFP or TALE DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFP or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
[0072] A “functional” protein, polypeptide or nucleic acid includes any protein, polypeptide or nucleic acid that provides the same function as the wild-type protein, polypeptide or nucleic acid. A “functional fragment” of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid. A functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions. Methods for determining the function of a nucleic acid (e.g., coding function, ability to hybridize to another nucleic acid) are well-known in the art. Similarly, methods for determining protein function are well-known. For example, the DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See, Ausubel et al., supra. The ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, both genetic and biochemical. See, for example, Fields et al. (1989) Nature 340:245-246; U.S. Patent No. 5,585,245 and International Patent Publication No. WO 98/44350.
[0073] A “vector” is capable of transferring gene sequences to target cells. Typically, “vector construct,” “expression vector,” and “gene transfer vector,” mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression vehicles, as well as integrating vectors.
[0074] A “reporter gene” or “reporter sequence” refers to any sequence that produces a protein product that is easily measured, preferably although not necessarily in a routine assay. Suitable reporter genes include, but are not limited to, sequences encoding proteins that mediate antibiotic resistance (e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance), sequences encoding colored or fluorescent or luminescent proteins (e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase), and proteins which mediate enhanced cell growth and/or gene amplification (e.g., dihydrofolate reductase). Epitope tags include, for example, one or more copies of FLAG, His, myc, Tap, HA or any detectable amino acid sequence. “Expression tags”
include sequences that encode reporters that may be operably linked to a desired gene sequence in order to monitor expression of the gene of interest.
[0075] The terms “subject” and “patient” are used interchangeably and refer to mammals such as human subjects and non-human primates, as well as experimental animals such as rabbits, dogs, cats, rats, mice, and other animals. Accordingly, the term “subject” or “patient” as used herein means any mammalian subject or patient to which the altered cells of the invention and/or proteins produced by the altered cells of the invention can be administered. In some embodiments, the subject has a confirmed diagnosis of SCD. In some embodiments, the subject has a confirmed diagnosis of severe SCD.
[0076] As used herein, “SCD” or “sickle cell disease” refers to a disease characterized by the presence of hemoglobin S (Hb S), either from homozygosity for the sickle mutation (Hb SS) or compound heterozygosity with another beta globin variant (eg, sickle-beta thalassemia, Hb SC disease). The hallmarks of SCD include vaso-occlusive phenomena and hemolytic anemia.
[0077] As used herein “severe SCD” or “severe sickle cell disease” refers to a sickle cell disease having one or more of the following manifestations consistent with Bone Marrow Transplant Clinical Trial Network (BMT CTN) guidelines: (1) clinically significant neurologic event (stroke) or any neurological deficit lasting >24 hours; (2) history of 2 or more episodes of ACS in the 2-year period preceding informed consent despite adequate supportive care measures (i.e. , asthma therapy); (3) three or more pain crises per year in the 2-year period preceding informed consent (requiring IV pain management in the outpatient or inpatient hospital setting); (4) history of two or more episodes of priapism with subject seeking medical care in the 2-year period preceding informed consent; (5) administration of regular RBC transfusion therapy in the year preceding informed consent, defined as receiving 8 or more transfusions to prevent vaso-occlusive clinical complications (i.e., pain, stroke, or ACS); and/or (6) an echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >2.5 m/s.
[0078] In some embodiments, the subjects disclosed herein are eligible for treatment for sickle cell disease. For the purposes herein, such a subject can be one who is experiencing, has experienced, or is likely to experience, one or more signs, symptoms or other indicators of sickle cell disease; has been diagnosed with sickle cell disease, whether, for example, newly diagnosed, and/or is at risk for developing sickle cell disease. One suffering from or at risk for suffering from sickle cell disease may optionally be identified as one who has been screened for abnormally low levels of hemoglobin in their blood or plasma.
[0079] As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: decreasing one or
more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), delay or slowing the progression of the disease, ameliorating the disease state, decreasing the dose of one or more other medications required to treat the disease, and/or increasing the quality of life.
[0080] As used herein, “delaying” or “slowing” the progression of sickle cell disease means to prevent, defer, hinder, slow, retard, stabilize, and/or postpone development of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated.
[0081] As used herein, “at the time of starting treatment” refers to the time period at or prior to the first exposure to a sickle cell disease therapeutic composition such as the compositions disclosed herein. In some embodiments, “at the time of starting treatment” is about any of one year, nine months, six months, three months, second months, or one month prior to a sickle cell disease drug. In some embodiments, “at the time of starting treatment” is immediately prior to coincidental with the first exposure to a sickle cell disease therapeutic composition.
[0082] As used herein, “based upon” includes (1) assessing, determining, or measuring the subject characteristics as described herein (and preferably selecting a subject suitable for receiving treatment; and (2) administering the treatment(s) as described herein.
[0083] A “symptom” of sickle cell disease is any phenomenon or departure from the normal in structure, function, or sensation, experienced by the subject and indicative of sickle cell disease.
[0084] The term “supportive surgery” refers to surgical procedures that may be performed on a subject to alleviate symptoms that may be associated with a disease.
[0085] The term “immunosuppressive agent” as used herein for adjunct therapy refers to substances that act to suppress or mask the immune system of the mammal being treated herein. This would include substances that suppress cytokine production, down-regulate or suppress self-antigen expression, or mask the MHC antigens. Examples of such agents include 2-amino-6-aryl-5-substituted pyrimidines (see, U.S. Patent No. 4,665,077); nonsteroidal anti-inflammatory drugs (NSAIDUA); ganciclovir, tacrolimus, glucocorticoids such as cortisol or aldosterone, anti-inflammatory agents such as a cyclooxygenase inhibitor, a 5 - lipoxygenase inhibitor, or a leukotriene receptor antagonist; purine antagonists such as azathioprine or mycophenolate mofetil (MMF); alkylating agents such as cyclophosphamide; bromocryptine; danazol; dapsone; glutaraldehyde (which masks the MHC antigens, as described in U.S. Patent No. 4,120,649); anti-idiotypic antibodies for MHC antigens and MHC fragments; cyclosporin A; steroids such as corticosteroids or glucocorticosteroids or glucocorticoid analogs, e.g., prednisone, methylprednisolone, and dexamethasone;
dihydrofolate reductase inhibitors such as methotrexate (oral or subcutaneous); hydroxychloroquine; sulfasalazine; leflunomide; cytokine or cytokine receptor antagonists including anti-interferon-alpha, -beta, or -gamma antibodies, anti-tumor necrosis factor-alpha antibodies (infliximab or adalimumab), anti-TNF-alpha immunoahesin (etanercept), anti-tumor necrosis factor-beta antibodies, anti-interleukin-2 antibodies and anti-IL-2 receptor antibodies; anti-LFA-1 antibodies, including anti-CD11a and anti-CD18 antibodies; anti-L3T4 antibodies; heterologous anti-lymphocyte globulin; pan-T antibodies, preferably anti-CD3 or anti- CD4/CD4a antibodies; soluble peptide containing a LFA-3 binding domain (International Patent Publication No. WO 90/08187 published 7/26/90); streptokinase; TGF-beta; streptodornase; RNA or DNA from the host; FK506; RS-61443; deoxyspergualin; rapamycin; T-cell receptor (Cohen et al., U.S. Patent No. 5,114,721); T-cell receptor fragments (Offner et al. (1991) Science 251 :430-432; International Patent Publication No. WO 90/11294; Janeway (1989) Nature 341 :482; and International Patent Publication No. WO 91/01133); and T cell receptor antibodies such as T10B9.
[0086] “Corticosteroid” refers to any one of several synthetic or naturally occurring substances with the general chemical structure of steroids that mimic or augment the effects of the naturally occurring corticosteroids. Examples of synthetic corticosteroids include prednisone, prednisolone (including methylprednisolone), dexamethasone, glucocorticoid and betamethasone.
[0087] “Iron chelation” is a type of therapy to remove excess iron from the body. Each unit of blood given in a transfusion comprises about 250 milligrams of iron, and the body cannot excrete it except in small (~1 mg) amounts that are lost in skin and perspiration. Excess iron is trapped in the tissues of vital organs, such as the anterior pituitary, heart, liver, pancreas and joints. When the iron reaches toxic levels, damage can result in diseases such as diabetes, cirrhosis, osteoarthritis, heart attack, and hormone imbalances. Hypothyroidism, hypogonadism, infertility, impotence and sterility can result from these hormone imbalances. If not addressed, excess iron can result in complete organ failure and death. Iron reduction is accomplished with chelation therapy, which is the removal of iron pharmacologically with an iron-chelating agent such as desferrioxamine or deferasirox.
[0088] A “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications, other therapeutic products to be combined with the packaged product, and/or warnings concerning the use of such therapeutic products, etc.
[0089] A “label” is used herein to refer to information customarily included with commercial packages of pharmaceutical formulations including containers such as vials and package inserts, as well as other types of packaging.
[0090] It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the invention will become apparent to one of skill in the art.
[0091] Practice of the methods, as well as preparation and use of the compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001 ; Ausubel et a/., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, “Chromatin” (P.M. Wassarman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, “Chromatin Protocols” (P.B. Becker, ed.) Humana Press, Totowa, 1999.
Methods of treatment
[0092] In some embodiments, the subject has received a diagnosis of severe SCD. Severe SCD was defined as having 1 or more of the following manifestations consistent with Bone Marrow Transplant Clinical Trial Network (BMT CTN) guidelines: (1) clinically significant neurologic event (stroke) or any neurological deficit lasting >24 hours; (2) history of 2 or more episodes of ACS in the 2-year period preceding informed consent despite adequate supportive care measures (i.e. , asthma therapy); (3) three or more pain crises per year in the 2-year period preceding informed consent (requiring IV pain management in the outpatient or inpatient hospital setting); (4) history of two or more episodes of priapism with subject seeking medical care in the 2-year period preceding informed consent; (5) administration of regular RBC transfusion therapy in the year preceding informed consent, defined as receiving 8 or more transfusions to prevent vaso-occlusive clinical complications (i.e., pain, stroke, or ACS); and/or (6) an echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >2.5 m/s.
[0093] In some embodiments, the subject is required to have adequate physiological function consistent with BMT CNT guidelines to receive the treatments described herein. As a non-limiting example, in certain embodiments, adequate physiological function may be measured by (a) Karnofsky/Lansky Performance Scale score >60; (b) cardiac function - left ventricular ejection fraction (LVEF) >40% or left ventricular shortening fraction >26% by cardiac echocardiogram (ECHO) or by multiple gated acquisition (MLIGA) scan (c) pulmonary function - pulse oximetry with a baseline oxygen (02) saturation of >85% and diffusing capacity for carbon monoxide (DLCO) >50% (corrected for hemoglobin); and (d) hepatic function - alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5* the upper limit of normal as per local laboratory: serum conjugated (direct) bilirubin <3* the upper limit of normal for age as per local laboratory. If direct bilirubin is >0.5 mg/dL, subject must have either a liver magnetic resonance imaging (MRI) with a liver iron content (LIC) <10 mg/g dry weight, or a liver biopsy demonstrating absence of bridging fibrosis, liver cirrhosis, and active hepatitis in order to participate (results of liver biopsies obtained within the past 12 months are allowed).
[0094] In some embodiments, described herein are modified autologous HSC/PC that are delivered to a subject with SCD according to the disclosed methods. Two mRNAs encoding the right and left ZFN partners are delivered to the harvested HSC/PC which are targeted to the BCL11a erythroid enhancer sequence. In some embodiments, the mRNAs include SB- mRENHI and SB-mRENH2. In some embodiments, the CD34+ HSC/PCs are harvested {e.g., apheresis) after mobilization in the subject by treating the subject with one or more doses of plerixafor prior to isolation and the mobilized cells. In some embodiments, at least about 25 x 106 CD34+ HSPCs/kg are harvested in total or per apheresis cycle and may be cultured for any length of time. The resulting genetically modified cells may be cultured and descendants thereof will include the specific BCL11A genetic modification {e.g., less than 1% of cells having off-target (non-BCL11 A) modifications), but not necessarily the mRNA(s). Cells comprising the BCL11A knockout can then be infused into the subjects. In some embodiments, additional modifications, such for example inactivation of HLA genes may be made in the specific BCL11A genetically modified cells.
[0095] In some embodiments, the methods described herein disclose genetically modified cells that are hematopoietic stem cells e.g., CD34+ HSC/PC) isolated from the subject, optionally in which the CD34+ HSC/PCs are mobilized {e.g., at least 25 x 106 CD34+ HSPCs/kg) in each subject by treatment with one or more doses of plerixafor prior to isolation and the mobilized cells are harvested by one or more apheresis cycles.
[0096] Methods of altering expression of hemoglobin, including for use in the treatment of SCD, as provided herein, include methods that result in a change from baseline of clinical
laboratory hemoglobin fractions (adult hemoglobin, HbA and fetal hemoglobin, HbF) in terms of both changes in grams/dL plasma and percent HbF of total Hb in a subject. See, e.g. FIG. 4.
[0097] In some embodiments, the methods of treatment described herein result in a change from baseline in the number and percent of F cells. F cells are RBCs that contain measurable amounts of HbF. Evaluation of a change in F cells as a result of the treatment methods can be measured by methods known in the art (see e.g., Wood et al. (1975) Blood 46(5):671). In some embodiments, the number and/or percentage of F cells is increased in a subject treated as described herein, as compared to an untreated subject.
[0098] HbF normally only plays a minor role in normal adult physiology. In patients with SCD, clinical studies demonstrate that mortality and disease severity correlate with HbF levels. See, e.g., Sankaran (2011). Am Soc Hematol Educ Program Book. 2011 :459-465. HbF achieves this disease amelioration by reducing HbS content and disrupting HbS polymer formation within the red cell. The effects of low, elevated, and high HbF levels are depicted in FIG. 1. Elevation of HbF concentration up to 20% is a primary mechanism for the activity of hydroxyurea (HU). Further, patients with concurrent SCD and persistent high levels of HbF (20% to 30%) due to the condition of hereditary persistence of fetal hemoglobin (HPFH) are asymptomatic throughout life. (Xu et al. (2011) Science 334(6058): 993-6). These studies support a therapeutic approach of increasing HbF as a mechanism for treating SCD.
[0099] In some embodiments, use of the methods of treatment disclosed herein may result in a change of SCD-related disease biomarkers. In some embodiments, changes in the SCD- related disease biomarkers may include, but are not limited to, changes in iron metabolism and/or changes in levels of erythropoietin, haptoglobin and hepcidin levels. In some embodiments, the methods of treatment may result in a change in a patient’s symptoms associated with iron overload associated with baseline transfusion therapy. Changes in iron overload symptoms may include a decrease in endocrine dysfunction caused by iron deposition in endocrine organs. Endocrine dysfunction may be evaluated by measurement of factors (levels and/or activity) such as, but not limited to, thyroid hormones, IGF-1 , morning cortisol, adrenocorticotropic hormone (ACTH), HbA1C, and/or vitamin D. Determination of all the above factors, including HbA, HbF, erythropoietin, haptoglobin, hepcidin, thyroid hormones, IGF-1 , cortisol, ACTH, and vitamin D may be measured by standard clinical laboratory protocols.
[0100] In some embodiments, provided herein are methods of treatment that reduce, delay, and/or eliminate additional treatment procedures as compared with a subject that has not been treated with the methods and compositions as disclosed herein, for example wherein an effective amount of modified HSC/PC are administered to a subject in need thereof,
wherein the subject has a reduced, delayed, and/or eliminated need for additional treatment procedures after treatment. In some embodiments, the additional treatment procedures can include, but are not limited to, a bone marrow transplant, PRBC and/or other blood component transfusions, and treatments related to iron chelation therapy.
[0101] In some embodiments, the uses and methods of treatment described herein will result in a decrease in the need for (use of) RBC transfusions and infusion of other blood products including, but not limited to, platelets, intravenous immunoglobin (IVIG) , plasma and granulocytes in a subject with sickle cell disease. Change in the use of RBC and other blood product infusions in a subject treated with the methods and compositions of the invention can be evaluated by keeping a log of use for the subject. The log can be used to calculate an annualized frequency and volume of packed red blood cells (PRBC) after infusion with the compositions disclosed herein, and compared to the subject’s past PRBC and other blood products usage prior to treatment.
[0102] In some embodiments, disclosed herein is a method of reducing, delaying or eliminating the SCD-related disease biomarkers following treatment with the methods and compositions in a subject with SCD as compared with the subject prior to treatment with the methods and compositions disclosed herein. In some embodiments, the subject is administered an effective amount of modified HSC/PC such that the subject has reduced, delayed or eliminated SCD-related disease biomarkers after treatment. In some embodiments, levels of HbF increase by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400% or more (or any value therebetween) following treatment by the methods disclosed herein. In some embodiments, the effects of the disclosed methods on the subject are realized within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
[0103] In another aspect, disclosed herein is a method of reducing, delaying or eliminating the use of PRBC transfusions and infusion of other blood products including, but not limited to, platelets, intravenous immunoglobin (IVIG), plasma and granulocytes following treatment with the methods and compositions in a subject with SCD as compared with a subject that has not been treated with the methods and compositions of the invention. In some embodiments, the use of PRBC and/or other blood product is decreased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any value therebetween in a subject treated with the methods disclosed herein as compared to the subject prior to receiving treatment. In some embodiments, the use of PRBC and/or other blood product infusions is eliminated.
In another aspect, disclosed herein is a method of reducing, delaying or eliminating the symptoms associated with iron overload in a subject with sickle cell disease. In some embodiments, markers of endocrine dysfunction as a result of iron deposition in endocrine
organs (for example, thyroid markers, IGF-1 , morning cortisol, HbA1C and Vitamin D) become normalized in a subject after treatment with the methods and compositions of the invention as compared to the marker levels prior to treatment. In some embodiments, iron overload in the liver and heart is decreased in a subject following treatment with the methods and compositions disclosed herein as compared with the subject prior to treatment. Iron overload can be evaluated by standard MRI procedures. In some embodiments, iron over load in the liver and/or heart detected by MRI is decreased by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any value therebetween in a subject treated with the methods disclosed herein as compared to the subject prior to receiving treatment.
[0104] In some embodiments, ex vivo therapies for SCD are described using the genetically modified cells as described herein. In some embodiments, the genetically modified cells are autologous cells obtained from the subject to be treated, which cells are then genetically modified as described herein and administered back to the same subject. Cells obtained from the subject may be mobilized using treatment with plerixafor. See, e.g., llchida et al. (2020) Haematologica. 105(10): e497-e501. In the methods described herein, any amount of cells may be mobilized, for example about 5 x 105, about 10 x 105, about 15 x 105, about 20 x 105, about 5 x 106, about 10 x 106, about 15 x 106, about 20 x 106, about 25 x 106 CD34+ HSPCs/kg for genetic modification are mobilized in the subject.
[0105] Plerixafor reversibly inhibits binding of stromal cell-derived factor-1-alpha (SDF- 1a), expressed on bone marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4), resulting in mobilization of CD34+ HSPCs from bone marrow into peripheral blood. Plerixafor is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. However, the use of G-CSF in patients with SCD is contraindicated due to risk of vaso-occlusive crisis. See, e.g., Tisdale JF et al. (2017) Blood 130 (S1): 990.
[0106] In some embodiments, mobilized CD34+ HSPCs are collected from each subject one or more days {e.g., 3, 4, 5, 6, 7 or more days) after mobilization by apheresis, for example on 2 or more consecutive days until sufficient cells are collected. In some embodiments, at least about 1 x 104 to 1 x 107 e.g., 25 x 106) CD34+ HSPCs/kg are collected. If needed, a second mobilization and apheresis cycle may be performed 1 , 2, 3, or more weeks after the first cycle. In some embodiments, a portion of collected cells are subject to genetic modification as described herein and the remainder maintained {e.g., cryopreserved) in the event a rescue treatment for the subject is indicated.
[0107] In some embodiments, the modified HSPC are evaluated prior to returning to the subject. In some embodiments, the modified cells are evaluated for the presence and type of
nuclease-induced mutations in the BCL11A enhancer region. In some embodiments, the mutations can be insertions of nucleotides, deletions of nucleotides or both (“indels”). In some embodiments, the cells are evaluated for off-target cleavage by the nucleases. In some embodiments, the cells are evaluated for insertions and/or deletions within BCL11 A (on-target modifications) and/or other non-BCL11A region (off-target modifications). In some embodiments, the cells are evaluated for molecular translocations and/or karyotyping of the cellular chromosomes following nuclease cleavage. In some embodiments, the cells are evaluated for off-target transcriptional activity. In some embodiments, the cells are evaluated for endotoxin load. In some embodiments, the cells can be evaluated for one or more of the above characteristics.
[0108] The autologous cells are genetically modified as described herein and cryopreserved e.g., using a controlled rate freezer) according to standard techniques with each aliquot {e.g., infusion bag) having a total cell count of approximately 1.0 x 108 to 2.0 x 108 cells and can be stored in vapor phase liquid nitrogen (at < -150°C) at the manufacturing facility until they are ready to be shipped to the site where they will be administered to a subject.
[0109] In certain aspects, the ex vivo therapies comprise thawing the frozen genetically modified HSPC and infusing the cells into the subject, preferably within about 15 to about 45 minutes of thawing. The volume of frozen modified HSPC administered is determined by the subject’s weight. Vital signs (blood pressure, temperature, heart rate, respiratory rate and pulse oximetry) can be monitored prior to infusion and afterwards. In some embodiments, the subjects are monitored using blood tests as well as analysis of HbF levels (baseline levels of HbF fractions (A and F in g/dL) and percent HbF is determined based on the last assessment on or prior to the date of first administration of IV busulfan), endocrine function, and/or performing MRIs to assess iron load. In some embodiments, the ex vivo therapies result in neutrophil and platelet recovery to within normal levels in the subject in about two to four weeks of infusion. Subjects may also receive PRBC transfusions 0, 1 , or more times following HSPC infusion. In some embodiments, total hemoglobin levels in the subject remain stable or continue to rise by week 2, 3, 4, 5, 6, 7, or more after infusion with the modified HSPC.
[0110] In any of the methods described herein, the subject can receive conditioning therapy prior to ex vivo therapy with genetically modified cells, for example, via intravenous (IV) administration of one or more myeloablative condition agents prior to infusion with the modified CD34+ HSC/PC. In some embodiments, the myeloablative condition agent is busulfan. In some embodiments, the busulfan is used with other agents such as cyclophosphamide.
[0111] Busulfan can be administered using known effective doses and regimens. According to standard procedures, for example, busulfan is dosed at between about 0.5 to 5 mg/kg (or any value therebetween). In some embodiments, subjects will receive a myeloablative regimen of busulfan (about 3.2 mg/kg/day; IV via central venous catheter) for up to 4 days (total dose of about 12.8 mg/kg prior to infusion), for example on Days -6 through -3 before infusion of the modified HSPC on Day 0. IV busulfan may be dosed once daily (total of 4 doses) or every 6 hours (total of 16 doses) according to study center practices or guidelines. After the first dose, the IV busulfan dose can be adjusted based on pharmacokinetic sampling and study center practices to target an area under the curve (AUG) of 4,000-5,000 mmol*min for daily dosing or an AUG of 1 ,000-1 ,250 mmol*min for every 6 hour dosing for a total regimen target AUG of 16,000-20,000 mmol*min. IV busulfan pharmacokinetic targeting may be modified for subsequent subjects. Optionally, therapeutic drug monitoring is conducted to determine clearance of busulfan after 4 days of dosing is complete.
[0112] Any dose of genetically modified cells can be used, for example, between 3 x 106 cells/kg and 20 x 106 cells/kg e.g., where the cells are formulated with approximately 1 .0- 2.0 x 108 cells per bag at a concentration of approximately 1 x 107 cells/mL). In some embodiments, a dose of about 3 x 106 cells/kg to about 20 x 106 cells/kg (or any value therebetween) of the genetically modified cells is administered {e.g., via intravenous infusion) to the subject. In some embodiments, the cells are formulated in infusible cryomedia containing 10% DMSO. In some embodiments, the cells are formulated with approximately 1.0- 2.0 x 108 cells per bag at a concentration of approximately 1 x 107 cells/mL. In any of the methods described herein, cell dosages may be determined as total cell dose or as a CD34+ cell dose, which can be calculated as follows: CD34+ dose = [total cell dose] x [CD34+ %].
[0113] In some embodiments, the dose of genetically modified cells administered to the subject is between about 3.2 x 106 cells/kg and 9.7 x 106 cells/kg. In some embodiments, the dose of genetically modified cells administered to the subject is about 5.17 x 106 cells/kg. In some embodiments, the dose of cells administered to the subject is between about 3.2 x 106 cells/kg and 9.7 x 106 cells/kg. In some embodiments, the dose of cells administered to the subject is about 5.17 x 106 cells/kg.
[0114] In some embodiments, the subject has delayed, reduced or eliminated need, for example, for additional therapeutic procedures after receiving a total dose of between about 3.0 x 106 to about 20 x 106 cells/kg.
[0115] In some embodiments, the subject has delayed, reduced or eliminated need, for example, for additional therapeutic procedures after receiving a total dose of between 3.2 x 106 cells/kg and 9.7 x 106 cells/kg. In some embodiments, the subject has delayed, reduced
or eliminated need, for example, for additional therapeutic procedures after receiving a total dose of about 5.17 x 106 cells/kg.
[0116] In some embodiments, the methods and compositions disclosed herein comprise dosing of a composition of the invention (for example, the modified HSC/PC), for example, via a peripheral vein catheter. In some embodiments, the composition is administered to the subject which is then followed by administration of normal saline (NS) or phosphate buffered saline (PBS).
[0117] Following infusion, the modified HSPC may be monitored in the patient to determine engraftment efficiency and/or modification heterogenicity. This can be done, for example, by determining the genetic modification (“indel”) profile. Cell samples may be purified from the peripheral blood, bone marrow aspirate or other tissue samples (preferably about 5 x 104 to 1 x 107 cells) and subject to genomic DNA isolation for assessment. Bone marrow aspirate or other tissue samples may be taken at various timepoints, including at between about 6-9 months. In some embodiments, the indel profile is monitored over time to determine the likelihood of any one particular cell type (indel profile) aberrantly overgrowing the population. In some embodiments, the cells and subject are monitored before and/or after administration, for example to determine the indel profile of cells isolated from peripheral blood samples, bone marrow aspirates, or other tissue sources in comparison with the indel profile of the infused cells to in order to monitor stability of the graft in the subject. In some embodiments, genomic DNA from cells isolated from a treated subject is isolated and the region comprising the BCL11A target sequence is amplified. In further embodiments, the percent modified cells within the cell population is determined and re-tested over time post dosing to evaluate stability of the modified cell population with the treated subject.
[0118] The methods may further comprise monitoring the subject’s vital signs prior to, during and/or after administration of the genetically modified cells; and/or assessing hemoglobin, neutrophil and/or platelet levels in the subject prior to administration of the genetically modified cells to determine baseline levels of hemoglobin in the subject. In some embodiments, hemoglobin, neutrophil and/or platelet levels in the subject after administration of the genetically modified cells increase or remain stable as compared to baseline levels for weeks or months after administration.
[0119] Optionally, the subject may receive one or more PRBC transfusions prior to and/or after administration of the genetically modified cells. In any of the methods described herein, after administration of the composition to the subject, the need for additional therapies such as a bone marrow transplant, blood component, iron chelation, and/or therapy PRBC transfusions in the subject are reduced or eliminated. In some embodiments, the need for
additional therapies in the subject is reduced or eliminated within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days after administration of the genetically modified cells.
[0120] In some of the methods or uses described herein, the subject has a confirmed diagnosis of sickle cell disease (SCD). In some embodiments, the subject has a confirmed diagnosis of severe SCD.
[0121] Disclosed herein are methods of treating a SCD in a subject in need thereof by administering (e.g., by infusion) a genetically modified cell in which BCL11A is inactivated in the cell to the subject such that HbF production in the subject is increased and one or more clinical symptoms of sickle cell disease are decreased.
[0122] The subjects with SCD that are treated may exhibit one or more of the following: (1) a change from baseline of clinical laboratory hemoglobin fractions (adult hemoglobin, HbA and fetal hemoglobin, HbF) in grams/dL plasma and/or percent HbF of total Hb; (2) alteration (e.g., to or near normal levels) of SCD-related disease biomarkers such biomarkers of iron metabolism; and/or levels of erythropoietin, haptoglobin and/or hepcidin; (3) reduction or elimination of symptoms in the subject associated with iron overload associated with baseline transfusion therapy; (4) reduction or elimination of the need for blood product infusions, including PRBC transfusions, platelet infusions, I VIG, plasma transfusion and/or granulocyte transfusion; and/or (5) a change from baseline (pre-treatment levels) in the number and percent of F cells.
[0123] In some applications, provided herein is a method of improving or maintaining (slowing the decline) of SCD-related disease biomarkers in a human subject having sickle cell disease as compared with a subject that has not been treated with the methods and compositions of the invention. In other applications, provided herein is a method of decreasing the need (dose level or frequency) for PRBC or other blood product infusions in a subject with SCD as compared with the subject prior to treatment with the methods and compositions of the invention. In yet another aspect, provided herein is a method of reducing iron overload in a patient with sickle cell disease that occurs from chronic blood product infusions.
[0124] In some embodiments, a subject with SCD is assessed for improvement in SCD. In some embodiments, the improvement in SCD is assessed by the decrease, amelioration, or elimination of one or more clinical symptoms of SCD. In some embodiments, the subject with SCD is assessed using a health-related quality of life (HRQoL) survey. In some embodiments, the subject with SCD is assessed using the Patient-Reported Outcomes Measurement Information System 57 (PROMIS-57). PROMIS-57 is a collection of 8-item short forms assessing physical and mental well-being in patients with SCD. Exemplary PROMIS measures include pain impact, pain behavior, physical functioning, anxiety, depression, fatigue, satisfaction with discretionary social activities, satisfaction with social
roles, sleep disturbance, and sleep-related impairment. See, e.g., Keller S etal. (2017) Health Qua! Life Outcomes. 15(1):117; DeWalt, et al. (2007) Med Care. 45(5 Suppl 1):S12— 21. In the clinical study disclosed herein, the PROMIS-57 survey may be administered at the Screening visit, Week 26, Week 52, Week 78. End of Study Visit, and Eady Termination Visit. [0125] In some embodiments, a subject with SCD can be assessed using the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me). Keller SD, et al. (2014). Health Qual Life Outcomes. 22:125.
[0126] In some embodiments, a subject with SCD can be assessed using the Karnofsky Performance Scale. This is a simple, widely-accepted tool for evaluating functional impairment in patients. Each subject will be evaluated and scored at the specified visit using the Karnofsky Performance Status Scale Definitions Rating Criteria. See, e.g., Canver & Orkin (2016). Blood. 127(21):2536-2545.
Nucleases targeting BCL11A
[0127] Disclosed herein are compositions comprising one or more mRNAs encoding one or more zinc finger proteins (ZFNs) that cleave an endogenous BCL11A sequence e.g., an endogenous BCL11A enhancer sequence). In some embodiments, the one or more mRNAs comprise SB-mRENH1 mRNAs and/or SB-mRENH2 mRNAs (SEQ ID NO:15 and SEQ ID NO:16, respectively). See U.S. Patent No. 10,563,184; U.S. Patent Publication No. 2018/0087072. Also disclosed are pharmaceutical compositions comprising one or more of the same or different mRNAs, including compositions comprising SB-mRENH1 and SB-mRENH2 mRNAs.
[0128] In some embodiments, the target sites for the ZFNs disclosed herein are within a BCL11A gene. See, e.g., U.S. Patent Nos. 10,563,184; 9,963,715; 9,650,648; U.S. Patent Publication Nos. 2015/0132269; 2018/0111975; and 2019/0177709.
[0129] BCL11A is a transcription factor that is active in both neurological development and hematopoiesis. Genome-wide association and functional follow-up studies in cell and animal models have shown that BCL11A is an important silencer of HbF expression. In a seminal study involving a humanized mouse model of SCD, genetically engineered BCL11 A disruption in erythroid cells led to an absence of hemoglobin switching, maintenance of high levels of HbF, and improvements in hematologic and pathologic characteristics of SCD. (Xu et al. (2011) Science 334(6058): 993-6).
[0130] Thus, inhibition of BCL11A appears to be a potentially effective strategy for treating P-globin disorders such as SCD in human subjects. However, targeting the BCL11A gene for therapeutic approaches poses challenges due to the crucial role of BCL11A in development and hematopoiesis (Brendel et al. (2016) J Clin Invest 126(10:3868-3878). An alternative
strategy targets an erythroid-specific enhancer (ESE) element that is located in the second intron of the BCL11 A and that is required for BCL11A expression in erythroid cells but not in other lineages. The enhancer element was found to contain a common genetic variation associated with higher HbF levels (Bauer et al. (2013) Science 342(6155):253-7). It was hypothesized that modification of this erythroid-specific enhancer of the BCL11A gene could boost endogenous HbF levels in erythroid cells without deleterious effects on global BCL11A function (Hardison & Blobel (2013) Science 342(6155): 206-7).
[0131] Disclosed herein are genetically modified cells {e.g., red blood cell (RBC) precursor cell such as a CD34+ hematopoietic stem cell or erythroid precursor cell) comprising a genetic modification within an endogenous BCL11A enhancer sequence, such that the BCL11 A gene is inactivated in the cell. Also provided are cell populations comprising these genetically modified cells; genetically modified cells descended from therefrom; cell populations comprising the genetically modified cells and cells descended therefrom; and compositions comprising the genetically modified cells and/or cells descended therefrom. The cells, cell populations, and compositions described herein may be autologous (from the subject) and/or allogeneic cells. Furthermore, the genetically modified cells may include one or more additional genetic modifications, including but not limited to cells in which one or more selfmarkers or antigens are inactivated (knocked-out).
[0132] In some embodiments, the methods disclosed herein comprise a knock out of the BCL11A enhancer sequence in a cell to block the expression of the BCL11A protein. The methods and compositions of the invention also can be used in any circumstance wherein it is desired to knock out the BCL11A erythroid enhancer in a hematopoietic stem cell such that mature cells (e.g., RBCs) derived from these cells contain the therapeutic knockout. These stem cells can be differentiated in vitro or in vivo and may be derived from a universal donor type of cell which can be used for all subjects. Additionally, the cells may contain a transmembrane protein to traffic the cells in the body. Treatment can also comprise use of subject cells containing the therapeutic transgene where the cells are developed ex vivo and then introduced back into the subject. For example, HSC/PC containing a BCL11A erythroid enhancer knockout may be inserted into a subject via an autologous bone marrow transplant. [0133] Thus, described herein are methods for altering hemoglobin expression for the treatment and/or prevention of sickle cell disease. In some embodiments a ZFN pair comprising first and second (left and right) ZFNs, namely a 6-finger ZFN comprising a ZFP designated 63014 comprising the recognition helix regions as shown in Table 1 (e.g., encoded by mRNA SB-mRENH1) and a 5-finger ZFN comprising a ZFP designated 65722 comprising the recognition helix regions as shown in Table 1 (e.g., encoded by mRNA SB-mRENH2) is used for altering hemoglobin levels in an isolated cell or cell of a subject. In some
embodiments, the ZFN pair binds to a 33-base pair (combined) target site in the erythroid- specific enhancer of the human BCL11A gene at location chr2:60, 495, 250-60, 495, 290 in the GRCh38/hg38 assembly of the human genome. In some embodiments, one mRNA encodes both ZFNs of the pair. Alternatively, separate mRNAs, each encoding one ZFN of the pair are employed. In some embodiments, the mRNA sequences are SEQ ID NO:15 and SEQ ID NO:16.
[0134] In some embodiments, the ZFN useful in the compositions and methods disclosed herein {e.g., a ZFN in which the members of the ZFN pair (left and right) ZFNs are delivered by two separate mRNAs) include mRNAs designated SB-mRENH1 and SB-mRENH2. In some embodiments, the ZFNs in the BCL11A-specific pair are delivered (e.g., to the HSC/PC) via electroporation, for example, wherein one AAV comprises the left ZFN (e.g., SB-mRENH1) and another comprises the right ZFN (e.g., SB-mRENH2).
[0135] In some embodiments, the cells are removed from the subject (autologous) and treated with nucleases that target a gene involved in the regulation of fetal hemoglobin (HbF) production. In some embodiments, the gene is a repressor of HbF production. In some embodiments, the gene is the BCL11A gene. In some embodiments, the nucleases target and cleave the erythroid-specific enhancer region of the BCL11A gene. In some embodiments, the nucleases are delivered to the cells as mRNAs. In some embodiments, the cleavage of the erythroid-specific enhancer region results in error-prone repair of the cleavage site by the cellular repair machinery such that a binding site for the erythroid transcription factor GATA1 (see Vierstra et al. (2015) Nat Methods 12(10):927-30; Canver et al. (2015) Nature 527(7577): 192-7) is disrupted. In some embodiments, the nucleases target the erythroid-specific enhancer region of the BCL11A gene such that it is not expressed in hematopoietic stem cells. Enhancer regions targeted may be within or outside the coding region including but not limited to +58, +55 and/or +62 regions within intron 2 of endogenous BCL11A, numbered in accordance with the distance in kilobases from the transcription start site of BCL11A, which enhancer regions are roughly 350 (+55); 550 (+58); and 350 (+62) nucleotides in length. See, e.g., Bauer et al. (2013) Science 343:253-257; U.S. Patent Nos. 9,963,715; 10,072,066; and U.S. Patent Publication Nos. 2015/0132269 and 2018/0362926.
[0136] In some embodiments, the cells (populations of cells and compositions comprising these cells and populations of cells) described herein are specifically genetically modified by the mRNA(s) at the BCL11A locus, including genetically modified cell populations (and compositions comprising these cells) in which less than 10% (0 to 10% of any value therebetween), preferably less than 5% (0 to 5% or any value therebetween), even more preferably less than 1 % of the cells (0 to 1% or any value therebetween) and even more preferably less than 0.5% (0 to 1 % or any value therebetween) of the genetically modified cells
include genetic modifications made by the mRNA(s) outside the BCL11A locus (but may include additional modifications such as inactivation of HLA markers). In some embodiments, the nuclease is encoded by an mRNA and the mRNA optionally comprises elements for increasing transcriptional and translational efficiency.
[0137] In some embodiments, described herein is a composition comprising genetically modified cells specifically modified at the BCL11 A locus by the mRNA(s) as described herein, including in which less than 10% (0 to 10% or any value therebetween), preferably less than 5% (0 to 5% or any value therebetween), even more preferably less than 1% of the cells (0 to 1% or any value therebetween) and even more preferably less than 0.5% (0 to 1% or any value therebetween) of the genetically modified cells include genetic modifications made by the mRNA(s) outside the BCL11A locus (but may include additional modifications such as inactivation of HLA markers). In further embodiments, the polynucleotides encoding the zinc finger nuclease may comprise a left ZFN known as SB63014 (see, U.S. Patent No. 10,563,184 and U.S. Patent Publication No. 2018/0087072), encoded by a mRNA SB-mRENH1 . In some embodiments, the right ZFN is SB65722 (see, U.S. Patent No. 10,563,184 and U.S. Patent Publication No. 2018/0087072), encoded by a mRNA SB-mRENH2.
[0138] In some embodiments, the left and right (first and second) ZFNs of the ZFN are carried on the same vector and in other embodiments, the paired components of the ZFN are carried on different vectors. For example, two mRNAs vectors, one designated SB-mRENH1 mRNA (an mRNA encoding the ZFN comprising the ZFP designated 63014) and the other designated SB-mRENH2 mRNA (an mRNA encoding the ZFN comprising the ZFP designated 65722).
[0139] The examples disclosed herein relate to exemplary embodiments of the present disclosure in which the nuclease comprises a zinc finger nuclease (ZFN). It will be appreciated that this is for purposes of exemplification only and that other nucleases or nuclease systems can be used, for instance homing endonucleases (meganucleases) with engineered DNA-binding domains and/or fusions of naturally occurring of engineered homing endonucleases (meganucleases) DNA-binding domains and heterologous cleavage domains and/or a CRISPR/Cas system comprising an engineered single guide RNA.
Cells
[0140] In one aspect, described herein are host cells, including isolated hematopoietic stem cells (HSPC such as CD34+), comprising the ZFNs and/or polynucleotides {e.g., mRNAs) as described herein. Cells may be isolated from healthy subjects or, alternatively, are autologous cells obtained from a subject with the condition to be treated {e.g., SCD) and purified using standard techniques. The ZFNs genetically modify the cells via insertions and/or
deletions following cleavage. Subsequently, expanded (cultured) cells may no longer include the ZFNs (or polynucleotides encoding these ZFNs) but maintain the genetic modifications in culture e.g., insertions and/or deletions within BCL11a). Genetically modified cells as described herein exhibit different ratios of globin (a-, p- and y-globin levels) as compared to untreated (non-genetically modified) cells. In some embodiments, the ratio of y-globin to - globin and of y-globin to a-globin is increased about 2 to 5 or more-fold, including 3 to 4-fold as compared to untreated (untransfected) HSPCs. Furthermore, the genetically modified cells described herein differentiate into all hematopoietic lineages, including erythroid progenitors (CFLI-E and BFLI-E), granulocyte/macrophage progenitors (CFU-G/M/GM), and multipotential progenitors (CFU-GEMM) and exhibit normal karyotypes and morphology, which is indicative of a reconstitution of hematopoiesis.
[0141] Also provided herein are genetically modified cells, for example, HSC/PC comprising a targeted knockout of the BCL11 A erythroid enhancer. The knockout is created by treating harvested HSC/PC with mRNAs encoding the right and left ZFN partners which when translated, will result in an active ZFN. The ZFN cleaves the BCL11A erythroid enhancer such that a double strand break in the DNA occurs. The cellular machinery repairs the double strand break using error-prone non-homologous end joining (NHEJ) which results in the insertion and deletion of nucleotides (indels) around the cleavage site.
[0142] Both autologous {e.g., subject-derived) and allogenic (healthy donor derived) HSC/PC can be used in the performance of the method.
[0143] The cells as described herein are useful in cell therapy for treating and/or preventing sickle cell disease in a subject with the disorder. In the case of modified stem cells, after infusion into the subject, in vivo differentiation of these precursors into cells expressing the functional protein (from the inserted donor) also occurs.
[0144] Pharmaceutical compositions comprising the cells as described herein are also provided. In addition, the cells may be cryopreserved prior to administration to a subject.
[0145] The cell populations (and compositions) described herein comprise genetically modified cells specifically at the BCL11A locus, including genetically modified cell populations in which less than 10% (0 to 10% of any value therebetween), preferably less than 5% (0 to 5% or any value therebetween), even more preferably less than 1% of the cells (0 to 1% or any value therebetween) and even more preferably less than 0.5% (0 to 1% or any value therebetween) of the cells include genetic modifications outside the BCL11A locus (but may include additional modifications such as inactivation of HLA markers).
[0146] The genetically modified cells may be stem cells (e.g., CD34+ HSC/PC, ST-400) and may be autologous or allogeneic (e.g., isolated from healthy donors) and the allogeneic cells may be further modified (e.g., in addition to BCL11A inactivation), for example to remove
one or more self-antigens e.g., HLA complexes) to from the allogeneic cells. See, e.g., U.S. Patent Nos. 8,945,868; 10,072,062; U.S. Patent Publication No. 2018/0362926. Autologous cells may be mobilized in the subject prior to modification ex vivo by treating the subject with one or more doses of plerixafor and the mobilized cells are harvested by one or more apheresis cycles. Optionally, at least about 25 x 106 CD34+ HSPCs/kg are mobilized in the subject. The cells may be genetically modified to inactivate BCL11A using one or more nucleases, for example wherein the nucleases are introduced into the cell as mRNAs as disclosed herein (SEQ ID NO:15 and SEQ ID NO:16). Following ex vivo genetic modification, the cells may be evaluated for insertions and/or deletions within BCL11A.
[0147] Isolated cells and isolated populations of cells comprising one or more mRNAs and/or one or more pharmaceutical compositions comprising these mRNAs are also provided. Also described are compositions comprising genetically modified cells and cells descended therefrom, including, but not limited to, progeny of the genetically modified cells. The genetically modified progeny cells may be obtained by in vitro methods (culture of the genetically modified cells) and/or in vivo following administration of the genetically modified cells to a subject. Thus, the genetically modified progeny cells may include fully or partially differentiated progeny descended from the genetically modified cells. In some embodiments, the genetically modified cell compositions comprise genetically modified hematopoietic stem cells (also referred to as hematopoietic progenitor stem cells (HPSC) or hematopoietic stem cell/precursor cells (HSC/PC)) and/or genetically modified cells descended or produced (cultured) therefrom, including genetically modified cells in which the BCL11A sequence is cleaved and hemoglobin {e.g., HbF and/or HbA) levels in the cells are increased e.g., 3 to 4- fold or more) as compared to cells which are not genetically modified. Some, all or none of the genetically modified cells of the cell populations and compositions of cells described herein may comprise one or more mRNAs and/or pharmaceutical compositions comprising these mRNAs. Thus, described herein are cells, cell populations and compositions comprising these cells, which cells, cell populations and compositions comprise genetically modified cells comprising the mRNAs described herein and cells descended therefrom. The cells, cell populations and compositions comprising these cells and cell populations may comprise autologous and/or allogeneic cells.
[0148] Pharmaceutical compositions comprising genetically modified cells {e.g., erythroid progenitor cells such as HPSCs that exhibit increased globin expression as compared to unmodified cells) as described herein are also provided.
[0149] Methods of manufacturing (making) genetically modified isolated cells (or cell populations or compositions comprising genetically modified cells and cells descended therefrom) are also provided, including methods of making genetically modified populations of
cells in which a BCL11 A sequence (e.g., enhancer sequence) is genetically modified such that hemoglobin {e.g., HbF and/or HbA) levels in the genetically modified cells are increased as compared to unmodified cells e.g., 2 or more fold). In some embodiments, the methods comprising administering one or more mRNAs (or pharmaceutical compositions comprising the one or more mRNAs) as described herein to the cell e.g., via transfection). The cells may be autologous and/or allogeneic and may be HSPCs. In some embodiments, the methods further comprise culturing the genetically modified cells to produce a composition comprising a population of genetically modified cells {e.g., HPSC cells) and/or genetically modified cells descended therefrom {e.g., other erythroid progenitor cells and/or mature erythroid cells such as RBCs) exhibiting increased globin production. The compositions may comprise genetically modified cells comprising the mRNAs and/or genetically modified cells descended from such cells that no longer comprise the mRNAs but maintain the genetic modification (BCL11A- specific modifications).
[0150] Pharmaceutical compositions comprising genetically modified cell populations and/or cells descended therefrom are also provided.
[0151] In some embodiments, the methods and compositions disclosed herein relate to treating a subject with cells that have been modified ex vivo. In some embodiments, the cells are isolated from the subject, modified ex vivo, and then returned to the subject. In other embodiments, the cells are isolated from healthy donors, modified ex vivo, and then used to treat the subject. In further embodiments, the cells isolated from healthy donors are further modified ex vivo to remove self-markers {e.g., HLA complexes) to avoid rejection of the cells by the subject. In some embodiments, the cells isolated are stem cells. In further embodiments, the stem cells are hematopoietic stem cell/progenitor cells {e.g., CD34+ HSC/PC). In some embodiments, the CD34+ HSC/PC are mobilized in each subject by treatment with one or more doses of plerixafor. In some embodiments, the dose of plerixafor used is about 240 pg/kg/day. In further embodiments, the mobilized cells are harvested by one or more apheresis cycles.
[0152] Mobilized human CD34+ HSPCs may be collected by apheresis from healthy or SCD subjects and purified prior to administration of (transfection with) one or more mRNAs (or pharmaceutical compositions comprising the one or more mRNAs) as described herein. In some embodiments, the purified HSPCs are transfected with ZFN mRNAs SBmRENHI (SEQ ID NO:15) and SBmRENH2 (SEQ ID NO:16) to manufacture SAR445136.
[0153] Transfected genetically modified CD34+ HSPCs (SAR445136) may be cultured, harvested and/or frozen for use. After harvesting, compositions comprising genetically modified cells (at least 50%, preferably at least 70% or more, even more preferably at least 75-80% or more of the cells are genetically modified following mRNA administration,
preferably specifically modified at the BCL11A enhancer sequence as compared to other genetic loci) as described herein may include HSPCs as well as cells descended therefrom, for instance HSPC differentiated into all hematopoietic lineages, including erythroid progenitors (CFLI-E and BFLI-E), granulocyte/macrophage progenitors (CFU-G/M/GM), and multi-potential progenitors (CFU-GEMM). In some embodiments, some, none or all of the genetically modified cells of the composition (population) of cells comprise one or more of mRNAs.
[0154] In another aspect, provided herein is an article of manufacture comprising a package (for example, a bag) comprising compositions comprising genetically modified autologous HSC/PC as described herein. The article of manufacture {e.g., bag) may be formulated for frozen storage, for example in CryoStor® CS-10 cryomedia (SigmaAldrich) containing 10% DMSO. Each bag can contain any concentration of cells. In some embodiments, each bag contains approximately 1 .0 - 2.0 x 108 cells per bag at a concentration of approximately 1 x 107 cells/mL.
[0155] In some embodiments, disclosed herein are compositions comprising (1) BCL11A gene ESE-modified CD34+ HSPC at 10 x 106 cells/mL; and (2) 1 mL of cryopreservation buffer containing 10% dimethyl sulfoxide (DMSO). In some embodiments, the cryopreservation buffer is CryoStor® CS10. In some embodiments, the composition is SAR445136.
Delivery
[0156] The ex vivo delivery of nucleases, polynucleotides encoding these nucleases, donor polynucleotides and compositions comprising the proteins and/or polynucleotides described herein may be delivered to the harvested HSC/PC by any suitable means.
[0157] Methods of delivering nucleases as described herein are described, for example, in U.S. Patent Nos. 6,453,242; 6,503,717; 6,534,261 ; 6,599,692; 6,607,882; 6,689,558; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, the disclosures of all of which are incorporated by reference herein in their entireties.
[0158] Nucleases and/or donor constructs as described herein may also be delivered using vectors containing sequences encoding one or more of the zinc finger, TAL-effector domain and/or Cas protein(s). Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno-associated virus vectors, etc. See, also, U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, incorporated by reference herein in their entireties.
[0159] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding nucleases and donor constructs in cells (e.g., mammalian
cells) and target tissues. Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see, Anderson (1992) Science 256:808-813; Nabel & Feigner (1993) TIBTECH 11 :211-217; Mitani & Caskey (1993) TIBTECH 11 :162-166; Dillon (1993) TIBTECH 11:167- 175; Miller (1992) Nature 357:455-460; Van Brunt (1988) Biotechnology 6(10):1149-1154; Vigne (1995) Restorative Neurology and Neuroscience 8:35-36; Kremer & Perricaudet (1995) British Medical Bulletin 51(1):31-44; Haddada et al., in Current Topics in Microbiology and Immunology Doerfler and Bohm (eds.) (1995); and Yu et al. (1994) Gene Therapy 1:13-26.
[0160] Methods of non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipidmucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.
[0161] Additional exemplary nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus Therapeutics Inc, (see for example U.S. Patent No. 6,008,336). Lipofection is described in e.g., U.S. Patent Nos. 5,049,386; 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, International Patent Publication Nos. WO 91/17424, WO 91/16024.
[0162] The preparation of lipidmucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal (1995) Science 270:404-410; Blaese et al. (1995) Cancer Gene Ther. 2:291-297; Behr et al. (1994) Bioconjugate Chem. 5:382-389; Remy et al. (1994) Bioconjugate Chem. 5:647-654; Gao et al. (1995) Gene Therapy 2:710-722; Ahmad et al. (1992) Cancer Res. 52:4817-4820; U.S. Patent Nos. 4,186,183; 4,217,344; 4,235,871; 4,261 ,975; 4,485,054; 4,501,728; 4,774,085; 4,837,028; and 4,946,787).
[0163] Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGenelC delivery vehicles (EDVs). These EDVs are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see, MacDiarmid et al. (2009) Nature Biotechnology 27(7):643).
[0164] The use of RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered ZFPs take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be used to treat cells in vitro and the modified cells are administered to subjects (ex vivo). Conventional viral based systems for the delivery of ZFPs include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated, vaccinia and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been measured in many different cell types and target tissues.
[0165] Recombinant adeno-associated virus vectors (rAAV) are a promising alternative gene delivery system based on the defective and nonpathogenic parvovirus adeno-associated type 2 virus. All vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system. (Wagner et al. (1998) Lancet 351(9117):1702-3; Kearns et al. (1996) Gene Ther. 9:748-55). Other AAV serotypes, including by non-limiting example, AAV1 , AAV3, AAV4, AAV5, AAV6, AAV8, AAV 8.2, AAV9 and AAV rh10 and pseudotyped AAV such as AAV2/8, AAV2/5 and AAV2/6 can also be used in accordance with the present invention. In some embodiments, AAV serotypes that are capable of crossing the blood brain barrier are used.
[0166] Replication-deficient recombinant adenoviral vectors (Ad) can be produced at high titer and readily infect a number of different cell types. Most adenovirus vectors are engineered such that a transgene replaces the Ad E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues in vivo, including nondividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity. An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for anti-tumor immunization with intramuscular injection (Sterman et al. (1998) Hum. Gene Ther. 7:1083-9). Additional examples of the use of adenovirus vectors for gene transfer in clinical trials include Rosenecker et al. (1996) Infection 24(1):5-10; Sterman et al. (1998) Hum. Gene Ther. 9(7): 1083-1089; Welsh et al. (1995) Hum. Gene Ther. 2:205-18; Alvarez et al. (1997) Hum. Gene Ther. 5:597-613; Topf et al. (1998) Gene Ther. 5:507-513; Sterman et al. (1998) Hum. Gene Ther. 7:1083-1089.
[0167] Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and i 2 cells or PA317 cells,
which package retrovirus. Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The missing viral functions are supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line is also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g. , heat treatment to which adenovirus is more sensitive than AAV.
[0168] Compositions comprising genetically modified cells as described herein may be delivered to a subject in any suitable manner, including by infusion. Prior to administration of composition comprising the genetically modified cells, the subject may be treated with (administered) one or more myeloablative condition agents one or more times, for example, busulfan administered: intravenously (IV) at between about 0.5 to 5 mg/kg for one or more times; IV at about 3.2 mg/kg/day; IV via central venous catheter for 4 days total dose of about 12.8 mg/kg prior to infusion on Days -6 through -3 before infusion of the composition comprising the genetically modified cells on Day 0; or IV once daily or every 6 hours.
[0169] Any dose of genetically modified cells can be used, for example, between about 3 x 106 cells/kg and about 20 x 106 cells/kg (e.g., where the cells are formulated with approximately 1.0- 2. O x 108 cells per bag at a concentration of approximately 1 x 107 cells/mL). [0170] Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions available, as described below (see, e.g., Remington’s Pharmaceutical Sciences, 17th ed., 1989).
[0171] Formulations for both ex vivo and in vivo administrations include suspensions in liquid or emulsified liquids. The active ingredients often are mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients include, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, the composition may contain minor amounts of auxiliary substances, such
as, wetting or emulsifying agents, pH buffering agents, stabilizing agents or other reagents that enhance the effectiveness of the pharmaceutical composition.
[0172] In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only and are not to be construed as limiting the scope of the invention in any manner.
EXAMPLES
[0173] The foregoing description of the specific embodiments will so fully reveal the general nature of the disclosure that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present disclosure. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.
Example 1 : ZFN design
[0174] The ZFN pair is made up of a 6-finger ZFN (encoded by mRNA SB-mRENH1) and a 5-finger ZFN (encoded by mRNA SB-mRENH2) that binds to a 33 base pair (combined) target site in the erythroid-specific enhancer of the human BCL11A gene at location chr2:60, 495, 250-60, 495, 290 in the GRCh38/hg38 assembly of the human genome. The preparation of the ZFN and polynucleotides encoding them is as follows: The SB- mRENHIand SB-mRENH2 mRNAs are produced in vitro by methods known in the art. The mRNAs comprise sequences encoding the ZFN partners, and also comprise features such as nuclear localization sequences and peptides. Table 1 shows the helices associated with each partner ZFN (see U.S. Patent No. 10,563,184; U.S. Patent Publication No. 2018/0087072):
[0175] The complete nucleotide sequence for the SB-mRENH1 mRNA (1725 nucleotides) is shown below (SEQ ID NO: 15): gggagacaagcuuugaauuacaagcuugcuuguucuuuuugcagaagcucagaauaaacgcucaacuuuggcagaucgaauu cgccauggacuacaaagaccaugacggugauuauaaagaucaugacaucgauuacaaggaugacgaugacaagauggccccca agaagaagaggaaggucggcauccacgggguacccgccgcuauggcugagaggcccuuccagugucgaaucugcaugcagaac uucagugaccaguccaaccugcgcgcccacauccgcacccacaccggcgagaagccuuuugccugugacauuugugggaggaaa uuugcccgcaacuucucccugaccaugcauaccaagauacacacgggcagccaaaagcccuuccagugucgaaucugcaugcag aacuucaguuccaccggcaaccugaccaaccacauccgcacccacaccggcgagaagccuuuugccugugacauuugugggagg aaauuugccaccuccggcucccugacccgccauaccaagauacacacgcacccgcgcgccccgaucccgaagcccuuccaguguc gaaucugcaugcagaacuucagugaccaguccaaccugcgcgcccacauccgcacccacaccggcgagaagccuuuugccugug acauuugugggaggaaauuugccgcccaguguugucuguuccaccauaccaagauacaccugcggggauccaucagcagagcc agaccacugaacccgcacccggagcuggaggagaagaaguccgagcugcggcacaagcugaaguacgugccccacgaguacau cgagcugaucgagaucgccaggaacagcacccaggaccgcauccuggagaugaaggugauggaguucuucaugaagguguacg gcuacaggggaaagcaccugggcggaagcagaaagccugacggcgccaucuauacagugggcagccccaucgauuacggcgug aucguggacacaaaggccuacagcggcggcuacaaucugccuaucggccaggccgacgagauggagagauacguggaggagaa ccagacccgggauaagcaccucaaccccaacgagugguggaagguguacccuagcagcgugaccgaguucaaguuccuguucg ugagcggccacuucaagggcaacuacaaggcccagcugaccaggcugaaccacaucaccaacugcaauggcgccgugcugagcg uggaggagcugcugaucggcggcgagaugaucaaagccggcacccugacacuggaggaggugcggcgcaaguucaacaacggc gagaucaacuucagaucuugauaacucgagucuagaagcucgcuuucuugcuguccaauuucuauuaaagguuccuuuguucc cuaaguccaacuacuaaacugggggauauuaugaagggccuugagcaucuggauucugccuaauaaaaaacauuuauuuuca uugcugcgcuagaagcucgcuuucuugcuguccaauuucuauuaaagguuccuuuguucccuaaguccaacuacuaaacuggg ggauauuaugaagggccuugagcaucuggauucugccuaauaaaaaacauuuauuuucauugcugcgggacauucuuaauua aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaacuag
[0176] The complete nucleotide sequence for SB-mRENH2 mRNA (1680 nucleotides) is shown below (SEQ ID NO: 16): gggagacaagcuugaauacaagcuugcuuguucuuuuugcagaagcucagaauaaacgcucaacuuuggcagaucgaauucg ccuagagaucuggcggcggagagggcagaggaagucuucuaaccugcggugacguggaggagaaucccggcccuaggaccaug gacuacaaagaccaugacggugauuauaaagaucaugacaucgauuacaaggaugacgaugacaagauggcccccaagaaga agaggaaggucggcauucaugggguacccgccgcuauggcugagaggcccuuccagugucgaaucugcaugcagaaguuugcc cgcaacgaccaccgcaccacccauaccaagauacacacgggcgagaagcccuuccagugucgaaucugcaugcagaacuucagu cagaaggcccaccugauccgccacauccgcacccacaccggcgagaagccuuuugccugugacauuugugggaggaaauuugcc cagaagggcacccugggcgagcauaccaagauacacacgggaucucagaagcccuuccagugucgaaucugcaugcagaacuu cagucgcggccgcgaccugucccgccacauccgcacccacaccggcgagaagccuuuugccugugacauuugugggaggaaauu ugcccgccgcgacaaccugcacucccauaccaagauacaccugcggggaucccagcuggugaagagcgagcuggaggagaaga aguccgagcugcggcacaagcugaaguacgugccccacgaguacaucgagcugaucgagaucgccaggaacagcacccaggac cgcauccuggagaugaaggugauggaguucuucaugaagguguacggcuacaggggaaagcaccugggcggaagcagaaagc cugacggcgccaucuauacagugggcagccccaucgauuacggcgugaucguggacacaaaggccuacagcggcggcuacaau cugccuaucggccaggccgacgagaugcagagauacgugaaggagaaccagacccggaauaagcacaucaaccccaacgagug guggaagguguacccuagcagcgugaccgaguucaaguuccuguucgugagcggccacuucagcggcaacuacaaggcccagc ugaccaggcugaaccgcaaaaccaacugcaauggcgccgugcugagcguggaggagcugcugaucggcggcgagaugaucaaa gccggcacccugacacuggaggaggugcggcgcaaguucaacaacggcgagaucaacuucugauaacucgagucuagaagcuc gcuuucuugcuguccaauuucuauuaaagguuccuuuguucccuaaguccaacuacuaaacugggggauauuaugaagggcc uugagcaucuggauucugccuaauaaaaaacauuuauuuucauugcugcgcuagaagcucgcuuucuugcuguccaauuucu auuaaagguuccuuuguucccuaaguccaacuacuaaacugggggauauuaugaagggccuugagcaucuggauucugccua
auaaaaaacauuuauuuucauugcugcgggacauucuuaauuaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaaaaacuag
Example 2: Clinical study of zinc finger nuclease-modified autologous CD34+ hematopoietic stem/progenitor cells for sickle cell disease
[0177] A study was undertaken in humans to test the safety and tolerability of using modified hematopoietic stem/progenitor cells (HSPCs) to treat sickle cell disease (SCD).
[0178] Sickle cell disease (SCD) is an inherited condition caused by pathologic variants in both alleles of the p-globin gene, affecting approximately 100,000 patients in the US. Strouse J. (2016) Handbook Clin Neurol. 138:311-24. Elevated fetal hemoglobin (HbF) levels have been shown to ameliorate symptoms and improve survival in SCD patients. Hebert N, et al. (2020). Am J Hematol. 95:1235-1245.
[0179] SAR445136 is a novel therapeutic product which is composed of a patient’s own
(autologous) hematopoietic stem/progenitor cells (HSPC) in which the BCL11A gene is modified to enable production of disease modifying levels of HbF. The target for gene editing is an erythroid-specific enhancer (ESE) in the BCL11A gene. Mutations at the ESE locus down-regulate BCL11A expression specifically in erythroid precursors, resulting in elevated levels of HbF synthesis. Following myeloablation of the patient’s bone marrow, the genetically modified HSPC are returned to the donor to repopulate the hematopoietic lineages including erythrocytes. As an autologous bone marrow transplant, there is minimal risk of stem cell rejection or graft-versus-host disease. Newly synthesized RBCs derived from the edited SAR445136 stem cell population may have an HbF level that is protective against the pathophysiologic changes underlying SCD.
Primary Endpoints
[0180] The primary objective of the study is to evaluate the safety and tolerability of SAR445136 in subjects with severe SCD. The primary safety and tolerability endpoints are as follows: (1) Survival at post-transplantation Day 100, Week 52, and Week 104 (Last Study Visit); (2) Successful engraftment as defined in the protocol; and (3) occurrence of adverse events (AEs) and serious adverse events (SAEs).
Secondary Endpoints
[0181] The secondary objectives of the study are to evaluate the success and kinetics of SAR445136 stem cell collection, manufacturing, and engraftment and SAR445136 efficacy. The endpoints related to the success and kinetics of SAR445136 stem cell collection, manufacturing, and engraftment are as follows: (1) CD34+ HSPC yield from plerixafor stem cell mobilization; (2) proportion of subjects who achieve sufficient stem cell mobilization for
rescue aliquot and SAR445136 production; (3) yield of ZFN-edited CD34+ HSPC (investigational product); (4) time to initial neutrophil recovery following SAR445136 infusion (first of 3 consecutive days with an absolute neutrophil count [ANC] >500/pL); (5) time to platelet recovery following SAR445136 infusion (first of 3 consecutive measurements with a platelet count >50,000/pL at least 1 week [7 days] following last platelet transfusion); (6) maintenance of ANC >500/pL and platelet count >50,000/pL to last patient visit; and (7) reconstitution of immune function post-SAR445136 transplantation, including but not limited to lymphocyte counts and immunoglobulin levels.
[0182] The endpoints related to efficacy include change from baseline in blood markers, including peripheral blood HbF, %F cells, and HbS; peripheral blood total Hb concentration; and markers of hemolysis including reticulocyte count, lactate dehydrogenase (LDH), haptoglobin, and serum bilirubin. Other efficacy endpoints include change from baseline in clinical assessments, including frequency and severity of SCD-related clinical events (e.g., VOC, pain episodes, etc.); quality of life (QoL) measures including fatigue; and RBC transfusion requirements, such as annualized number and total volume.
Exploratory Endpoints
[0183] Exploratory objectives of the study relate to changes in clinical parameters, features of the edited cell product, and biomarkers of disease. The exploratory endpoints may include the following: (1) changes from pretransplant baseline in clinical laboratory tests, physical examination, and vital sign parameters (2); assessment of on-target BCL11A gene modification in drug product and its correlation with HbF response (3) assessment of on-target BCL11A gene modification in peripheral blood white blood cell (WBC) populations and bone marrow erythroid progenitors from SAR445136 transplantation through the last study visit (4) assessment of off-target editing profile that may include karyotyping in SAR445136 retains and post-infusion peripheral blood and bone marrow samples up to the last study visit; (5) assessment of subject DNA sequence variation that may be associated with study safety or efficacy outcomes; and/or (6) changes from baseline through last study visit in SCD-related hematologic disease biomarkers in blood cells, plasma, or serum; end-organ function/imaging, including but not limited to central nervous system (CNS), lung, and kidney, as well as neuropsychological and neurocognitive function.
Inclusion Criteria
[0184] Diagnosis and inclusion criteria for the study included eight adult subjects with a diagnosis of severe SCD, 18 to 40 years of age at screening, who were willing and able to undergo autologous HSPC transplantation.
[0185] The male and female participating subjects were between the ages of 18 and 40 years old, inclusive, at the time of informed consent with clinical diagnosis of SCD and confirmed molecular genetic diagnosis of an HbSS or HbSp0 genotype. Subjects completed age appropriate cancer screening, used double- barrier method of contraception through the entire study period, and consented to receive blood transfusions.
[0186] The subjects had a diagnosis of severe SCD. Severe SCD was defined as having 1 or more of the following manifestations consistent with Bone Marrow T ransplant Clinical T rial Network (BMT CTN) guidelines: (1) clinically significant neurologic event (stroke) or any neurological deficit lasting >24 hours; (2) history of 2 or more episodes of ACS in the 2-year period preceding informed consent despite adequate supportive care measures (i.e. , asthma therapy); (3) three or more pain crises per year in the 2-year period preceding informed consent (requiring IV pain management in the outpatient or inpatient hospital setting); (4) history of two or more episodes of priapism with subject seeking medical care in the 2-year period preceding informed consent; (5) administration of regular RBC transfusion therapy in the year preceding informed consent, defined as receiving 8 or more transfusions to prevent vaso-occlusive clinical complications (i.e., pain, stroke, or ACS); and/or (6) an echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity >2.5 m/s.
[0187] The subjects were required to have adequate physiological function consistent with BMT CNT guidelines. For example, adequate physiological function was measured by (a) Karnofsky/Lansky Performance Scale score >60; (b) cardiac function - left ventricular ejection fraction (LVEF) >40% or left ventricular shortening fraction >26% by cardiac echocardiogram (ECHO) or by multiple gated acquisition (MLIGA) scan (c) pulmonary function - pulse oximetry with a baseline oxygen (02) saturation of >85% and diffusing capacity for carbon monoxide (DLCO) >50% (corrected for hemoglobin); and (d) hepatic function - alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5* the upper limit of normal as per local laboratory: serum conjugated (direct) bilirubin <3* the upper limit of normal for age as per local laboratory. If direct bilirubin is >0.5 mg/dL, subject must have either a liver magnetic resonance imaging (MRI) with a liver iron content (LIC) <10 mg/g dry weight, or a liver biopsy demonstrating absence of bridging fibrosis, liver cirrhosis, and active hepatitis in order to participate (results of liver biopsies obtained within the past 12 months are allowed). Subjects with hyperbilirubinemia as a consequence of hyperhemolysis or who experienced a sudden, profound change in the serum hemoglobin after an RBC transfusion were not excluded.
[0188] Lastly, the subjects had to be clinically stable and medically eligible to undergo stem cell mobilization and myeloablative hematopoietic stem cell transplantation (HSCT) based on institutional medical guidelines.
Exclusion Criteria
[0189] The key exclusion criteria for subjects in the study were as follows: previous receipt of an autologous or allogeneic HSCT or solid organ transplantation; previous treatment with gene therapy; current enrollment in an interventional study or having received an investigational drug within 30 days of study enrollment; pregnant or breastfeeding female; female or male who plans to become pregnant or impregnate a partner, respectively, during the anticipated study period; known to have a y-globin allelic variant associated with clinically significant altered oxygen affinity; a diagnosis of hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration >20% at screening; medical contraindication to use plerixafor, apheresis, or busulfan; ANC <1000 cells/pL; platelet count <100,000 cells/pL known history of platelet alloimmunization precluding ability to provide transfusion support, extensive RBC alloimmunization precluding ability to provide transfusion support; treatment with prohibited medications in the previous 30 days (e.g., prohibited medications are shown in Table A; see supplementary tables section below); clinically significant, active bacterial, viral, fungal, or parasitic infection (based on Investigator’s judgement); screening laboratory testing demonstrating a diagnosis of any of the following: (a) human immunodeficiency virus (HIV), active hepatitis B virus infection (HBV) defined as positive for hepatitis B surface antigen [HBsAg] and hepatitis B core antibody [HBcAb] followed by detectable HBV DNA to confirm, or (c) active hepatitis C virus infection (HCV) defined as positive for hepatitis C antibody followed by detectable HCV RNA (US Centers for Disease Control and Prevention); any major organ dysfunction involving brain, kidney, liver, lung, or heart, including but not limited to the following: (a) congestive heart failure New York Heart Association (NYHA) Class 3 or 4, or patient with a past history of congestive heart failure NYHA Class 3 or 4 in whom ECHO or MUGA scan performed within 3 months prior to Screening showed an LVEF of <40%; and/or (b) pulmonary hypertension on treatment; Fridericia’s corrected QT interval (QTcF) >500 ms based on screening electrocardiogram (ECG); history of significant bleeding disorder; current diagnosis of uncontrolled seizures; history of active malignancy in the past 5 years (nonmelanoma skin cancer or cervical cancer in situ permitted), any history of hematologic malignancy, or family history of a cancer predisposition syndrome without negative testing results in the study candidate; known allergy or hypersensitivity to plerixafor, busulfan, or investigational product excipients (human serum albumin, dimethyl sulfoxide (DMSO), and Dextran 40); and any other reason that, in the opinion of the Investigator and/or Sponsor, that would have rendered the subject unsuitable for participation in the study.
Withdrawal Criteria
[0190] The key subject withdrawal criteria were as follows: request by the subject to withdrawal; request of the Investigator and/or Sponsor if she/he thinks the study is no longer in the best interest of the subject; pregnancy of subject prior to IV busulfan infusion; subject judged by the Investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results; subject’s drug product does not fulfill release criteria or is otherwise determined to be unsuitable to administer to the subject (e.g., due to manufacturer/shipping problems); and/or withdrawal request at the discretion of the institutional review board (IRB), Office of Human Research, regulatory authority (e.g., FDA), Investigator, and/or the Sponsor. If a subject withdrew consent or discontinued from the study post-study treatment, a conference between the Investigator and the Medical Monitor took place to ensure and document that the subject understood the importance of the study follow-up and that the study treatment could not be revised even if the subject dropped out of the study follow-up. If the subject agreed, a reduced follow-up testing schedule may have been arranged including telephone calls and clinical laboratory tests to assess AEs and clinical status for up to 104 weeks after infusion. Subjects continued to be followed for overall survival unless consent to do so was withdrawn.
Study Design
[0191] The study was performed on subjects with sickle cell disease. Briefly, eligible subjects underwent mobilization and apheresis with plerixafor 240 ug/kg/day for up to 3 days to collect autologous CD34+ HSPCs at a minimum of 10 x 1 o6 CD34+ HSPC/kg per apheresis cycle to achieve the minimum SAR445136 dose. Additional apheresis cycles were permitted to achieve the minimum cell dose and rescue aliquots. Autologous HSPCs were transfected ex vivo with ZFN mRNAs SB-mRENH1 and SB-mRENH2, which target the ESE region of the BCL11A locus to manufacture SAR445136.
[0192] Subjects received conditioning therapy with a myeloablative dose of intravenous (IV) busulfan before being infused with the modified HSPCs. A single IV infusion of 3 to 20 x 106 CD34+ HSPC/kg was administered at least 72 hours after the final busulfan myeloablation dose. Subjects were monitored for stem cell engraftment and hematopoietic recovery, adverse events (AEs), clinical and laboratory markers of hemolysis, total Hb and HbF, percentage of F cells and sickle-cell related events post-SAR445136 infusion. Health-related quality of life (HRQoL) was assessed via the PROMIS-57 survey at four timepoints (screening, Week 26, Week 52, early termination visit). The sequence and timing of events in the study are shown in FIG. 3.
[0193] Schedule of screening, stem cell mobilization with plerixafor, apheresis, and conditioning with IV busulfan are shown in Table B (see supplementary tables section below). [0194] Administration of plerixafor and mobilization in each subject took between 4 to 7 days. Plerixafor was administered subcutaneously (SQ) at a recommended dose of 240 pg/kg/day. Plerixafor dosing, timing, or route of administration was modified or discontinued at the discretion of the Investigator based on the clinical status of the subject or if the WBC exceeded 100,000/pL.
[0195] The apheresis procedure required a temporary central IV catheter after one or more rounds of plerixafor administration. The minimum yield to secure sufficient stem cells for both the manufacturing of the investigational product and the rescue aliquot is approximately 10.0 x 106 CD34+ HSPC/kg. A yield of 20 x 106 CD34+ HSPC/kg may be required to achieve the target SAR445136 dose of 10 x 106CD34+ HSPC/kg. Lower yields from a single apheresis cycle were acceptable but may trigger additional rounds of mobilization/apheresis. The timing of subsequent apheresis was at the discretion of the Investigator based on the subject’s clinical status. The time from stem cell harvest to edited stem cell infusion (SAR445136) was approximately 20 weeks.
[0196] An aliquot of unmanipulated cells from the apheresis was also collected and stored at the site if needed to secure a rescue treatment. The rescue aliquot portion comprised a minimum of 1.5 x 106 CD34+ HSPC/kg. The remaining CD34+ HSPC were transfected ex vivo with ZFN mRNAs targeting the BCL11A locus to manufacture the investigational product SAR445136. The rescue aliquot was cryopreserved unmodified and stored at the study site for back-up infusion if the subject did not demonstrate evidence for engraftment by Day 42 post-SAR445136 infusion or developed subsequent graft failure with aplasia. In addition, the rescue treatment may have been administered at any time after SAR445136 infusion at the discretion of the investigator.
[0197] After removal and storage of the rescue treatment, the remainder of the subject’s mobilized and harvested cells were sent by courier to the GMP manufacturing facility. A CD34+ cell selection followed by transfection with ZFN mRNAs SB-mRENH1 and SB- mRENH2 to disrupt the erythroid-specific enhancer of the BCL11A gene was performed to generate the modified HSPC study drug. The modified HSPC were cryopreserved and stored until all the clinical protocol segments up to and including the Baseline visit procedures are completed and the subject is ready for infusion. The modified HSPC were cryopreserved in 50 mL CryoMACS® freezing bags (fill volume of approximately 10 to 20 mL; total cell count of approximately 1.0 x 108 to 2.0 x 108 cells) using a controlled rate freezer. Multiple freezing bags were used if cell yield exceeds the capacity of a single bag. Infusion bags were stored
in vapor phase liquid nitrogen (at < -150oC; with temperature monitoring) at the manufacturing facility until they were ready to be shipped to the clinical study center.
[0198] SAR445136 components include (1) BCL11A gene ESE-modified CD34+ HSPC at 10 x 106 cells/mL, and (2) 1 mL of cryopreservation buffer (CryoStor® CS10) containing 10% dimethyl sulfoxide (DMSO).
[0199] After release of the modified HSPC for clinical use, the subjects proceeded with IV busulfan conditioning in a dedicated transplant unit for approximately 4 to 7 days total. Subjects received a myeloablative regimen of busulfan (3.2 mg/kg/day; IV via central venous catheter) for 4 days (total dose of 12.8 mg/kg, which is considered standard-of-care for autologous transplantation) on Days -6 through -3 before infusion of SAR445136 on Day 1 (72 hour rest period prior to infusion). After the first dose, the IV busulfan dose was adjusted based on pharmacokinetic (PK) sampling and study center practices to target an area under the curve (AUC) of 4,000-5,000 pmol*min for daily dosing. PK samples taken and analyzed after the first IV busulfan dose may have been used to adjust the third IV busulfan dose, and PK samples taken after the second IV busulfan dose may have been used to adjust the fourth IV busulfan dose. Seizure prophylaxis was required starting prior to and continuing at least 24 hours after the final dose of IV busulfan conditioning and iron-chelating agents were discontinued 2 weeks prior to IV busulfan.
[0200] Modified HSPC infusion: After myeloablative conditioning with intravenous busulfan, patients received the thawed CD34+ HSPCs (SAR445136) product by central venous catheter infusion. The frozen modified HSPC were thawed and infused, such that the thawing of the infusion bags would take approximately 2-5 mins/bag and the cells were within 40 minutes (from start of thaw to completion of infusion). The volume of frozen modified HSPC was determined by the subject’s weight. Vital signs (blood pressure, temperature, heart rate, respiratory rate and pulse oximetry) were monitored prior to infusion and afterwards.
[0201] Once given the study drug, the subjects were monitored for routine lab work. In addition, assessment of any adverse events and blood cells were assayed for gene modification. The tests, assessments, and events after SAR445136 infusion are shown in Table B. Tests, assessments, and events included evaluation of HbF levels, analysis of endocrine function, and MRIs performed to assess iron load. Kinetics and success of hematopoietic reconstitution, duration of hospitalization after conditioning, screening for potential development of hematological malignancies, overall function by Karnofsky performance score, efficiency of apheresis procedure, difference between % indels in SAR445136 product and indels detected in bone marrow and blood following SAR445136 infusion were also evaluated. Additional post-infusion assessments and their schedules are shown in Table C.
[0202] An Adverse Event (AE) is any untoward medical occurrence in a subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Determination of whether an abnormal laboratory value, vital sign result, and/or ECG result meet the definition of an AE was made by the Investigator. Abnormal results are not considered AEs unless 1 or more of the following criteria are met: (1) the result meets the criteria for an SAE (2) the result requires the subject to receive specific corrective therapy or (3) the result is considered by the Investigator to be clinically significant. Myeloablation is intended through the use of the pretransplant conditioning regimen (busulfan at the full, myeloablative dose) and required for treatment efficacy. As such, hematologic abnormalities that are a direct consequence of the conditioning regimen are not considered AEs in this study and need not be reported as such unless the abnormality is of unanticipated severity or duration. Complications that are associated with these hematologic abnormalities (i.e. , fever, infection, and bleeding) must be reported as AEs.
[0203] A Serious Adverse Event (SAE) is any AE that results in any of the following outcomes: death, life-threatening threatening event (j.e., an event that places the subject at immediate risk of death); however, this does not include an event that, had it occurred in a more severe form, might have caused death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect in the offspring of an exposed subject, or a medically important event.
Results
[0204] Hb fractionation following SAR445136 infusion:
[0205] Eight (8) subjects have underwent mobilization and apheresis to date (September 22, 2021). Of these 8 subjects, 5 achieved successful target yields ranging from 3.4 to 13.8 x 106 CD34+ HSPC/kg per apheresis day (mean: 6.49 x 106 CD34+ HSPC/kg per apheresis day) in one apheresis cycle (4.45 to 10.9 x 106 CD34+ HSPC/kg per2-day cycle). Two subjects failed to mobilize; one discontinued due to intercurrent cholangitis. One subject is scheduled for infusion. Baseline patient characteristics of the 4 subjects infused are shown in Table 5.
[0206] Pre-apheresis peripheral blood WBC ranged from 23.2 to 36.9 x 103/pL (mean: 28.7 x 103/pL) and percent CD34+ was 0.09% to 0.36 % (mean: 0.22%) with absolute CD34+ counts of 20 to 80 pL (mean: 60 pL). Four of the mobilized subjects were successfully infused with SAR445136 at a single dose ranging from 3.2 to 9.7 x 106 CD34+ HSPC/kg (mean: 5.17 x 106 CD34+ HSPC/kg). All 4 subjects engrafted with a median time to platelet and neutrophil recovery of 24.5 and 21 .5 days, respectively. No rescue doses were required.
[0207] All 4 patients improved clinically since SAR445136 infusion. Measurements of HbF and HbS (mean and standard deviation) in all infused subjects are presented in FIG. 4. Total Hb stabilized at 9-10 g/dL by week 26 post-SAR445136 infusion along with improvements in the clinical markers of hemolysis in all 4 subjects.
[0208] The percent HbF levels were 1 % to 11% at screening, and increased to a range of 15% to 29% by Week 13 in all 4 subjects. The percent HbF levels increased to a range of 14% to 39% by Week 26 in all four subjects with at least 26 weeks follow up, and persisted at 35% in 1 subject at 65 weeks follow up (FIG. 4). The percent HbF level was 38% in one subject at 91 weeks.
[0209] Percent F cells increased to a range of 48% to 94% in all four subjects with at least 26 weeks follow up, and persisted at 99% in 1 subject with 91 weeks follow up. The fourth subject had 94% F cells at 26 weeks follow up. (FIG. 5).
[0210] All four treated subjects showed HbF/F cell levels above the threshold for preventing HbS polymerization. By week 26 all four treated subjects reached a level of greater than/equal to 10 pg of HbF/F cells, and this level was sustained in 2/3 patients with longer follow-up (FIG. 6). It has been recently suggested that there is a HbF/Fcell range above which with no HbS polymerization and no symptoms in HbS-HPFH (hereditary persistence of fetal hemoglobin) genotype are observed. (Steinberg MH. (2020) Blood. 136(21): 2392- 2400).
[0211] BCL11A Gene Modification:
[0212] The SAR445136 investigational drug product had on-target BCL11A gene modification (61-78% indels) in all 4 subjects. The BCL11A gene modification results (% indels) for each of the 4 infused patients are shown in Tables 6-9. At 26 weeks post- SAR445136 infusion, the indel frequency ranged from 17-34% (mean =25%) in unsorted bone marrow in all 4 subjects. In the subject with 91 weeks follow up, the marrow indel frequency was 28% and 26% at weeks 26 and 52, respectively (see Table 6).
[0213] Safety and Tolerability:
[0214] Of the 4 subjects that have been infused, SAR445136 was generally well tolerated with no infusion related reactions. Reported AEs were consistent with plerixafor mobilization and busulfan myeloablation therapy. One SAE of sickle cell anemia with crisis (VOC) was
reported about 9 months after SAR445136 infusion in 1 subject; no other SCD-related events were reported in the 4 subjects. (FIG. 7). No AEs or SAEs were reported as attributed to SAR445136.
[0215] Quality of Life:
[0216] These preliminary results showed a trend of improvement exceeding the proposed minimally clinically important difference in all PROMIS-57 HRQoL measured domains except for sleep disturbance and pain interference.
Conclusion
[0217] These preliminary data provide proof-of-concept (POC) efficacy and safety results and confirm the potential therapeutic value of ZFN-mediated modification of the BCL11A ESE region and SAR445136 infusion to address current unmet needs of patients with SCD. All 4 infused subjects showed increases in total Hb, HbF, and %F cells. SAR445136 was well tolerated in all four patients infused to date, with a single post-infusion VOC reported in one subject about 9 months after infusion. Clinical improvements in PROMIS-57 domains were also observed. There was natural enrichment of modified erythroid lineage cells in the blood with elevated HbF, sufficient for a clinical benefit. This suggests that modification of a minority of HSCs may be sufficient for a clinical benefit.
[0218] In conclusion, SAR445136 has the potential to induce hematologic changes in a subject and could provide a level of protection against the clinical sequelae of SCD.
[0219] All patents, patent applications and publications mentioned herein are hereby incorporated by reference in their entirety.
[0220] Although disclosure has been provided in some detail by way of illustration and example for the purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications can be practiced without departing from the spirit or scope of the disclosure. Accordingly, the foregoing descriptions and examples should not be construed as limiting.
SUPPLEMENTAL TABLES
Abbreviations: AE=adverse event; DNA=deoxyribonucleic acid; DXA=dual-energy x-ray absorptiometry; ECG=electrocardiogram; ECHOechocardiogram; HbF=fetal hemoglobin; HbS=sickle hemoglobin; HSPC=hematopoietic stem and progenitor cell; ICF=informed consent form; IV=intravenous; MRA=magnetic resonance angiography; MRI=magnetic resonance imaging; MUGA= multi pie gated acquisition; PBL=peripheral blood lymphocyte; PBMC=peripheral blood mononuclear cell; PFT=pulmonary function test; PK= pharmacokinetics; PROMIS-57=Patient-Reported Outcomes Measurement Information System 57; SAE=serious adverse event; SCD=sickle cell disease; WBC=white blood cell
Footnotes:
1 Any scheduled vaccinations (e.g., influenza) were completed at least 30 days prior to the conditioning phase.
2 It was at the discretion of the Investigator, in consultation with the Medical Monitor, to waive any procedure if the procedure had been performed within the standard interval of scheduled study visits.
3 Reviewed select Inclusion/Exclusion criteria to ascertain subject's eligibility to continue in the study.
4 A minimum of 1 year of transfusion history prior to Screening was required to be eligible to participate in the study. Up to 3 years of history was recorded if available.
5 A physical examination was conducted on each subject at specified visits.
6 Conducted on Day 1 of stem cell mobilization.
7 Vital signs were monitored before, during, and after the infusion in accordance with study site practice.
8 For female subjects with childbearing potential only. Pregnancy testing was conducted on Day 1 of stem cell mobilization and within 2 days of conditioning.
9 Bone marrow aspiration was completed at the time of central IV catheter placement.
16 Subjects were monitored throughout the study for the potential development of hematopoietic malignancies using clinical history, physical examinations, laboratory assessments, and bone marrow aspirations.
17 Scheduling of gamete cryopreservation was initiated as soon as possible after mobilization. All procedures related to gamete cryopreservation were completed prior to busulfan administration.
18 Plerixafor dosing, timing, or route of administration may have been modified or discontinued at the discretion of the Investigator based on the clinical status of the subject or if the WBC exceeds 100,000/pL.
19 If the first apheresis cycle did not mobilize the minimum number of CD34+ HSPC required for both SAR445136 drug manufacturing and the rescue treatment, the stem cell mobilization procedure may have been repeated. The timing of repeat apheresis cycles were at the discretion of the Investigator based on the subject’s clinical status.
20 At the Baseline Visit, subjects may have had an optional busulfan PK assessment following a single low dose.
21 Subjects did not proceed to conditioning procedure with IV busulfan until a sufficient quantity of rescue treatment was obtained and SAR445136 was manufactured, passed quality control and release testing, and was confirmed as received at the study site.
23 Seizure prophylaxis was required starting prior to and continuing at least 24 hours after the final dose of IV busulfan conditioning. Iron- chelating agents were discontinued 2 weeks prior to busulfan administration and may be restarted after successful SAR445136 engraftment or at the discretion of the Investigator. Concomitant acetaminophen or metronidazole was avoided.
24 AE and SAE data was collected from signature of the ICF through the final study visit.
Abbreviations: AE= adverse event; DXA=dual-energy x-ray absorptiometry; ECHOechocardiogram; EOS=end of study visit, HbF=fetal hemoglobin; HSPC=hematopoietic stem and progenitor cells; MUGA=multiple gated acquisition; PBL= peripheral blood lymphocytes; PBMC=peripheral blood mononuclear cells; PFT=pulmonary function test; PROMIS-57=patient-reported outcomes measurement information system 57; SAE= serious adverse event; SCD=sickle cell disease; Wk=week
Footnotes:
1 A physical examination was conducted on each subject at specified visits.
2 Unscheduled bone marrow aspiration may also be conducted at any time if clinically indicated, e.g., to evaluate the potential development of hematological malignancy.
3 Dose of SAR445136 was administered IV as a 1-time dose no sooner than 72 hours after the final dose of IV busulfan in the conditioning phase.
4 More frequent monitoring if the prevalence of a single allele is >10% was at the discretion of the Investigator.
5 Vital signs were monitored before, during, and after the infusion and in accordance with study site practice.
6 AE and SAE data were collected from mobilization through final study visit.
Claims
1. An ex vivo method of treating sickle cell disease (SCD) in a subject, the method comprising: administering to the subject in need thereof a composition comprising a genetically modified cell comprising a red blood cell (RBC) precursor cell, wherein the precursor cell comprises SB-mRENH1 mRNAs and SB-mRENH2 mRNAs, which encode a ZFN pair; and a genomic modification made following cleavage by the ZFN pair, wherein the modification is within an endogenous BCL11A enhancer sequence.
2. The method of claim 1, wherein the sickle cell disease is severe sickle cell disease.
3. The method of claim 1 or 2, wherein the subject has adequate physiological function by BMT CNT guidelines prior to administering of the composition.
4. The method of any one of claims 1-3, wherein the composition further comprises a cell descended from the genetically modified cell comprising the SB-mRENH1 mRNAs and the SB-mRENH2 mRNAs.
5. The method of any one of claims 1-4, wherein the fetal hemoglobin (HbF) production in the subject is increased after administration of the composition.
6. The method of any one of claims 1-5, wherein one or more clinical symptoms of sickle cell disease in the subject are decreased, ameliorated, or eliminated.
7. The method of claim 6, wherein one of the clinical symptoms in the subject that is decreased, ameliorated, or eliminated is vaso-occlusive crisis (VOC).
8. The method of any one of claims 1-7, wherein a change from baseline of clinical laboratory hemoglobin fractions in grams/dL plasma and/or percent HbF of total hemoglobin (Hb) is achieved in the subject.
9. The method of any one of claims 1-8, wherein levels of SCD-related disease biomarkers in the subject are altered following treatment.
58
10. The method of claim 9, wherein the biomarkers are changes in iron metabolism and/or changes in levels of erythropoietin, haptoglobin and/or hepcidin.
11. The method of any one of claims 1-10, wherein the clinical symptoms associated with iron overload or associated with baseline transfusion therapy in the subject are ameliorated or eliminated.
12. The method of any one of claims 1-11, wherein the need for RBC transfusions and infusion platelet transfusion, intravenous immunoglobin (I VIG) transfusion, plasma transfusion and/or granulocyte transfusion in the subject is reduced or eliminated.
13. The method of any one of claims 1-12, wherein the number and/or percent of F cells in the subject is modified following administration of the composition.
14. The method of any one of claims 1-13, wherein the genetically modified cells are autologous or allogeneic.
15. The method of any one of claims 1-14, wherein the BCL11A-genetically modified cells further comprise one or more additional genetic modifications.
16. The method of any one of claims 1-13, wherein the genetically modified cells are hematopoietic stem cells isolated from the subject.
17. The method of claim 16, wherein the hematopoietic stem cells are CD34+ hematopoietic stem or precursor cells (HSC/PC) and the CD34+ HSC/PC are mobilized in the subject by treatment with one or more doses of plerixafor.
18. The method of claim 17, wherein at least 25 x 106 CD34+ HSPCs/kg are mobilized in the subject and the mobilized cells are harvested by one or more apheresis cycles.
19. The method of any one of claims 1-18, further comprising administering one or more myeloablative condition agents to the subject prior to administration of the composition comprising the genetically modified cells.
20. The method of claim 19, wherein the myeloablative agent comprises busulfan.
21. The method of any one of claims 1-20, wherein the dose of genetically modified cells administered to the subject is between about 3 x 106 cells/kg and 20 x 106 cells/kg.
59
22. The method of any one of claims 1-20, wherein the composition administered to the subject comprises a dose of cells between about 3.2 x 106 cells/kg and about 9.7 x 106 cells/kg.
23. The method of any one of claims 1-20, wherein the composition administered to the subject comprises a dose of cells about 5.17 x 106 cells/kg.
24. The method of any one of claims 1-23, wherein the genetically modified cells administered to the subject are formulated with approximately 1.0-2.0 x 108 cells per bag at a concentration of approximately 1 x 107 cells/mL.
25. The method of any one of claims 1-24, wherein the genetically modified cells are cryopreserved prior to administration to the subject.
26. The method of any one of claims 1-25, further comprising monitoring the subject’s vital signs prior to, during and/or after administration of the genetically modified cells.
27. The method of any one of claims 1-26, further comprising assessing hemoglobin, neutrophil and/or platelet levels in the subject prior to administration of the genetically modified cells to determine baseline levels of hemoglobin in the subject.
28. The method of claim 27, wherein hemoglobin, neutrophil and/or platelet levels in the subject after administration of the genetically modified cells increase or remain stable as compared to baseline levels for weeks or months after administration.
29. The method of any one of claims 1-28, further comprising assessing the subject using a health-related quality of life (HRQoL) survey.
30. The method of any one of claims 1-29, further comprising assessing the subject using the Patient-Reported Outcomes Measurement Information System 57 (PROMIS-57).
31 . The method of any one of claims 1-30, further comprising assessing the subject using the Karnofsky Performance Scale.
32. The method of any one of claims 1-31 , wherein the subject receives one or more packed red blood cell (PRBC) transfusions prior to and/or after administration of the genetically modified cells.
60
33. The method of any one of claims 1-32, wherein the need for additional therapies such as a bone marrow transplant, blood component and/or iron chelation therapy PRBC transfusions in the subject is reduced or eliminated.
34. The method of claim 33, wherein the need for additional therapies is reduced or eliminated within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more days of administration of the genetically modified cells.
61
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163228988P | 2021-08-03 | 2021-08-03 | |
US63/228,988 | 2021-08-03 | ||
US202163280482P | 2021-11-17 | 2021-11-17 | |
US63/280,482 | 2021-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023014839A1 true WO2023014839A1 (en) | 2023-02-09 |
Family
ID=83689911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/039341 WO2023014839A1 (en) | 2021-08-03 | 2022-08-03 | Methods for the treatment of sickle cell disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023014839A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018039440A1 (en) * | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
WO2020205838A1 (en) * | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
-
2022
- 2022-08-03 WO PCT/US2022/039341 patent/WO2023014839A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018039440A1 (en) * | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
WO2020205838A1 (en) * | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
Non-Patent Citations (4)
Title |
---|
CARMEN F BJURSTRÖM ET AL: "Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 5, 1 January 2016 (2016-01-01), US, pages e351, XP055552882, ISSN: 2162-2531, DOI: 10.1038/mtna.2016.52 * |
KAI-HSIN CHANG ET AL: "Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34 + Hematopoietic Stem and Progenitor Cells", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 4, 1 March 2017 (2017-03-01), GB, pages 137 - 148, XP055552856, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2016.12.009 * |
LESSARD SAMUEL ET AL: "Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, Increased Fetal Hemoglobin, and Reduced Sickling in Erythroid Cells Derived from Sickle Cell Disease Patients", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, 13 November 2019 (2019-11-13), pages 974, XP086666598, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2019-126048 * |
MORAN KEVIN ET AL: "Ex Vivo Gene-Edited Cell Therapy for Sickle Cell Disease: Disruption of the BCL11A Erythroid Enhancer with Zinc Finger Nucleases Increases Fetal Hemoglobin in Plerixafor Mobilized Human CD34+ Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 2190, XP086596279, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-116998 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
US20190100801A1 (en) | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures | |
CA3124564A1 (en) | Methods and compositions for the treatment of fabry disease | |
JP2023501590A (en) | Therapy for hematopoietic cell malignancies using genetically engineered T cells that target CD70 | |
JP2024019738A (en) | Non-disruptive gene therapy for treatment of mma | |
AU2021200872B2 (en) | Compositions and methods for enhanced gene expression of PKLR | |
CA3168089A1 (en) | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients | |
CA3042467A1 (en) | Treatment of krabbe disease with umbilical cord blood transplantion (ucbt) and increased galactocerebrosidase (galc) expression | |
AU2019318420A1 (en) | Method for the treatment of mucopolysaccharidosis type II | |
US20230381225A1 (en) | Methods for the treatment of beta-thalassemia | |
AU2009314704A1 (en) | Foxp3+ natural kiler T-cells and the treatment of immune related diseases | |
JP6423987B2 (en) | Controlled gene expression method | |
WO2023014839A1 (en) | Methods for the treatment of sickle cell disease | |
CA3106693A1 (en) | Method for the treatment of mucopolysaccharidosis type i | |
CN115348868A (en) | Genetically engineered T cells expressing BCMA-specific chimeric antigen receptors and their use in cancer therapy | |
US20220177918A1 (en) | Methods for treating inherited eye defects | |
JP7374502B2 (en) | OCA-B peptide conjugates and treatment methods | |
WO2023122099A2 (en) | Crispr-based gene editing to preserve splicing and expression of foxp3 isoforms 1 and 2 | |
WO2024044697A2 (en) | Compositions and methods for treatment of fabry disease | |
Mcdougald | Reprogramming The Retina: Next Generation Strategies Of Retinal Neuroprotection And Gene Therapy Vector Potency Assessment | |
WO2019040747A1 (en) | In utero transplantation of factor viii-expressing cells for treatment of hemophilia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22787028 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |